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Preface
The Economic Assessment Office (EAO) of the Advanced
Technology Program (ATP) seeks to measure the economic impacts
of ATP’s funding of high-risk, enabling technologies and also to
increase understanding of underlying relationships between
technological change and economic phenomena, to further the
program’s ability to achieve its mission. To this end, the EAO
compiles data, conducts economic studies, and commissions
studies by outside research organizations and economists. The
study described by this report was carried out by the Center for
Economics Research at Research Triangle Institute (RTI), under
contract to the ATP.
The RTI study was intended to achieve four goals:
Z to estimate potential benefits of an inclusive portfolio group
of ATP projects;
Z to perform seven case studies within the portfolio group
using a consistent methodology;
Z to develop an evaluation framework that ATP could
consider for possible adoption—for evaluating a wide
variety of technologies with medical applications; and
Z to inform the emergent ATP focused program in tissue
engineering of the potential for economic benefit in this
technology field.
The four goals were largely achieved by the study.
A case study approach was taken, one of a multiple of evaluation
techniques used by the ATP. Case study entails detailed
investigation of projects to evaluate technical accomplishments,
commercialization progress, the role played by the ATP, and
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economic outcomes. Since ATP-funded projects are in relatively
early-stage research and development, assessment of potential
economic outcomes depends necessarily on numerous projections
and estimates for future conditions; understandably, this part of the
analysis entails considerable uncertainty.
Results of the RTI study relating to each of the four goals, together
with ATP’s perspective on the results, are as follows.

GOAL 1—ANALYSIS OF PORTFOLIO
BENEFITS
RTI’s study estimated many billions of dollars of social returns from
the group of tissue engineering technologies in ATP’s portfolio,
large spillover benefits, and an impressive contribution to benefits
attributable to the ATP. By considering all of the tissue engineering
projects underway at the time of the study, the study was able to
avoid selection bias and presented the first analysis of ATP-funded
projects at the portfolio level. While the ATP is obviously gratified
that RTI’s findings lend further evidence that the program is on the
way to meeting its mission, it recognizes the substantial
uncertainties entailed in the analysis and realizes that the eventual
economic outcome from this portfolio of projects may be
considerably different from today’s projections. A principal
limitation of the study is that it does not sufficiently treat the
uncertainties entailed in the estimates.
RTI developed quantitative estimates for the key analytical concepts
that ATP requested: social and private returns, and social return on
public investment. The measures were given in terms of net
present value and internal rate of return. Sensitivity analysis was
performed for four variables in the estimation of social returns and
five variables for the estimation of private returns. With the
exception of one of the projects, the projected benefits remained
large as input values were varied in the sensitivity analysis.
Nevertheless, the results as presented do not adequately convey the
uncertainties that are inherent in such analyses of prospective
returns.
None of the technologies examined are yet actually in use by
doctors. The analyses are ex ante, not ex post. Companies—
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particularly small companies, which are prominent in this group—
go out of business with great frequency. Short-run cash-flow
crunches, unforeseen technical obstacles that arise at the last
moment, patient complications that derail clinical trials,
unanticipated alternative technologies that suddenly make obsolete
what had previously been envisioned as a great new technology,
and countless other surprise developments can overturn even the
most promising of ideas. If any of these unexpected developments
were to occur for any of the seven projects, the private and social
benefits would decrease and the economic return would be lower
than estimated.
The risk that the technology will not successfully move forward into
actual use, even if it has been successful from a research
standpoint, is likely relatively low for several of the technologies,
and somewhat higher for others. In future studies, the ATP will
require more extensive sensitivity analysis and more careful
modeling of probabilities; the ATP will request reporting of results
in terms of ranges or confidence intervals, rather than point
estimates, to better reflect and emphasize the uncertainty of results
in prospective analysis of returns.

GOAL 2—CONSISTENT APPROACH ACROSS
CASE STUDIES
The goal of consistently applying the same framework to all seven
case studies for comparability was generally successful. The one
important difficulty with respect to consistency that was
encountered proved to be not with the model itself, but with
obtaining all of the necessary data needed to apply all elements of
the model to each of the cases. In particular, the model included
utility weights known as quality-adjusted life-years (QALYs) as
measures of the value of patient pain and suffering, but this
information was not available for all of the specific medical
conditions relevant to each of the technologies.
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GOAL 3—A GENERAL MODEL FOR
EVALUATING MEDICAL TECHNOLOGIES
The study provided a useful first step in developing an evaluation
framework for medical technologies that had the capability of
accounting for improvements in patient outcomes. Development of
this early model has helped us identify issues for further discussion
and has highlighted potentially productive approaches to consider
in completing an evaluation framework for medical technologies.
The model correctly identified three ways that ATP funding can
make a difference:
Z ATP funding can accelerate a project by causing it to have
an earlier start or by speeding the rate of performance.
Z ATP funding can increase the probability of project success.
Z ATP funding can widen a project’s scope.
The study identified the economic burden of a disease as including
the following three cost categories:
Z direct medical costs (i.e., costs of medical treatment);
Z indirect costs (i.e., loss in productivity and unpaid care giver
time); and
Z intangible costs (i.e., pain and suffering of patients with
acute and chronic diseases and illnesses).
As acknowledged in the study, indirect costs were omitted from
both the model and the case-study applications.
The outcomes of the model were expressed in terms requested by
the ATP: measures for the social return on public investment, the
social return on total investment, and the private return to the
innovating firms. The social return on public investment is based in
the model on a comparison between a “world with ATP” and a
hypothetical “world without ATP,” and focuses on those social
benefits that are attributable to the ATP award. The social benefits
concept includes benefits that extend beyond the private benefits
captured by the innovating companies, what economists call
“spillover” effects. As modeled by RTI, the spillover effects include
an estimated value for patient pain and suffering avoided, to the
extent that such patient benefits are not captured by the firms in
their pricing of their new medical treatments. To assign a value to
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the impacts on patients, the model incorporates the concept of
QALYs, where utility weights are used to account for different
health states associated with different chronic and acute medical
conditions.
Limitations of the model or its application include the following.
Not included in the modeling of spillovers is an assessment of the
value of knowledge gained by other firms from the research carried
out by the ATP awardees, so-called “knowledge spillovers.” The
model also makes no allowances for evaluating projects that are
interrelated, to avoid double counting in the case of overlapping
technologies, or to take into account complementary effects of
synergistic technologies. The model is presented and applied for a
single application, whereas all the technologies evaluated are in
fact multiple-application technologies. In addition, indirect
medical costs are not included in the model. From the standpoint
of empirical implementation of the model, information needed to
support the QALY approach may not be available for all medical
technologies and may require additional research to derive. A
critical parameter for estimating the distribution of benefits,
between private benefits captured by the innovators and spillover
benefits to the patients, is the pricing of the medical treatments, and
this is an issue deserving of more investigation since it bears heavily
on the results. Finally, as pointed out previously, additional
attention to the estimation of probabilities is desirable.

GOAL 4—INFORMATION FOR ATP’S
EMERGENT FOCUSED PROGRAM
The study’s estimated benefits for the portfolio of seven tissue
engineering projects, though likely more uncertain than indicated
in the study, nevertheless suggests a very strong potential for
national benefits from new approaches to the treatment of diseases
and illnesses that offer lower treatment costs in combination with
better patient outcomes. The opportunities for an ATP Focused
Program in the emerging field of tissue engineering seem
promising.
We plan to extend our efforts to improve the evaluation of medical
technology investments in two major directions. First, we expect to
refine and improve both the theoretical modeling and the empirical
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estimation of the impact of public investments. Second, with the
passage of time we intend to revisit projects that have been the
subject of ex ante analysis to provide an ex post analysis of
economic returns; this will enable us to compare prospective and
retrospective analyses and hence to identify shortcomings in the
early analysis.
In summary, it is important to note that the RTI study is an early
effort at modeling and measuring economic returns for new
technologies. This type of modeling, too, is an emerging field, and
the existing methods and tools of evaluation are as yet inadequate
to the task. Yet, it is important—and, in fact, required by law—that
federal agencies be accountable for and report on the inputs,
outputs, and outcomes of the programs they operate for the benefit
of the nation. Assessing the social impact of government cost
sharing of high-risk research to develop breakthrough,
infrastructural, and multiapplication technologies lies at the frontier
of program evaluation and offers both theoretical and practical
challenges. RTI did a good job with a very tough task. Our
criticisms of the study do not reflect poor performance on the part
of RTI; rather, our comments are indicative of the challenges in
developing and applying such a model. We welcome comments
and advice from the evaluation community on ways to improve
modeling and analysis of economic benefits.
Rosalie T. Ruegg
Director, Economic Assessment Office
Advanced Technology Program
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Executive Summary
The National Institute of Standards and Technology’s (NIST’s)
Advanced Technology Program (ATP) began in 1990 as a costsharing program to assist U.S. industry in pursuing high-risk,
enabling technologies with potential for significant national
economic benefit.
ATP conducts economic analyses of these technologies to assess
the short- and long-run impact of ATP-funded projects on project
participants and on others in the economy. As part of this effort,
Research Triangle Institute (RTI), under contract to NIST, addressed
the specific challenges of developing and employing a framework
for estimating social and private returns on ATP-funded innovations
used in medicine.
This executive summary provides an outline of the study’s
methodology and summarizes key findings. Chapter 1 of the report
gives a complete overview of the study, describing objectives and
methodology, the specific tissue engineering projects, and findings
and conclusions. Chapter 2 explains the methodology in greater
detail. Chapter 3 provides case by case analysis of each of the
seven ATP-funded tissue engineering projects.
Our approach to modeling the social and private returns on ATPfunded projects in medical technologies is based on the
methodology recommended by Mansfield (1996). We modify
Mansfield’s methodology for the specific case of medical
innovations. In particular, we use nonmarket methods to value the
benefits of new medical treatments. Nonmarket valuation methods
are useful for valuing benefits of new technologies that are not
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priced in markets—cleaner water or air, reductions in crime, or, as
in this case, improvements in health.
ATP-funded medical technologies may improve the long-run health
outcomes of thousands of patients each year with acute and
chronic diseases. They may also reduce the cost of health care.
Valuing these effects requires extending conventional benefit-cost
models and applying methodologies commonly used in health
economics.
The economic burden of a disease is usually divided into three
components: direct medical costs, indirect costs, and intangible
costs. Direct medical costs are costs of medical treatment. Indirect
costs are the societal costs associated with the loss in productivity
due to illness and unpaid caregiver time. Intangible costs measure
the patient’s pain and suffering. Our methodology measures how
ATP-funded technologies change both the direct medical costs and
the intangible costs of a disease. Changes in indirect costs are
generally not included in our estimates.
Social return on public
investment quantifies the
incremental improvement
in social outcomes
attributable to ATP
investment.

The primary emphasis of the methodology developed and used in
this study is to evaluate the social return on public investment for
ATP projects. From a public policy perspective, this evaluation
factor is central, because it quantifies the incremental improvement
in social outcomes attributable to ATP’s investment.
Our methodology allows ATP funding to affect the development of
medical technology in three ways:
Z Accelerate the technology’s benefits: ATP funding can
catalyze and accelerate the R&D phase, bringing benefits to
the private sector, patients, and society sooner and for a
greater number of years than without ATP funding. In some
cases, ATP funding may persuade a company to conduct
research in a technology that it otherwise would not pursue.
Z Increase the likelihood of success: By reducing the cost of
R&D to the companies developing the technology, ATP
funding can increase the amount of R&D conducted and
increase the likelihood that a project will be technically
successful.
Z Widen the technology’s applications: ATP funding can also
widen the scope of the project, enabling the company to
apply its technology to additional diseases or patient
populations.
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To determine the social return on public investment, we
constructed two scenarios for each project: one with ATP funding
and one without ATP funding. The with-ATP scenario can differ
from the without-ATP scenario through any of the three impact
channels described above. We first calculated the social benefits
and costs for each scenario and then calculated the difference in
the stream of benefits and costs between the with-ATP and the
without-ATP scenarios.
Social return on investment
quantifies the net benefits
to society resulting from
public and private
investment in ATP-funded
technologies.
Private return on
investment considers only
the investment costs and
revenues to the companies
participating in the
technology’s development.

Social return on investment quantifies the extent to which the
nation is better off as a result of public and private investment in
the development of these technologies. The concept of social
return considers the costs of public investment and the value of
medical benefits to individuals in addition to private investment
costs and private company profits.
Private return on investment is a component of social return on
investment. The concept of private return considers only
investment costs and revenues of companies carrying out the
research, commercialization, and manufacturing of the new
technologies and does not consider either costs of public
investment or value of medical benefits to individuals.
Social return on public investment is based on a comparison
between social return with ATP and social return without ATP; that
is, between cell A and cell C in Figure E-1.

Figure E-1. Social and
Private Returns With and
Without ATP

Social Returns

Private Returns

With ATP

A

B

Without ATP

C

D

To demonstrate the feasibility of the methodology, we examined
one specific application for each of seven multiple-application
tissue engineering projects funded from 1990 to 1996. Assuming
that these technologies are developed and used for the specific
applications we studied, our analysis shows the following expected
benefits:
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Z The expected social return on ATP public investment in
these technologies, or the increment to social returns
attributable to ATP funding, is estimated at $34 billion in
net present value.
Z The expected social rate of return on ATP public investment
in these technologies is estimated at an annual rate of
116 percent.
Z The expected total social return on public and private
investment in these technologies is estimated at $112 billion
in net present value, or an annual rate of 115 percent.
Z The expected total private return on investment in these
technologies to ATP-award companies and their partners in
commercialization and production is estimated at
$1.6 billion in net present value, or an annual rate of
12 percent. Of the $1.6 billion in net present value of
private returns, $914 million is estimated to be attributable
to ATP funding.
These results illustrate two important points about ATP’s role in
funding these technologies:
Z ATP plays a significant role in increasing the expected
social and private returns on these projects.
Z The social returns are far greater than the private returns.
Private companies will therefore tend to underinvest in
these technologies. The wide disparity between social and
private returns indicates the importance of public incentives
to the private sector to pursue these technologies.
This study analyzed only
the preliminary
applications of these
technologies; their longterm impact may be much
greater than suggested
here.

The study analyzed only the preliminary applications of these
technologies. Because these technologies provide the scientific
basis for a wide range of applications, their long-term impact may
be much greater than suggested here, as companies apply their
discoveries to a variety of medical applications. In addition, the
knowledge generated by these initial applications may lead to
advances in additional, unrelated areas by other companies.
Because none of these technologies has yet reached the
commercial marketthough several are in clinical trialsthe
results of this analysis are based on the expectations of the
innovators and other informed individuals. Whether these
expectations will be realized is uncertain. However, the
methodology will allow us to update these results as data on the
actual costs and benefits of the projects become available.

E-4

1

Overview
The National Institute of Standards and Technology’s (NIST’s)
Advanced Technology Program (ATP) began in 1990 as a costsharing program to assist U.S. industry in pursuing high-risk,
enabling technologies with significant potential for commercial and
national economic impact.
ATP conducts economic analyses of these technologies to measure
the short- and long-run impacts of the specific development projects
it funds on the project participants and on others in the economy.
ATP’s evaluation strategy includes, among other activities, the
development of evaluation methodologies and case studies of ATP
projects (Ruegg, 1996) and continuous improvement of the methods
and data used to estimate the economic impact of ATP innovations.
As part of ATP’s methodology development effort, Research
Triangle Institute (RTI), under contract to NIST, addressed the
special challenges of developing and employing a framework for
estimating social and private returns to ATP-funded innovations
used in medicine. We developed a methodology for measuring the
benefits resulting from improving patient health, reducing the cost
of medical care, and creating new business opportunities for the
innovators and their partners. We also demonstrated the feasibility
of this approach by applying the methodology to seven ATP-funded
technologies in tissue engineering.
This report describes RTI’s general approach to assessing the
impact of ATP funding on the social benefits of these technologies.
It also describes our procedures for applying the methodology to
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seven tissue engineering case studies and reports the results of these
analyses.
This chapter provides an overview of the entire study. It describes
the project’s objectives and scope, reviews the methodology, and
explains why this approach is valid for evaluating ATP projects with
medical applications. This chapter also summarizes our findings
from the seven ATP-funded projects in tissue engineering that serve
as case studies for applying the methodology and offers conclusions
about the validity of the methodology and the meaning of the
results. The other chapters of this report provide a more thorough
discussion of these topics.

1.1

PROJECT OBJECTIVES AND SCOPE
The primary objective of this project was to develop a methodology
for estimating the expected social economic return on public
investment in ATP-funded projects with medical applications.
Medical technologies present specific methodological challenges
that have not been addressed in ATP’s previous methodological
development efforts.

The primary
objective of this
project was to
develop a
methodology for
estimating the
expected social
economic return on
public investment in
ATP-funded projects
with medical
applications.

The second objective was to illustrate this methodology by applying
it to seven ATP-funded projects in tissue engineering. Tissue
engineering integrates discoveries from biochemistry, cell and
molecular biology, genetics, material science, and biomedical
engineering. It produces materials that can be used either to
replace or correct poorly functioning components in humans or
animals (NIST, 1997). These seven projects, which comprise all of
the tissue engineering projects funded from 1990 to 1996,
constitute a “virtual program” in tissue engineering.1
The third objective was to estimate the social return on public
investment in seven ATP projects chosen for the case studies.
Estimating the return on public investment in these ATP-funded
projects was difficult not only because of the methodological
challenges, but also because of the shortage of ex post empirical
data. None of the tissue engineering technologies chosen for this
study have been commercialized (although some are in clinical
trials), and many of the ATP-funded projects are still underway.
1The ATP has since announced a “formal” focused program competition in tissue

engineering; the first proposals were awarded in October 1997.
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Thus, the analysis of these projects is very preliminary and focuses
only on the first applications of these multiple-application
technologies.
Our final objective was to provide insight regarding the factors that
affect the social return on public investment in ATP-funded projects
with medical applications. By examining how the results of the
case studies differ across projects, we can draw some conclusions
about the characteristics of ATP projects that tend to improve their
expected social benefits.
In developing and implementing a methodology for measuring the
social and private returns on ATP projects in tissue engineering, we
limited the scope of the analysis in several ways. First, ATP asked
that we examine seven projects in tissue engineering, with specific
emphasis on four of the seven. Thus, for those four projects, the
methodology and data collection were more detailed and complete
than for the other three projects.
Second, we examined only one application of each of the seven
projects. The technologies being developed through these projects
will probably lead to a number of other applications, both by the
innovating companies and by other companies that may receive
knowledge “spillover” benefits through dissemination of research
results. However, because time, resources, and data were limited,
we focused on the single application for each project that our
industry informants told us would be the most likely to be
commercialized in the near term.
Third, we limited the time horizon for evaluating each project. The
time horizon includes an R&D phase, a commercialization phase,
and a production phase. We assume that the production phase
would last only 10 years before the technology would be replaced
by a newer technology. Thus, the time horizon of costs and
benefits for specific projects varies from 14 to 18 years, and the
time horizon for the costs and benefits of all the projects combined
is 20 years.
Our assumption that technologies will only be produced and used
for 10 years is based on the fact that medical technologies are
replaced over time with improved techniques. However, there is
little research quantifying this process; better information about
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how quickly the value of a medical innovation depreciates over
time could lead in the future to a more realistic assumption
regarding the relevant time horizon.
In addition, our methodology and assumptions reflect two
important conditions that affect the economic analysis of all ATP
projects:
Z The limitations of available data. ATP needs a method that
can provide early forecasts of economic returns and be
updated as needed. ATP needs early assessments of the
potential returns of a project before ex post data are
available. We can update these early estimates once the
actual benefits and costs of these technologies become
more apparent, as recommended by Mansfield (1996).
Z The need for flexibility. ATP funds a variety of projects that
affect medical costs and outcomes. To maximize the
flexibility of the method, ATP needs a model that we can
adapt to analyze other medical technologies.

1.2

METHODOLOGY
The primary emphasis of this study is the development of a
methodology for evaluating the social return on public investment
in ATP projects. From a public policy perspective, this evaluation
factor is central, because it quantifies the improvement in social
outcomes attributable to ATP’s investment.

From a public
policy perspective,
the social return on
public investment is
the central factor for
determining the
impact of ATP,
because it quantifies
the increment in
expected social
outcomes that is
attributable to ATP’s
investment.
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As shown in Figure 1-1, our methodology allows for ATP funding to
fundamentally affect the development of medical technology in
three ways:
Z Accelerate the technology’s benefits: ATP funding can
catalyze and accelerate the R&D phase, bringing benefits to
the private sector, patients, and society sooner and for a
greater number of years than without ATP funding. In some
cases, ATP funding may persuade a company to conduct
research in a technology that it otherwise would not pursue.
Z Increase the likelihood of success: By reducing the cost of
R&D to the companies developing the technology, ATP
funding can increase the amount of R&D conducted and
increase the likelihood that a project will be technically
successful.
Z Widen the technology’s applications: ATP funding can also
widen the scope of the project, enabling the company to
apply its technology to additional diseases or patient
populations.
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Figure 1-1. Elements Determining Social Return on Public Investment and Social Return on
Investment

ATP Investment

Accelerate
Benefits

Increase
Likelihood of
Success

Private Investment

Widen
Applications

Social Return on
Investment without
ATP

Social Return on
Investment with ATP

Social Return on
Public Investment

Determining the social
return on public investment
requires comparing the
social return on investment
with ATP funding to the
social return on investment
without ATP funding.

To determine the social return on public investment in ATP
projects, we constructed two scenarios: one with ATP funding, and
one without ATP funding. The with-ATP scenario can differ from
the without-ATP scenario through any of the three ATP impact
mechanisms described above. Figure 1-1 shows that to determine
the expected social return on public investment we first calculated
the social return on investment for each scenario and then
calculated the return attributable to ATP from the difference in the
stream of expected net social benefits in the with-ATP and withoutATP scenarios.
The social return on investment quantifies the extent to which the
nation is better off as a result of public and private investment in
the development of these technologies. The social return on
investment includes the value of medical benefits to patients
receiving new treatments, the value of changes in the cost of health
care to all stakeholders in the medical care system, revenues to
private companies, and ATP and private-sector investment costs.
The private return on investment is a component of social return on
investment. The private return on investment considers the costs
and revenues to the companies carrying out the research,
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commercialization, and manufacturing of the new technologies, but
does not consider public investment, the full value of medical
benefits to patients, and changes in health care cost.
1.2.1

Constructing the Timeline of R&D Costs and Benefits
Investments in new technology often do not result in benefits to
society or to private companies for a number of years. This is
especially true in the biotechnology industry, where regulatory
hurdles, such as multiphase clinical trials, may lengthen the R&D
process. A simplified stylized characterization of the time path of
investments and revenues includes three phases:
Z R&D phase: R&D is the primary focus of the firm’s
activities and investment during this phase. Public
investment in ATP funding occurs at this time.
Z Commercialization phase: Private investment in marketing
and manufacturing occurs during this phase, but only if the
R&D phase has been technically successful.
Z Production phase: During this phase, manufacturers
produce a product that embodies the technology providing
revenues to companies and benefits to patients. Costs and
benefits in the production phase occur only if R&D has
been technically successful.
Some activities of these three phases may overlap. For example,
the company may develop a commercialization strategy early in the
R&D phase and may continue to conduct commercialization
activities during the production phase. However, this simplified
version provides a useful framework for developing scenarios of
social and private returns. In the sections that follow, we describe
when costs and benefits occur relative to this timeline.

1.2.2

Measuring the Impact of ATP on Social Returns
As explained above, we assume that ATP funding affects the
innovation process by accelerating the development of the medical
technology, increasing the likelihood of technical success, and
widening the technology’s applications. Without ATP funding we
expect a lower probability of technical success, a delay of the
benefits of the innovation, or a narrower scope of the technology’s
applications. The magnitude and importance of these effects vary
by project.
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R&D acceleration
lengthens the window of
market opportunity in our
model. We assume that a
newer treatment or
technology will replace the
ATP-funded technology 10
years after its expected
commercialization date in
the with-ATP scenario.
Thus, if we expect a
technology to reach the
market in 2000, we assume
that a new technology will
take its place in 2010. If
the without-ATP scenario
includes a 2-year project
delay, market introduction
does not occur until 2002,
but the end of the market
opportunity window is still
2010. Thus, when ATP
funding accelerates R&D
by 2 years, the with-ATP
scenario allows for 2
additional years of benefits.

Accelerating Benefits. Because ATP funding accelerates R&D, the
R&D phase in the with-ATP scenario is shorter than the R&D phase
in the without-ATP scenario. Commercialization, production, and
the associated benefits to private companies and patients all occur
sooner. Social benefits are greater for two reasons:
Z the time horizon for these technologies is fixed, so the total
number of years during which benefits accrue to companies
and patients increases when the R&D phase is shorter (see
sidebar); and
Z discounting implies that benefits that occur earlier are
valued more than benefits that occur later.
Increasing Probability of Technical Success. The probability of
technical success affects the expected value of net benefits to
society. To arrive at the expected value of net benefits, we
multiplied all costs and benefits that occur after the R&D phase by
the probability of technical success.
To assess ATP’s influence on the likelihood of success, we assume a
simple relationship between the price of R&D to the company, total
R&D effort by the company, and the probability of technical
success. ATP funding reduces the price of R&D to the company,
which leads to an increase in R&D effort applied to the project.
We assume that an increase in R&D effort leads to an increase in
the probability of technical success. Therefore, the with-ATP
scenario includes the possibility of an increased probability of
technical success and consequently a higher expected value for the
stream of benefits.
Widening Technology Scope. ATP funding may also enable a
company to research a wider range of applications of the
technology. The with-ATP scenario may include, for example,
benefits to a larger class of patients, treatments for a greater number
of diseases or injuries, or changes in a greater number of health
outcomes.

1.2.3

Determining Medical Benefits to Patients
ATP-funded medical technologies may improve the long-run health
outcomes of thousands of patients per year with acute and chronic
diseases. The magnitude of these health benefits of new
technology depends on both the magnitude of the health
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improvement of an individual patient and the number of patients
that will be treated.
The medical benefits of
ATP-funded medical
technologies depend on
both the per-patient
benefits and the number of
patients that will be
treated.

Valuing Per-Patient Changes in Health Outcomes
Determining the value of changes in health outcomes is difficult
because market prices that accurately reflect the values of these
health outcomes are not available. We use nonmarket methods to
assess the value of medical goods and services to patients. These
methods use data other than market prices to determine the value
that patients place on improvements in health outcomes.
We employed a three-step methodology to determine the value of
the health benefits of a new technology. As illustrated in
Figure 1-2, the first step is to model the impact of the new
technology on health outcomes. Our methodology for modeling
health outcomes involves developing either a chronic disease
model or an acute illness and injury model for each affected
disease or condition. These models use medical statistics and the
results of clinical trials to show how the number of patients
experiencing different health states or health outcomes changes
when doctors adopt the new treatment developed with ATP
funding.
The second step is to assess how those changes in health outcomes
affect the well-being of the patient (i.e., how the quality and length
of life is affected). We use the quality-adjusted life-year (QALY) to
measure the utility associated with different health states. The
QALY combines morbidity and mortality into a single measure that
ranges from zero (death) to one (a year in perfect health). Through
extensive surveys of patients, health researchers have established
QALY values for a variety of different health states.
The third step is to determine a dollar value for the change in the
patient’s well-being. We used recent empirical estimates of the
economic value of a QALY based on willingness-to-pay (WTP)
values for avoiding illness and accidents (Mauskopf and French,
1991; Moore and Viscusi, 1988b).
Determining the Number of Beneficiaries
The social benefits of a new technology depend not only on the
value of health improvements to each patient, but also on the
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Figure 1-2. Valuing Per-Patient Changes in Health Outcomes

Step Required

RTI’s Methodology

1
Model the impact of the
new technology on health
outcomes

Develop a chronic disease
model or an acute illness and
injury model for each
affected disease or condition

2
Quantify impact in terms of
changes in patient wellbeing (utility)

Measure changes in health
outcomes in terms of
quality-adjusted life-years
(QALYs)

3
Place a monetary value
on changes in patient
well-being

To estimate the number of
patients to be treated with
the new technology in
each year, we collected the
predictions of early market
penetration from experts
and fit these estimates to a
widely accepted market
penetration model.

Translate QALYs into dollars
using published estimates of
the dollar value of a QALY

number of patients that will receive the new treatment in each year.
In the first few years after a new treatment becomes available, a
relatively small proportion of the medical profession will use the
new technology. Hence, only a small percentage of the total
patient population will receive the benefits from the innovation in
the early years of its use. How rapidly a technology spreads
depends on the degree of the improvement in health it provides
over existing treatments, how easy it is to use, and how costly it is
compared to the defender technology.
We projected the market penetration of each technology over time
by estimating a commonly accepted diffusion model, called the
Bass model. To estimate the Bass model, we needed to collect
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information about the early penetration of the technology and its
maximum market penetration after 10 years. Because these
technologies have not yet been commercialized, we asked experts
in the treatment of each disease to provide their estimates of these
parameters. We asked them to predict market penetration in the
first several years after introduction and the ultimate market
penetration after 10 years. We used these predictions to estimate a
Bass diffusion model, which provided 10-year forecasts of market
penetration.
1.2.4

Estimating Changes in Health Care Costs
Our model includes estimates of changes in the cost of health care
due to the use of ATP-funded technologies. We compared the
expected cost of treating patients with the new technology to the
cost of using the existing technology. Where appropriate, we also
incorporated the costs of treating the side effects and complications
associated with the new and defender technologies.

1.2.5

Estimating Private Return on Investment
Expected private returns to the companies engaging in R&D,
commericalization, and production of these technologies depend
on the following factors:
Z projected costs for the R&D, commercialization, and
production phases;
Z projected revenues for the production phase; and
Z probability of technical success.

In our framework, private
return on investment
includes the returns to the
innovator as well as other
companies that may play a
role in commercializing
and producing the
technology.
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ATP-funded companies may specialize in the R&D phase of the
innovation process, while other companies might carry out
commercialization and production. Companies that specialize in
R&D earn revenues by licensing their technology to other firms that
commercialize and produce new products. However, our
definition of private returns includes the costs and benefits from all
three phases regardless of whether the ATP-funded firm or another
firm carries out marketing and production. Thus, our definition of
private returns includes returns not only to the ATP-funded
company but also to other companies that may play a role in
commercializing and producing the technology.
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Analysis of private company costs and benefits requires information
about the company’s R&D, commercialization costs, fixed and
variable costs of production, revenue, and the probability of
technical success. Data on these items are difficult to obtain. We
followed a series of procedures, briefly described below, to develop
estimates and assumptions for the case studies:
Z R&D investment: For the with-ATP scenario, we assume
private R&D investment is equal to the total size of the ATPfunded project, minus the funds provided by ATP. For the
without-ATP scenario, we developed a simple model of the
impact of ATP funding on company R&D spending to derive
estimates of R&D spending in the absence of ATP.
Z Costs of commercialization and production: We used
industrywide cost information from the biotechnology and
pharmaceutical industries to estimate commercialization
and production costs as a percentage of expected revenues.
Z Revenues: In each year of the production phase, revenue is
equal to the per-unit price, as estimated by the companies,
multiplied by the quantity sold, which is estimated from the
diffusion model described above.
Z Probability of technical success: For the with-ATP scenario,
we used the companies’ own assessment of their technical
progress. For the without-ATP scenario, we reduced the
probability of technical success as a function of the
estimated decrease in total R&D effort.
1.2.6

Calculating Measures of Economic Return
We calculated measures of economic return from three
perspectives: the social return on public investment, the social
return on (public and private) investment, and the private return on
(private) investment.
For each of the three perspectives, we calculated two summary
measures of economic return: the net present value (NPV) and the
internal rate of return (IRR). NPV is the most accurate method for
evaluating the economic impact of a project. NPV is defined by
n

NPV =

NBt

∑ (1+r)t

(1.1)

t=1

where t indexes the year in which either benefits or cost occur, NBt
is the expected net benefit (benefit minus cost) in year t, n is the
number of years over which benefits or costs accrue, and r is a
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We use two
summary measures
of economic return:
the net present
value (NPV), and
the internal rate of
return (IRR).

prespecified discount rate. An NPV greater than zero indicates that
the discounted value of the benefits is greater than the discounted
value of the costs, so the project has positive net benefits.
The IRR is another commonly used measure of the economic
benefits from an investment. It is the discount rate that sets the NPV
to zero. Thus, to calculate the IRR, we set Eq. (1.1) to zero and solve
for r. We can interpret the IRR as the rate of return associated with
the investment project over the life of the project.
To calculate the social return on public investment, the annual
expected net benefit, NBt, in Eq. (1.1) is defined as the difference
between the annual social expected net benefit with ATP and
without ATP. For the social return on investment, NBt includes all
social benefits and costs, including medical benefits to patients,
changes in the cost of health care, benefits and costs to private
companies, and the cost of ATP public investment. For the private
return on investment, NBt includes only benefits and costs to
private companies.

The composite measure of
return for the seven
projects as a group is based
on a sum of expected
benefits and costs in each
year across all projects.

For social return on public investment, social return on investment,
and private return on investment, we also calculated composite
measures of NPV and IRR for the seven case study projects as a
group. We calculated the composites by summing the total
expected benefits and costs for each year for all the projects and
calculating NPV and IRR for all the projects as a group over the
time period covering the life of all projects.
Many of the variables in this model are measured with considerable
uncertainty. The estimates of expected return depend, in part, on
the opinions of representatives of ATP-funded companies and other
industry experts. These estimates of social and private returns
should be updated as new data become available.

1.3

CASE STUDIES OF SEVEN ATP PROJECTS IN
TISSUE ENGINEERING
ATP asked RTI to apply the methodology described above to a
single application for each of seven multiple-application tissue
engineering projects funded from 1990 to 1996. These seven
projects are described in Table 1-1.
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Table 1-1. Overview of ATP Projects Included in this Study

ATP Award
ATP Project Titlea

Project Sponsor

Competition
No.

Duration

Funding
Level

In-Depth Case Studies
Human Stem Cell and
Hematopoietic Expansion Systems
“Stem Cell Expansion”

Aastrom
Biosciences, Inc.

91-01

2 years

$1,220,000

Structurally New Biopolymers
Derived from Alpha-L Amino Acids
“Biopolymers for Tissue Repair”

Integra LifeSciences
Corporation

93-01

3 Years

$1,999,000

Disease Treatment Using Living
Implantable Microreactors
“Living Implantable Microreactors”

BioHybrid
Technologies Inc.
(lead company in
joint venture)b

93-01

3 years

$4,263,000

Treatment of Diabetes by
Proliferated Human Islets in
Photocrosslinkable Alginate
Capsules
“Proliferated Human Islets”

VivoRx, Inc.

94-01

3 years

$2,000,000

Fabrication Using Clinical
Prosthesis from Biomaterials
“Biomaterials for Clinical
Prostheses”

Tissue Engineering,
Inc.

92-01

3 years

$1,999,000

Application of Gene Therapy to
Treatment of Cardiovascular
Diseases
“Gene Therapy Applications”

Progenitor, Inc.

94-01

3 years

$1,996,000

Universal Donor Organs for
Transplantations
“Universal Donor Organs”

Alexion
Pharmaceuticals

95-01

3 years

$1,999,000

Brief Case Studies

aThroughout this report, we refer to each project by the abbreviated title listed below the full title.
bBioHybrid has recently been approved for a 2-year no cost project extension.

At the request of the ATP staff, we spent a greater share of our effort
and resources modeling and collecting data for the first four
projects listed in Table 1-1. ATP expected that for these projects
better information about the potential impact of the technology and
the costs of its development would be available. For these in-depth
case studies, we spent more time searching for secondary data in
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the medical literature, collected a greater quantity of data for the
diffusion forecasts, and used a more detailed medical benefits
modeling strategy.
We consulted a number of sources for information. The most
important sources of information about each technology were
representatives of the companies receiving ATP funding. We
interviewed representatives of each lead company and, in some
cases, also interviewed representatives of partner companies. We
also talked with a number of physicians and consulted a variety of
secondary data sources, including medical literature and statistical
databases, to develop estimates of costs and benefits.
Below, we provide brief descriptions of each of the technologies.
We describe the in-depth case study projects first, in chronological
order according to date of funding; then we move on to the brief
case study projects, also in chronological order.
1.3.1

Human Stem Cell and Hematopoietic Expansion
Systems
Aastrom Biosciences’ ATP project addresses improvement of bone
marrow and stem cell transplant, an increasingly popular therapy in
the U.S. A particular growth area is autologous bone marrow
transplant (ABMT), in which the patient’s own bone marrow or
stem cells are first harvested for safe-keeping and then replaced
after high-dose cancer chemotherapy. Physicians are rapidly
increasing the use of ABMT in treating a variety of cancers because
it allows patients to tolerate very high doses of chemotherapy with
less risk of infection and bleeding, improving the patients’ health
outcomes. Although ABMT has clear therapeutic advantages, it
remains a difficult, fairly risky, and expensive procedure.

The Aastrom CPS will
greatly reduce the
invasiveness,
inconvenience, cost, and
risks associated with
ABMT.
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The objective of this project was to develop a laboratory-scale
prototype bioreactor called a Cell Production System (CPS). The
Aastrom CPS will be able to culture and grow bone marrow cells,
reducing the need for invasive procedures to obtain sufficient bone
marrow or stem cells for ABMT. Instead, only a small quantity of
cells must be harvested, because they can be expanded within the
CPS to provide the quantity required for ABMT. This will greatly
reduce the invasiveness, inconvenience, costs, and risks of this
increasingly popular procedure.
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The proposed procedure offers the potential of removing tumor
cells and other undesirables in the bone marrow as well. The
current form of the bioreactor is suitable for growing bone marrow
cells; further advances may make growing blood cells themselves
possible, supplementing the blood donor system.
1.3.2

Structurally New Biopolymers Derived from Alpha-L
Amino Acids
Integra LifeSciences Corporation received ATP funding to develop a
novel synthetic polymer technology to create a cache of new
bioabsorbable polymers for use in biomedical implants. The
resulting new polymers will be designed and developed into
prototype orthopedic devices in collaboration with the Hospital for
Joint Diseases.
The concept of biodegradable medical implants has gained
acceptance over the years as researchers and practitioners have
realized that an implanted material does not have to be inert but
can be degraded and/or metabolized in vivo once its function has
been accomplished. This approach can alleviate some of the
problems associated with nondegradable implants, such as longterm safety and/or implant removal.

Integra’s polymer
technology will have broad
applications in
orthopedics, wound care,
cardiovascular repair, and
drug delivery. The initial
application is orthopedic
fracture fixation.

This platform technology has broad applications in orthopedics
(fracture fixation, cartilage and ligament repair), wound care,
cardiovascular repair, and drug delivery. However, in the near
term, Integra is focusing on the orthopedic fracture fixation market
to demonstrate success and generate revenue. The fracture fixation
applications, in order of expected market penetration, are
1. nonweight-bearing pins and screws;
2. dental and maxillofacial fixation devices; and
3. weight-bearing plates, screws, and rods.
Because the first of these three orthopedic applications is closest to
market, RTI focused on it.
Bioabsorbable fixation devices have two primary advantages over
the metal devices they will replace. Their use will minimize or
eliminate the need for a second surgery to remove the implant,
which eliminates the attendant costs and risks of such a surgery. In
addition, if the device works as anticipated (i.e., eventually being
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completely replaced by bone), it should reduce the likelihood of
secondary fractures resulting from the stress-shielding effect or the
presence of screw holes that serve as stress concentrators.
1.3.3

Disease Treatment Using Living Implantable
Microreactors
BioHybrid Technologies, Inc., is working on an ATP project to
develop the capability to implant specific cells into the human
body that produce hormones or other bioactive agents that the
patient cannot produce or is not producing in sufficient quantity.
BioHybrid’s approach is to encase the transplanted cells in
microspheres to isolate them from the immune system. These
“microreactors” have pores large enough to permit glucose;
nutrients; electrolytes; oxygen; and relatively small bioactive
species, like insulin, to pass but are small enough to block the
larger immunocytes and other relatively large molecules involved
in transplant rejection. Isolating the implanted cells from the
immune system opens up the possibility of using cells from sources
other than the recipient, for treatment of diseases such as diabetes.

The most immediate
application of BioHybrid’s
microreactor technology is
the treatment of insulindependent diabetes.

This “microreactor” technology has the potential to be applied to a
number of other therapeutic applications, including hemophilia,
Parkinson’s disease, Alzheimer’s disease, and hepatic failure.
However, the most immediate applicationthat considered for this
studyis for diabetic patients who are unable to produce insulin to
control blood glucose. This technology would be used in place of
multiple daily insulin injections.
The application will involve an outpatient procedure and a local
anesthetic. Encapsulated islet cells will be injected into the
peritoneal cavity under ultrasound control. Because the
transplanted islet cells have a finite life, the patient will receive an
injection once or twice a year. The dose and frequency of
treatment have not yet been finalized but will be determined
during the planned clinical trials.
If successful, the transplants will allow patients to achieve close to
normal glycemic control, virtually eliminating many of the risks of
long-term complications of diabetes, including retinopathy,
nephropathy, and renal disease.
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1.3.4

Treatment of Diabetes by Proliferated Human Islets
in Photocrosslinkable Alginate Capsules
VivoRx, Inc., is developing a new treatment for diabetes that will
consist of transplanting human islets that have been encapsulated
in immunoprotective membrane consisting of a novel material.
This material protects the cells from the host’s immune response.
This technology has potential applications for liver disease, thyroid
disease, Parkinson’s disease, and Alzheimer’s disease. However,
the most immediate applicationthat examined for this studyis
for the treatment of diabetes. It will eliminate the need for daily
insulin injections and will enable patients to achieve tight glycemic
control, reducing the risk of the common complications of
diabetes.

VivoRx has tested the
effectiveness of its diabetes
treatment using islet cells
from human cadaver
pancreata. The success of
these tests has encouraged
VivoRx to take the next
step in making this
treatment widely available:
providing proliferated
human islets for transplant.

The objective of VivoRx’s ATP project is to make this therapy
widely available by producing a source of human islet cells.
VivoRx is developing the culture conditions and methods for
proliferating human islets. They are simultaneously perfecting the
polymers and biomaterials that are required to achieve
immunoprotection and biocompatibility for the encapsulation
technology.
The application will involve an outpatient procedure and a local
anesthetic. Proliferated, encapsulated human islet cells are injected
into the peritoneal cavity. The procedure will be repeated once per
year or perhaps once every 2 years to replenish the cells. The dose
and frequency of treatment have not yet been finalized but will be
determined during the current Phase I/Phase II trials.
If successful, the procedure will allow patients to achieve close to
normal glycemic control, virtually eliminating many of the risks of
long-term complications of diabetes, including retinopathy,
nephropathy, and renal disease.

1.3.5

Fabrication of Clinical Prosthesis from Biomaterials
Tissue Engineering, Inc., developed materials and methods for
replacing damaged or dysfunctional tissues and organs in the body.
The replacement “prostheses” are designed to provide templates
that mobilize the body’s own cells and induce them to rebuild the
lost tissue, gradually replacing the prosthesis itself. Regeneration of
body parts requires a biomaterial with the specific structure, or
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“microarchitecture,” and the proper chemical signals and
components that the body’s tissue cells can recognize, respond to,
and remodel.
The objective of Tissue Engineering’s ATP project was to further the
development of its new class of biomaterials that provides the
needed structure. ADMAT, or animal-derived extracellular matrix,
provides an ordered, three-dimensional structure that can be used
to support tissue regeneration. The material can be spun and
woven into fibers, or formed into films, foams, and sheets using
techniques borrowed from the fabric industry. With ATP funding,
Tissue Engineering developed its basic ADMAT materials
technology to be able to produce a variety of ADMAT forms,
characterized the necessary properties of the ADMAT substrate to
promote cell growth and differentiation, characterized ADMAT for
immunogenicity, and developed cell banks to support five types of
proposed cell-incorporating prostheses.
ADMAT can be used for
vascular grafts, ligament
and tendon repair, and
peridontal and similar
reconstruction.

ADMAT can be used to enhance collagen scaffolds for vascular
grafts, ligaments, tendons, periodontal tissue, and similar
reconstructions. ADMAT alone can be used as a matrix on which
“glandular” cells such as insulin-producing cells, nerve cell
precursors, thyroid cells, and others can grow and function. At the
time of our survey, a likely early commercial application was
thought to be reconstruction of ligaments, tendons, and articular
cartilage. A specific sub-class of those therapies is the application
of ADMAT to repair the anterior cruciate ligament (ACL), which is
the application modeled for this project.
Banked tissue for repairing ACLs is in short supply, and the lack of
uniformity and predictability of this banked tissue leads to a high
failure rate. If the repair is accomplished by removing a portion of
the patient’s own patella tendon, the patient’s patella is weakened.
Thus, the new technology will improve the quality of life for
patients who suffer from ACL injuries.

1.3.6

Application of Gene Therapy to Treatment of
Cardiovascular Diseases
Progenitor, Inc.’s, original premise for its ATP project was to exploit
the versatility of primitive stem cells as the basis for treating a range
of ailments anchored in endothelial cells, which form blood vessels
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that make up the circulatory system. Endothelial cells are thought
to be common culprits in the emergence and development of
vascular-based diseases and medical crises, among them
hypertension, hardening of the arteries (atherosclerosis), heart
attacks (ischemia), and strokes. The present set of medical
treatments for these conditions is limited.
Progenitor’s first
application of its discovery
will be the diagnosis,
location, and staging of soft
tissue cancer metastases.
The resulting improvement
in diagnosis of these
metastases will allow more
effective cancer therapy.

Thus, one of the original goals of the project was to develop a
supply of transplantable endothelial cells from precursor stem cells
that can be genetically engineered or otherwise modified for
specific medical purposes. Progenitor originally envisioned that
this particular project goal would result in using these cells to
repair damaged vascular tissue, with the most immediate
application being the treatment of damage associated with
coronary angioplasty.
Other potential medical application areas originally identified by
Progenitor and included in the R&D were cancer treatments and
bone development. In the course of its research, Progenitor
discovered a molecule that provided an opportunity to strengthen
the goals and activities related to cancer treatments. However,
research continues in evaluating the utility of the molecule in
vascular biology, oncology, and bone development.
This molecule plays an important role in the growth, differentiation,
and proliferation of endothelial cells. Progenitor believes that
eventually this discovery will lead to a new treatment for solid
tumor cancers. However, its most immediate application is the
diagnosis, location, and staging of soft tissue metastases. The
resulting improvement in diagnostic techniques will allow for more
aggressive, effective cancer therapy at an earlier stage of metastasis,
improving patients’ prognosis.
Currently no technologies image soft tissue adequately to diagnose
metastasis at a very early stage. Thus, Progenitor’s product will not
replace any current technologies but will supplement the current
diagnostic techniques.

1.3.7

Universal Donor Organs for Transplantations
Alexion Pharmaceuticals’ ATP project offers an approach to solving
the shortage of donor organs for transplantation. Wider use of
organ transplants could offer many patients significant
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improvement in the quality and duration of their lives while
improving the cost-effectiveness of treatment. Patients with
prolonged waiting times are at risk for end-organ deterioration,
have an increased risk of transplant failure, or may die before a
donor organ becomes available (Mehta et al., 1995).
The single biggest roadblock to broader, more effective use of organ
transplants is a severe shortage of donor organs. As long as we are
restricted to allogeneic (human-to-human) transplants, the shortage
is likely to continue. Xenogeneic transplants—transplants from
other animals—are one possible solution. In most cases,
xenogeneic transplants fail because of hyperacute rejection (HAR),
which causes graft failures within minutes to hours.
The immediate availability
of UniGraft organs would
change the use of organ
transplantation by
Z eliminating long
waiting times for
donor organs and the
associated negative
medical effects,
Z

allowing surgeries to
be scheduled
optimally,

Z

eliminating the cost of
maintaining a
recipient in the
hospital while
awaiting a donor
organ, and

Z

eliminating the need
to keep a donor alive
on life support.

1.4

The objective of Alexion’s ATP project is to develop transgeneic
animals that express key human genes to eliminate the HAR
response. They plan to develop organs, called UniGraft organs,
from transgeneic pigs.
Although the transplant procedure for a UniGraft organ would be
identical to that used to transplant a human organ, immediate
availability of needed organs would dramatically change the
process of transplantation. Surgeries could be scheduled at the
time that is optimal for the patient, eliminating the costs of
maintaining a recipient in the hospital while awaiting an organ. If
UniGraft transplants replaced human transplants, they would also
eliminate the need to keep a donor alive on life support until the
removal surgery can take place. The costs to transport organs to
the patient would also decrease.
Although Alexion’s technology may enable the xenographic
transplant of hearts, kidneys, lungs, and islets, we modeled the
medical and economic benefits of transplanted xenogeneic hearts
only. This analysis illustrates the potential benefits of xenogeneic
transplants for other organs.

SUMMARY OF SPECIFIC FINDINGS
In this section, we summarize the results of our analysis of the
social return on public investment, the social return on investment,
and the private return on investment for the seven ATP projects
described in Section 1.3. We also provide an analysis of the
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observed variations in the estimates of project returns, assessing
why some projects provide higher expected returns than others,
given the methodology and assumptions used in this project. In
addition, we discuss some of the limitations of the model and the
analysis.
1.4.1
The composite social
return on public investment
represents the returns on all
of the projects taken
together.

Summary of Results
Table 1-2 shows the expected social return on public investment
for each of the ATP projects examined in this study and for all of
the projects taken together (the composite). These projects
demonstrate a wide range in net present value and internal rate of
return; as a group, they generate over $34 billion in social return
on public investment and an IRR of 116 percent annually over 20
years. These results mean that the ATP funding invested in these
projects provides a net benefit of over $34 billion dollars in
expected net benefits to the nation.

Table 1-2. Expected Social Return on Public Investment:
ATP Projects in Tissue Engineering for a Single Preliminary Application

Project Time
Horizon

ATP Project

NPV
(1996$ millions)

IRR
(%)

Stem Cell Expansion

1992 to 2009

$47

21%

Biopolymers for Tissue Repair

1994 to 2009

$98

51%

Living Implantable Microreactors

1994 to 2009

$17,750

148%

Proliferated Human Islets

1995 to 2008

$1,297

34%

Biomaterials for Clinical Prosthesis

1993 to 2010

$15,058

128%

Gene Therapy Applications

1995 to 2011

$945

111%

Universal Donor Organs

1995 to 2011

$783

92%

Compositea,b,c,d

1992 to 2011

$34,258

116%

aThe

composite measure of return is based on a sum of expected benefits and costs in each year across all projects.

bThe

time period for the composite measure includes all years from all the individual project periods.

cThe

composite NPV is not a simple sum of individual NPV because the time periods are different.

dThe

composite IRR is not an average of the individual project IRRs because IRR is not additive.

Table 1-3 compares expected social return on public investment to
expected social return on investment for each project. This
comparison provides perspective on the importance of ATP funding

1-21

A Framework for Estimating the National Economic Benefits of ATP Funding of Medical Technologies

Table 1-3. Social Return on Investment and Social Return on Public Investment:
ATP Projects in Tissue Engineering for a Single Preliminary Application

Expected Social Return
on Investment
NPV
(1996$ millions)

ATP Project
Stem Cell Expansion

IRR
(%)

Expected Social Return
on Public Investment
NPV
(1996$ millions)

IRR
(%)

$134

20%

$47

21%

$98

51%

$98

51%

$74,518

149%

$17,750

148%

$2,252

36%

$1,297

34%

$32,855

118%

$15,058

128%

Gene Therapy Applications

$2,411

106%

$945

111%

Universal Donor Organs

$2,838

91%

$783

92%

$109,229

115%

$34,258

116%

Biopolymers for Tissue Repaira
Living Implantable Microreactors
Proliferated Human Islets
Biomaterials for Clinical Prosthesis

Compositeb
aFor

Biopolymers, the two sets of figures are identical because all of the social return can be attributed to ATP
investment.

bSee

notes to Table 1-2 for an explanation of the derivation of the composite measure of return.

in catalyzing the social return on investment. As demonstrated by
the composite return, ATP funding is responsible for inducing
about 31 percent of the total social returns from all of these
projects over 20 years. For the individual projects, the effect of
ATP on social returns ranges from about 25 percent to 100 percent
of the social returns.
Social returns to these projects can vary with respect to the number
of patients treated, the value of the health benefits of the new
technology, their impact on health care costs, and the probability
of technical success. For example, our models of the applications
for “Stem Cell Expansion” and “Biopolymers for Tissue Repair”
include health care cost savings but no health benefits.2 The
projects “Living Implantable Microreactors” and “Proliferated
Human Islets” provide similar health benefits but differ with respect
to their impact on health care costs and their probability of
technical success.

2As explained in Chapter 3, these technologies both provide potential health

benefits; however, we were not able to obtain data to quantify these benefits.
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To demonstrate the pathways by which ATP funding induces this
increase in social returns, Table 1-4 shows how ATP funding affects
the three channels of social returns identified earlier. Recall that
ATP might affect the development of medical technologies by
accelerating the technology’s benefits, increasing the probability of
success, or widening the technology’s applications. Table 1-4
shows the magnitude of these impacts for each project. As
explained in Chapter 3, the acceleration effect contributes about
81 percent of ATP’s impact on social returns.
Table 1-4. Impact of ATP Funding on the Development of Medical Technologies for Seven
Tissue Engineering Projects

ATP Project
Stem Cell Expansion
Biopolymers for Tissue Repair

Project
Accelerationa
(years)

Increase in the
Probability of Success
(percent)

Widening of
Technology
Applicationsb

1 to 2

9%

None reported

At least 10

171%

Significant but not
quantified

2

11%

None reported

3 to 5

2%

None reported

Biomaterials for Clinical Prosthesis

2

1%

None reported

Gene Therapy Applications

2

20%

Some effects reported but
not quantified

1 to 2

16%

None reported

Living Implantable Microreactors
Proliferated Human Islets

Universal Donor Organs

aThis is the number of years of acceleration reported by the ATP-funded companies. For the 2-year ranges, we used

the lower number for our analysis. For the 3-year range, we used the midpoint of the range.
bOur model allows conceptually for ATP funding to widen the scope of a project. In practice, for the applications

examined in this study, there was little or no impact in all but two cases, which we did not quantify.

Clearly, ATP has the greatest impact on social returns for the
second project, “Biopolymers for Tissue Repair.” ATP accelerates
the benefits from this project by at least 10 years, has a significant
impact on the probability of success, and affects the scope of the
project. According to company officials, in the absence of ATP
funding, the company might not have developed this technology at
all or might have developed it so slowly that the market
opportunity for this technology would have passed before it was
ready for commercialization. Although the impact of ATP is less
dramatic for the remaining projects, it is clear that two of the three
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possible mechanisms by which ATP affects the R&D process are
important in increasing social returns.
Table 1-5 shows the composite private return on investment for all of
the ATP projects in tissue engineering.3 The composite NPV is about
$1.5 billion, and the impact of ATP funding on private returns is
equal to about $914 million.
Table 1-5. Composite Private Returns:
ATP Projects in Tissue Engineering for a Single Preliminary Applicationa

Project returns
Increment attributable to ATP
aSee

NPV (1996$ millions)

IRR (%)

$1,564

12%

$914

13%

notes to Table 1-2 for an explanation of the derivation of the composite measure of return.

The wide disparity between social and private returns indicates the
importance of ATP incentives to the private sector to pursue these
technologies. Because the social returns far outweigh the returns to
the companies developing, commercializing, and producing these
technologies, the private sector may underinvest in these kinds of
high-risk projects. Hence, ATP funding serves to provide the
incentives needed to stimulate the private sector’s investments in
these activities.
1.4.2

Sources of Project Variations
Tables 1-2 through 1-4 demonstrate a wide variation in the social
return on public investment and in the social return on investment,
in terms of both the NPV and the IRR. Some reasons for this
variation include the following:
Z Breadth of applications: Technologies that apply to more
patients and diffuse more quickly throughout the patient
population have a greater expected social return on
investment.
Z Significant health benefits: Technologies that lead to more
significant improvements in the health of patients over and
above the defender technology have a greater expected
social return on investment.
3Although we calculated the private returns for each project, we do not disclose

them to preserve the confidentiality of proprietary information.
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Z Cost-effectiveness: Technologies that offer health care
improvements at relatively lower costs provide greater
expected social return on investment.
Z Technical success: Technologies with a greater expected
probability of technical success have a higher expected
social return on investment.
The impact of ATP funding on the magnitude of social returns also
varies from one project to the next. The primary factors affecting
these differences, as demonstrated above, include
Z ATP impact on project timing: The number of years by
which ATP funding accelerates the R&D phase of the
project has an important impact on social returns.
Conditions that lead to high estimates of the acceleration
effect from ATP funding include the absence of alternative
capital sources and the risk of the project, as perceived by
the company and its potential sources of capital.
Z ATP impact on R&D funding and the probability of
technical success: The impact of ATP funding on the total
R&D investment has an important effect on the social return
on public investment because it affects the project’s
expected probability of technical success. The impact of
ATP funding depends on the company’s motivation and
ability to pursue the project in the absence of ATP funds.
For all but two projects, ATP stimulated increases in R&D
investment enough to make a significant difference in the
probability of technical success.
Z ATP impact on project scope: If ATP funding encourages
the company to pursue additional applications and patient
populations, the social return on the public investment will
increase. We did not explicitly model any scope effects for
the projects we examined. However, our study investigated
only one application of each of the technologies studied.
The scope effects may be evident in the number of
applications in which the technology is eventually used.
1.4.3

Methodological Limitations
The results of this study are subject to a number of methodological
limitations and assumptions that may affect the results. Some of the
limitations of our analysis include
Z analyzing only a single application of each technology,
Z omitting the value of some medical benefits that could not
be quantified, and
Z basing assumptions about costs and benefits on the
expectations of informed individuals.
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Single-Application Analysis
The study analyzed only one application for each project. Because
these technologies provide basic scientific platforms for many
applications, their long-term impact may be much greater than
suggested here, as companies apply their discoveries to a wide
variety of medical applications. In addition, the knowledge
generated by these initial applications may lead to advances in
additional, unrelated areas by other companies.
Limitations of the Health Benefits Models
The models we used to quantify the health benefits of these
technologies have limitations that may affect the results of the
study. In some cases, the medical benefits per patient did not
consider some effects that we could not quantify, usually because
the required data were not available. For example, although
Integra LifeSciences believes that its fracture fixation devices will
improve healing, clinical data to support an assessment of that
improvement are not available. Similarly, some of the cost savings
may be underestimated because of our inability to quantify them.
For example, we could not quantify the cost impact of changes in
intermediate health states resulting from the two new diabetes
treatments.
The economic burden of a disease is usually divided into three
components: direct medical costs, indirect costs, and intangible
costs. Direct medical costs are the total cost of medical treatment.
Indirect costs are the societal costs associated with the loss in
productivity due to illness and unpaid caregiver time. Intangible
costs measure the patient’s pain and suffering. Because we
measured the health benefits of these technologies in terms of
QALYs, our estimates capture how ATP-funded technologies
change both the direct medical costs and the intangible costs of a
disease. However, they may not capture changes in the indirect
costs. Improvements in the health of a patient population with a
particular illness or injury may reduce the indirect costs of the
disease, allowing those receiving an improved treatment to lead
more productive lives. These benefits to society may not be
captured by QALYs.
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Data Limitations
Because none of these technologies have yet reached the
commercial marketthough several are in clinical trialsthe
results of this analysis are based in part on the expectations of the
innovators and other informed individuals. We do not know at this
time whether these expectations will be realized. However, the
methodology we employed can be used to update our estimates as
better data on the actual costs and benefits of the projects become
available.

1.5

CONCLUSIONS
The primary objective of this project was to develop a
methodology for estimating the expected social economic returns
on public investment in ATP-funded projects with medical
applications. To address the specific methodological challenges
presented by new medical technologies, we used a currently
accepted framework for calculating private and social returns,
incorporating nonmarket methods for valuing the benefits of these
technologies to patients.
The second objective was to illustrate this methodology by
applying it to seven ATP-funded projects in tissue engineering. We
have demonstrated that this methodology is useful for analyzing
ATP-funded medical technologies, particularly under the following
conditions:
Z One or several primary applications are apparent.
Z The health outcome and resource cost differences between
the new and defender technologies can be quantified (e.g.,
because some clinical trials or other studies have produced
the required data).
Z The impact of changes in health outcomes on patients’
well-being has been quantified by other studies (e.g.,
QALYs for health outcomes or health states are available).
Z The market potential for the new technology is apparent.
Z The technology is sufficiently close to commercialization to
enable company representatives to project the costs of
commercialization and production.
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Aside from medical
technologies, this
methodology is also
applicable to other
situations in which
the technology
affects goods and
services whose
values are not
adequately reflected
in market prices.
For example,
technologies that
improve
environmental
quality or reduce
the crime rate
provide benefits that
are not traded in
traditional markets.

Aside from medical technologies, this methodology is also
applicable to other situations in which the technology affects goods
and services whose values are not adequately reflected in market
prices. For example, technologies that improve environmental
quality or reduce the crime rate provide benefits that are not traded
in traditional markets. Nonmarket valuation methods are required
to quantify these kinds of social benefits. As in this study, valuation
of these social benefits requires the methodology used in
determining the beneficiaries’ willingness to pay for these
improvements.
The third objective of this project was to estimate the social return
on public investment in seven ATP projects chosen for the case
studies and to estimate the impact of ATP funding on these returns.
This analysis yielded the following findings:
Z The expected social return on ATP public investment in
these technologies, or the increment to social returns
attributable to ATP funding, is estimated at $34 billion in
net present value.
Z The expected social rate of return on ATP public investment
in these technologies is estimated at an annual rate of
116 percent.
Z The expected total social return on public and private
investment in these technologies is estimated at $112 billion
in net present value, or an annual rate of 115 percent.
Z The expected total private return on investment in these
technologies to ATP-award companies and their partners in
commercialization and production is estimated at
$1.6 billion in net present value, or an annual rate of
12 percent. Of the $1.6 billion in net present value of
private returns, $914 million is estimated to be attributable
to ATP funding.
Z To the extent that the technologies will yield applications in
addition to those we investigated, it is likely that public and
private returns on these projects will be higher.
These results illustrate two important points about the role of ATP
in funding these technologies:
Z ATP plays a significant role in increasing the expected
social and private returns on these projects.
Z The social returns are far greater than the private returns.
Private companies will therefore tend to underinvest in
these technologies relative to what would be optimal from
society’s perspective. The wide disparity between social

1-28

Chapter 1 — Overview

and private returns indicates the importance of ATP’s
incentives to the private sector to pursue these technologies.
Our final objective was to provide insight regarding the factors that
affect the social return on public investment in projects with
medical applications. We found that three primary factors affect
the extent to which ATP funding influences social returns:
Z the number of years by which ATP funding accelerates the
R&D phase of the project;
Z the impact of ATP funding on the probability of technical
success; and
Z the impact of ATP funding on the scope of the project.
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Methodology
Our approach to modeling the social and private returns to ATP
funding in medical technologies is based on the methodology
recommended by Mansfield (1996). We modify Mansfield’s
methodology for the specific case of medical innovations. In
particular, we use nonmarket methods to value the benefits of new
medical treatments.
Our methodology focuses on evaluating the social return on public
investment for ATP-funded projects. Determining the social return
on public investment requires that we estimate social return on
investment under two scenarios: one with ATP funding and one
without ATP funding. As described in Chapter 1 and illustrated in
Figure 1-1, we developed the two scenarios by constructing
timelines of costs and benefits, including
Z medical benefits to patients,
Z changes in the cost of health care,
Z revenues to companies,
Z private investment and costs, and
Z public investment in ATP funding.
The with-ATP scenario and the without-ATP scenario can differ
with respect to three mechanisms of ATP impact:
Z project acceleration,
Z probability of technical success, and
Z project scope.
This chapter provides additional detail regarding our methodology
for constructing the two scenarios and calculating measures of
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economic return. Section 2.1 describes how we constructed the
timelines of investments and benefits from ATP-funded
technologies. Section 2.2 describes how we modeled the impact of
ATP on the benefits of ATP-funded technologies. Sections 2.3, 2.4,
and 2.5 discuss estimation of the three main components of social
returns:
Z medical benefits to patients,
Z changes in the cost of health care, and
Z costs and revenues to private companies.
In Section 2.6, we discuss how we calculated measures of social
and private returns once the two scenarios of benefits and costs had
been constructed. Section 2.7 discusses the limitations of the
methodology and suggests improvements.
This chapter does not discuss the details of applying this
methodology to each of the seven tissue engineering projects
analyzed for this study. That discussion, together with the results of
the analysis, is provided in Chapter 3.

2.1

THE TIMELINE OF R&D INVESTMENT COSTS
AND BENEFITS
One of the first challenges to modeling the social return on public
investment for ATP projects with medical applications was to
develop assumptions about the timing of the benefits and costs of
the new technology. The timing of these benefits and costs is
important because benefits and costs that occur earlier are more
valuable than those that are delayed. This is the basic principle of
discounting.

Discounting involves
adjusting the values of
future benefits and costs to
render them comparable to
the values placed on
current benefits and costs.
With discounting, the
timing of benefits and costs
becomes an important
determinant of economic
returns.
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Investments in new technology often do not result in benefits to
society or private companies for a number of years. The cycle of
investment and benefits for a product or service based on a new
medical technology typically consists of three phases:
Z R&D phase,
Z commercialization phase, and
Z production phase.
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These three phases of the innovation process, which are illustrated
in Figure 2-1, are not always sequential. However, this stylized
classification mirrors the typical evolution of a biotechnology
company. Early in the company’s evolution, R&D activities—
applying resources and scientific principles toward solving a
technical problem—are the primary focus. In the
commercialization phase that follows, the company invests in sales,
marketing, and manufacturing infrastructure. These activities bring
the results of R&D in the form of specific technology applications to
the market. Product sales revenues become significant in the
production phase as the company produces the product or service
that embodies the innovation (Burill and Lee, 1992).1 Companies
and society realize the benefits of investments in R&D in this final
phase.
Figure 2-1. The Timing of Costs and Benefits from Investments in New Technologies
Net
Benefit
($)

Social
Returns

Private
Returns

+

0
t+10 Years
Private
Investment

Public
Investment

R&D

Commercialization

t

Production

1We are speaking of the company narrowly as the business unit developing the

new technology, under the assumption that it produces no other products.

2-3

A Framework for Estimating the National Economic Benefits of ATP Funding of Medical Technologies

2.1.1

The R&D Phase
During the R&D phase, firms invest in R&D to increase the
probability of success on the project. Strategic R&D investment
models, such as those presented in Beath, Katsoulacos, and Ulph
(1989); Loury (1979); and Lee and Wilde (1980), commonly assume
that the probability of success in any year is a function of the R&D
that is spent in that year.
Pr = f(R)

(2.1)

Empirical studies conducted by Griliches, Pakes, and Hall (1987)
verified the plausibility of this assumption. They found a strong
contemporaneous relationship between aggregate R&D
expenditures and patenting and an estimated elasticity of about 0.3.
This aggregate relationship may not hold for specific projects, but it
does provide guidance for our assumptions in this model.
Similarly, while patenting activity may not be a perfect indicator of
the success of a project relative to specific technical objectives, it is
an indicator of technical success. Therefore, we assume that the
relationship between R&D spending and technical success is
similar to that found in the empirical literature on the impact of
R&D on patenting.
As R&D effort increases, the probability of discovering a technically
viable solution also increases. However, the research is eventually
subject to diminishing returns; each unit of effort or successive
draw from the distribution is less likely to yield a solution that is
superior to the best of the previous draws (Binswanger, 1978).2
Thus, as shown in Figure 2-2, the marginal probability of technical
success declines with increases in R&D effort.
2.1.2

The Commercialization Phase
An innovative application proceeds to the commercialization phase
if the R&D phase has been technically successful. In the
commercialization phase there is still no revenue from product
sales. In many cases, identifying where R&D ends and
commercialization begins is difficult. The commercialization phase

2This result holds under the assumption that each draw is randomly selected. The

rate of decline of return on investment in research is greater if researchers
investigate potential solutions in order of their potential benefits.
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Figure 2-2. The Total and
Marginal Probability of
Technical Success

Probability
1

Probability of
Technical Success

The probability of technical
success increases with
R&D effort but at a
decreasing rate.

0

R&D Effort
a) Total Probability

Probability
1

Marginal Probability
0

R&D Effort
b) Marginal Probability

includes substantial investments in product development
research—for example, the research required for regulatory review
or design of a production process. The key distinction between the
R&D phase and the commercialization phase in our model is that
uncertainty relates to technical success in the R&D phase.
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Uncertainty relates to market success in the commercialization
phase.
In our model, the private
return on investment
includes spillover benefits
between the innovator and
its partners in
commercialization and
production.

2.1.3

A company that conducts R&D may retain exclusive rights to
marketing, manufacturing, and distribution; license the technology
to other companies that will retain these rights; or arrange some
other type of agreement with a partner or licensee.3 Regardless of
the method the company uses to capture the benefits of its R&D,
our definition of private returns includes the benefits and costs of
all three stages of the process. Thus, in our model, the private
return on investment includes spillover benefits between the
innovator and its partners in commercialization and production.
The rationale for this assumption is explained more fully in
Section 2.5.
The Production Phase
The production phase includes all activities involved in producing
the product or service that embodies the technology in sufficient
quantities and consistency to meet quality standards at a price
customers are willing to pay. The company incurs costs for
production and marketing and earns revenue from the sale of
products. Patients benefit from the new technology as doctors
adopt the new technology. As shown in Figure 2-1, both private
and social returns may become positive during this phase.
This phase continues until the company ceases production of the
product or service. Determining the length of the production phase
of a new technology is very difficult because it requires forecasting
the emergence of new products that may supersede the product or
service in question. We assume for this study that the company
will manufacture the good or service for 10 years following its
expected introduction to the market in the with-ATP scenario. This
is an issue of considerable empirical uncertainty. The actual length
of the production phase depends on the emergence of new
technologies that replace the technology in question. The
Committee for Evaluating Medical Technologies in Clinical Use
(1985) notes that researchers have observed a variety of patterns
regarding the abandonment of medical technologies. Ten years
seems to be a reasonable assumption in the absence of empirical
3Many choices lie between selling all rights and retaining exclusive rights.
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evidence. Empirical research about the rate of depreciation of new
technologies and the longevity of their marketability could
contribute to the accuracy of forecasts of social and private returns.

2.2

MEASURING THE IMPACT OF ATP ON
TECHNOLOGY DEVELOPMENT
In our model, differences between the with-ATP and without-ATP
scenarios include (1) the duration of the R&D phase, (2) privatesector R&D investment and its consequences for the likelihood of
technical success, and (3) breadth of the technology’s applications.
The with-ATP scenario also incorporates the cost of ATP funding.
This section explains how we modeled these three channels of ATP
impact.

2.2.1

ATP’s Acceleration of R&D
Previous studies of the impact of ATP indicate that ATP funding
accelerates R&D and product introduction (Powell, 1996; Silber,
1996). Acceleration influences net benefits in our model for two
reasons. First, future benefits are discounted, so benefits that occur
sooner are valued more than benefits that occur later. Second, a
company may have a limited window of opportunity for
introducing the new technology. Late introduction of a new
product may reduce the time period during which the product is
successful in the market because newer, competing technologies
will eventually come to market.

If ATP funding accelerates
R&D and new product
introduction, the social and
private benefits accrue for
a greater number of years.

In our model, R&D acceleration caused by ATP funding lengthens
the period of market opportunity. We assume that a newer
treatment or technology will replace the ATP-funded technology 10
years after the expected commercialization date in the with-ATP
scenario. Thus, if we expect a technology to reach the market in
2000, we assume that a new technology will take its place in 2010.
If the without-ATP scenario includes a 2-year project delay, market
introduction does not occur until 2002, but the end of the market
opportunity window is still 2010. Thus, when ATP funding
accelerates R&D by 2 years, the with-ATP scenario allows for 2
additional years of benefits.
When ATP funding accelerates the R&D process, the production
phase, during which net social benefits are positive, begins sooner
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and lasts for a longer time, so social returns are greater. In
Figure 2-3, the solid line represents the with-ATP scenario, while
the dotted line represents the without-ATP scenario. In this
example, the with-ATP R&D phase lasts 3 years, as does the
commercialization phase. In the with-ATP scenario, production
begins and benefits begin to accrue to the companies and to society
in year t. In the without-ATP scenario, the R&D spending is spread
over 5 years (total R&D may also be lower in the absence of ATP
funding). Thus, the commercialization and production phases are
delayed for 2 years, and benefits begin to accrue in year t+2.
Because we assume the window of market opportunity closes at
year t+10, the without-ATP scenario includes 2 fewer years of
benefits.
Figure 2-3. Impact of Acceleration on Social Returns
Net
Benefit
($)
Social Returns
with ATP

Social
Returns
without ATP

+

0
t+10 Years

R&D

-

Commercialization
R&D
Commercialization

t+2
t
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2.2.2

ATP’s Impact on the Probability of Success
As the probability of technical success increases, so does the
expected value of net benefits to society. We calculated the
expected value of net benefits by multiplying all costs and benefits
that occur after the R&D phase by the probability of technical
success.
In our model, ATP funding affects the probability of technical
success by increasing the level of R&D effort. ATP funding
decreases the price of R&D to the firm, thus encouraging additional
R&D effort. As R&D effort increases, so does the probability of
technical success.
The degree to which ATP funding increases the probability of
technical success depends on
Z ATP’s impact on the cost of R&D to the firm,
Z the expected marginal benefit of R&D effort, and
Z the relationship between R&D effort and the probability of
technical success.
The Firm’s R&D Investment Decision
Companies invest in R&D to produce potential future profits.
Following Binswanger (1978), we consider the R&D process a
search or sampling process in which scientists sample from a
distribution of possible solutions to the problem they are trying to
solve. This sampling process requires the firm to expend real
resources (e.g., labor services, capital services, materials). “R&D
effort” is a composite input combining these resources. Increasing
R&D effort increases the probability of finding a successful
technology, which, in turn, increases the expected value of future
profits. Firms determine the optimal level of R&D by equating the
expected marginal benefits and costs of R&D at the margin.
The function representing marginal expected benefit of R&D effort
is the firm’s input demand function for R&D. As shown in
Figure 2-4, the function is decreasing in R&D effort because of
diminishing returns to R&D effort. The firm’s optimal level of R&D
is the level at which the marginal cost of R&D effort equals the
marginal benefit of R&D, or E* in Figure 2-4.
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Figure 2-4. The Firm’s Optimal Level of R&D Effort

Benefit,
Cost
($/R&D
Effort)

C

Marginal Cost

Marginal Benefit
E*

A firm’s optimal level of
R&D effort equates the
marginal expected benefit
of R&D with its marginal
cost.

R&D Effort

ATP’s Impact on R&D Price and Investment
The marginal cost of R&D effort is the cost of one additional unit of
the composite input “R&D effort.” Assuming the components of
R&D effort are purchased in competitive markets, their unit costs
are constant to the firm, and therefore the marginal cost of R&D
effort is constant (see Figure 2-4). The profit-maximizing firm will
choose the level of R&D effort at which the expected marginal
benefit equals the marginal cost.
ATP funding reduces the marginal cost of R&D effort to the firm.
Suppose that a dollar of R&D spending represents a composite unit
of R&D effort, and that in the without-ATP scenario, the marginal
cost of each unit of R&D effort is $1. If, in the with-ATP scenario, a
company receives $1 in ATP matching funds for every dollar it
invests in the project, then the marginal cost of R&D is reduced by
50 percent to 50 cents. As shown in Figure 2-5, the reduction in
the price of R&D increases the firm’s optimal level of R&D effort
from E1 to E2.
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Figure 2-5. Impact of ATP Funding on R&D Effort

Benefit,
Cost
($/R&D
Effort)

C1

Without ATP

C2

With ATP

Marginal Benefit

E1

E2

R&D Effort

The impact of a change in the marginal cost of R&D effort on the
quantity of R&D effort depends on the elasticity of the marginal
benefits function:
∂lnE
= ε,
∂lnC

Unless the expected
marginal benefits
curve is completely
inelastic (vertical),
ATP funding must
increase the total
quantity of R&D
effort.

(2.2)

where ε is the elasticity of the marginal benefits curve, E is R&D
effort, and C is the marginal cost of a unit of R&D effort. Thus, if
we know the elasticity of the marginal benefit function and the
change in the marginal cost of R&D effort due to ATP funding, we
can determine the change in R&D effort. Because $1 of R&D
spending represents a composite unit of R&D effort, the resulting
change in R&D effort is equal to a change in R&D spending on the
project.
The marginal benefit function is elastic if ε < -1; it is inelastic if
-1 < ε < 0, and completely inelastic if ε = 0. As long as ε is not
equal to zero, a decrease in the price of R&D will lead to an
increase in R&D effort. That is, unless the expected marginal
benefit curve is completely inelastic (vertical, with an elasticity of
0), ATP funding must increase the total quantity of R&D effort.
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The elasticity of a project’s marginal benefit function is difficult to
estimate. Because no empirical estimates of the marginal benefit
function or its elasticity were available for the tissue engineering
projects we analyzed, we made the following assumptions about
the elasticity of the marginal benefits curve based on our interviews
with the companies:
Z For companies that indicated a significant reduction in the
funding for the project in the absence of ATP, we assume
that their marginal benefit function is elastic with a value
of -2.
Z For companies that indicated that in the absence of ATP
they would have proceeded with the project but under
some possible funding constraints, we assume that their
marginal benefit function is relatively inelastic with a value
of -0.5.
Z For companies that told us that the absence of ATP funding
would have made little or no difference in the project's
funding level, we assume that the cost of R&D was
immaterial to their decision to proceed with the project and
that the elasticity of the marginal benefit function is -0.01.
Chapter 3 explains our assumptions for each company.
R&D Effort and the Probability of Technical Success
In our model, increases in R&D effort induced by ATP funding lead
to increases in the probability of technical success. In keeping with
the empirical literature discussed in Section 2.1, we assume that the
elasticity of the probability of technical success, Pr, with respect to
R&D effort, E, is equal to 0.3. Thus,
∂lnPr
= 0.3.
∂lnE

(2.3)

This assumption allows us to estimate the difference between the
with-ATP and without-ATP probability of technical success.
2.2.3

Widening the Scope of an ATP Project
ATP funding can also widen the scope of a project. Additional
resources from ATP funding may make it possible for a company to
consider additional applications of a technology or, for a given
application, expand the scope of research to include a wider
patient population. For example, additional research may adapt a
treatment for special populations such as children or the elderly.
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If ATP funding encourages a company to consider additional
applications or patient populations, the with-ATP scenario should
include the additional health benefits and costs. These increases in
scope may increase both private and social returns.

2.3

EVALUATING MEDICAL BENEFITS TO
PATIENTS
ATP-funded medical technologies may improve the long-run health
outcomes of thousands of patients per year with acute and chronic
diseases. They may also reduce the cost of health care. The
magnitude of the total health benefits of a new technology depends
on the benefit per patient and the number of patients that will be
treated.

2.3.1

Valuing Per-Patient Changes in Health Outcomes
To derive an estimate of the per-patient value of changes in health
outcomes attributable to new medical technologies, we followed
three steps:
Z Step 1: Model the technology’s impact on health outcomes
Z Step 2: Quantify changes in health outcomes in terms of
patient well-being
Z Step 3: Determine the monetary value of patient changes in
well-being
Modeling Differences in Health Outcomes
ATP supports technologies that are likely to have many
applications. Each technology usually has an immediate
application that is most likely to develop in the short term, as well
as applications that will probably develop later. The earlier
applications may be easier to analyze because the data regarding
their impacts on health outcomes, resource use, the timing of their
diffusion, and costs are more readily available and more reliable
than data regarding later and more uncertain applications.
For this study, we analyzed one application for each
technologythe application that the companies believe has the
greatest chance of near-term commercialization. However, later
applications may also have a significant welfare impact; our
inability to model these later applications probably results in an
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underestimation of the social and private returns on investments in
ATP-funded technologies.

The defender
technology is the
most widely used
current treatment
technology for the
specific application
of interest.

Mansfield (1996) emphasized the importance of clearly identifying
the alternative technology when estimating the returns on
investments in new technologies. For this study, the alternative to
the new medical technologythe defender technologyis the
current treatment technology for the specific application of interest.
Identifying a single defender technology for each application may
lead to either understatement or overstatement of the benefits of the
new technology. For some diseases or injuries, the appropriate
defender technology may depend on the patient’s age or medical
condition. The less uniform the current treatment for each
application, the more serious the implications of assuming that a
single defender technology applies to all patients. In some cases,
dividing the patient population into different groups according to
the most appropriate defender technology may improve the
accuracy of the results.
After identifying the technology’s application and its defender
technology, we modeled the health benefits of each application.
Some ATP-funded medical technologies affect the long-run health
outcomes of patients with chronic diseases that progress over time.
Other medical technologies affect acute illnesses and injuries
whose outcomes occur in a single period.

The chronic disease model
quantifies the impact of a
new technology on the
progression of a chronic
disease over time. The
acute illness and injury
model quantifies the
impact of a new
technology on the health
outcome of an acute illness
or injury.
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We developed two basic models to capture these possibilities: the
chronic disease model and the acute illness and injury model. The
chronic disease model incorporates a Markov probability matrix
that contains the probabilities that patients transition from one
health state to the next over time. The acute illness and injury
model, which is actually a single-period case of the chronic disease
model, is similar to the traditional decision-tree framework
commonly used to assess the impact of health interventions.
Chronic Disease Model. The chronic disease model, illustrated in
Figure 2-6, employs a multiple-step process that is repeated in each
year beginning with the first year in which the technology is
available. The model calculates benefits of the new treatment
technology for patients receiving the new treatment over the
remainder of patients’ lives.
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Figure 2-6. Chronic Disease Model of Health and Cost Impacts of New Technologies
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In the first step, the patients are allocated between the defender
technology and the new technology. The market forecasting
model, described in Section 2.3.2, determines this allocation.
In the second step, the patients are allocated among the health
states associated with the disease. If there are k health states, then
the number of patients in each health state in the first year defines a
vector y1 for the defender technology and z1 for the new
technology where the subscript 1 refers to the first year.
Each health state is associated with a quality-adjusted life-year
(QALY) value and a treatment cost. We discuss QALYs below and
treatment costs in Section 2.4. The vector of QALYs associated
with each health state is q, and the vector of costs associated with
each health state is c. The total annual QALYs for all patients
treated with the defender technology in the first year is y1’ q; the total
cost is y1’ c. For patients treated with the new technology, the
annual QALY and cost totals are z1’ q and z1’ c, respectively.
The chronic disease model
quantifies differences
between the new and
defender technologies with
respect to
Z the proportion of
patients in each health
state and
Z

the patient’s
probability of moving
from one health state
to the next.

It also incorporates the
expected penetration of the
new technology.

The transition probability matrix, X, for the defender technology
and W, for the new technology, specify the probabilities of
transitioning from one health state to another. For example, x12 is
the probability of moving from health state 1 to health state 2 while
being treated with the defender technology. X and W are two
separate matrices because the transition probabilities can differ
between the new and defender technologies.
At the end of each year, the vector of health states is multiplied by
the transition probability matrix to determine the distribution of
patients among health states at the beginning of the next year.
Differences between X and W cause differences between the future
health states of patients who are treated with the new technology
and patients who are treated with the defender technology. These
differences between future health states cause differences between
the total QALYs and treatment costs for the new technology and
those of the defender technology.
At the end of each year, some proportion of patients in the defender
technology cohort is switched to the new technology. This
proportion, together with the transition matrices, determines the
allocation of patients among health states the next year for both the
new and defender technology.
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Acute Illness and Injury Model. Acute illnesses and injuries do not
progress over time. The acute illness and injury model has many of
the same elements as the chronic disease model, but it is much
simpler: it is essentially a one-period chronic disease model.
Figure 2-7 illustrates how a decision between the new and defender
technologies leads to differences in the probability of health
outcomes and also associated costs and benefits. The open square
node represents the point at which a decision must be made
between the new and defender technologies. Each branch
following the decision node is associated with a choice of
treatment technology and a treatment cost. For each technology,
an open circle represents a chance node. Each branch following
the chance node represents the outcomes associated with the
illness or injury; each outcome is characterized by a probability, a
QALY, and a cost.
Figure 2-7. Acute Illness and Injury Model of Health and Cost Impacts of New Technologies

Health Outcome 1
Health Outcome 2
New Technology
Health Outcome 3
Health Outcome 4
Patient
Cohort

Health Outcome 1
Health Outcome 2
Defender Technology
Health Outcome 3
Health Outcome 4
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The acute illness and injury
model describes how the
new and defender
technologies leads to
different health outcomes
and their associated QALYs
costs.

The model calculates expected benefits and costs for each
technology by multiplying the probability of each health outcome
by the associated QALYs and costs. We compared the expected
benefits and costs of the two technology choices to determine the
net benefit of the new technology.
Model Data. Below, we describe the data required to implement
the health benefits models.
Patient Cohorts. The chronic disease model examines a single
cohort of patients and analyzes how this cohort transitions through
time from one health state to the next. The patient cohort is
defined as the number of people diagnosed with the relevant
disease.

For most chronic diseases,
the number of newly
diagnosed patients is small
compared to the pool of
patients in any given year.
For example, in 1996, the
number of patients who
could benefit from a new
treatment for diabetes was
1.6 million. The number of
new patients that enter this
cohort each year is
approximately 90,000.
Thus, by following only the
patients included in the
first cohort, we
underestimated the
benefits, but by a small
amount compared to the
total benefits.

Some patient populations change each year as some patients die or
experience other changes in health status that remove them from
the relevant population, while other patients are newly diagnosed.
To simplify the model, we analyzed a constant patient cohort and
did not add newly diagnosed patients in later years. The number of
new patients is probably small relative to the total pool of patients
at any one time. Thus, although the model ignores the benefits to
the newly diagnosed patients, the effect is probably relatively small.
This methodology parallels common practice in clinical trials of
new drugs and treatments (DCCTRG, 1996).
In the acute illness and injury model, the relevant patient
population is defined somewhat differently. Because acute illnesses
and injuries do not progress over time, it is not necessary to track a
cohort’s changes in health states. Therefore, the patient population
is the number of patients diagnosed with the particular injury or
illness in that year.
Information about the size of various patient populations is
available from medical databases provided by medical research
organizations, such as the American Diabetes Association, the
American Heart Association, the United Network for Organ
Sharing, and the National Institutes of Health.
Health States. The chronic disease model allocates patients among
the health states associated with the disease. For example, the
health states associated with the nephropathy resulting from
diabetes include no nephropathy, microalbuminceria,
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albuminceria, and end-stage renal disease. The initial allocation is
based on information from medical databases about the share of
patients in each health state at a given time. The transition matrix
and the switching probabilities from the model determine
allocations of patients across health states in subsequent years.
The acute illness and injury model requires specification of final
health outcomes rather than transitional health states, as in the
chronic disease model. The acute illness and injury model assumes
that a health outcome is permanent. For example, if an injury and
subsequent treatment leave a patient with impaired function of a
hand, the patient experiences this health outcome throughout life.
The differences between
the new technology
transition matrix and the
defender technology
transition matrix reflect the
impact of the new
technology on the
progression of the disease.

Transition Probabilities. The transition matrices X and W in
Figure 2-6 specify probabilities for transitions from one health state
to another. When a new technology affects the probability of
progressing from one health state to another, the transition
probability matrices differ between the new and defender
technologies.
The acute illness and injury model is a special case of the chronic
disease model in which there is only one period. In the acute
illness and injury model, a vector of health outcome probabilities
specifies a probability for each health outcome. This vector may
differ between new and defender technologies.
Transition and health outcome probabilities may be difficult to
obtain. For the defender technology, transition and outcome
probabilities may be available from medical studies of the
effectiveness of the treatment. For the new technology, if no
clinical trials have been completed, the only source of transition
and health outcome probabilities may be the expectations of
representatives of the companies conducting the research.
Switching Probability. For the chronic disease model, the
switching probability specifies the proportion of patients switched
from the defender technology in each year. The switching
probability is derived from a technology diffusion model that we
estimate. The diffusion model is described in Section 2.3.2.
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Quantifying Changes in Patient Well-Being
The changes in health states or health outcomes identified by the
acute and chronic disease models affect patient welfare. The
economic concept of individual welfare is “utility,” which is the
individual’s subjective sense of well-being associated with a
particular action or condition. Our health benefits models
incorporate QALYs as a measure of patient utility. This section
describes QALYs and why they are appropriate measures of
welfare. Then it discusses how health researchers determine QALY
values for different health states or health outcomes.
Quantifying Utility. Although utility is generally regarded as the
proper conceptual measure of individual welfare, it is
unobservable. An empirical surrogate is needed to provide a
cardinal measure of the value of the health benefits identified by
our models. The observable utility surrogate that is typically used
in benefit-cost analyses is the maximum dollar amount the
individual would be willing to pay for the expected welfare
improvement or the minimum amount he/she is willing to accept to
forego the improvement.
Although willingness to pay (WTP) and willingness to accept (WTA)
are not perfect surrogates for utility changes, the consensus among
economists is that WTP and WTA do provide the best available
utility surrogate (Tolley, Kenkel, and Fabian, 1994; Sloan, 1995;
Haddix et al., 1996). An obvious problem with these measures is
that they are conditional on an individual’s wealth or income.
Different people with similar preferences for the benefits provided
by new medical technologies could experience the same utility
change but have different WTP or WTA values if their incomes
were different.
In some cases WTP and WTA are revealed in markets. For
example, when an individual purchases a commodity in a market,
the monetary sacrifice is the price of the commodity. In such cases,
price is the appropriate WTP/WTA value of the welfare change of a
one-unit change in the individual’s consumption rate of the
commodity.4

4The price actually indicates the WTP for the marginal consumer. Inframarginal

consumers earn consumer surplus on their purchases; their actual WTP is
higher than the price.
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Because the health care
market is distorted by the
intervention of third
parties, market prices may
not reflect the value of their
resulting health outcomes;
nonmarket valuation
methods are required to
quantify their value.

However, the prices of goods such as health care do not reflect the
values of their benefits to patients. In this case, nonmarket methods
must be used to value the benefits of health care. These methods
include
Z expressed preference, in which individuals are surveyed
directly to elicit their WTP/WTA for the desirable change or
to prevent an undesirable change, and
Z revealed preference, which uses market data and
transactions for goods and services that include the
nonmarket commodity as one of their attributes to estimate
the value of the commodity. For example, if, all else being
equal, people are willing to accept lower wages for work
with less risk of injury or illness, the wage difference is a
proper WTP/WTA value of some of the health benefits of
the less risky occupation.
Although WTP provides the most comprehensive and theoretically
consistent measure of the value of health outcomes, it is also
difficult and expensive to implement. If neither expressed nor
revealed preference estimates are available from empirical studies
for the health outcome of interest, primary data must be collected
from individuals to assess their WTP/WTA values. This approach is
often not an option given the time and resource constraints of an
analysis.

A QALY is a
measure of the
utility associated
with health
outcomes that
combines morbidity
and mortality into a
single measure.

QALYs as a Measure of Utility. An alternative method for
measuring utility for health benefits is to measure and value the
change in a patient’s quality-adjusted life-years (QALYs). A QALY
is a measure of the utility associated with health outcomes that
combines morbidity and mortality into a single measure of annual
well-being. QALYs assign each health state a value between zero
and one, where zero corresponds to death and one to a year in
perfect health. The scale is based on the idea that the value of a
year of life varies depending on a person’s state of health. A year of
life in perfect health is worth more to a person than a year
experiencing a chronic and painful disease. QALYs quantify this
difference in well-being and therefore capture the effects of pain
and suffering. QALYs have been used extensively for cost-utility
analyses of new medical treatments and are well accepted among
the medical community. The Panel on Cost-Effectiveness in Health
and Medicine recommends using QALYs to measure morbidity and
mortality consequences of an intervention (Gold et al., 1996).
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The economic burden of a disease is usually divided into three
components: direct medical costs, indirect costs, and intangible
costs. Direct medical costs equal the total cost of medical
treatment. Indirect costs are the societal costs associated with loss
in productivity due to illness and unpaid caregiver time. Intangible
costs measure the costs due to the pain and suffering of the patient.
QALYs are generally assume to measure the change in both the
direct medical costs and the intangible costs of a disease. Changes
in indirect costs are generally not included in our estimates.
However, there is some debate about whether QALYs actually
include indirect costs; some researchers believe that when
providing their QALY estimates, patients include indirect costs in
their estimates.
Determining QALYs for Specific Health States. Health researchers
collect QALYs from patients using sophisticated survey methods.
The QALY values developed through these surveys are then used to
quantify the impact of health states and health outcomes on the
utility of a wider population. The extent to which the QALYs
developed from a sample are accurate predictors for the patients in
the study population depends on the extent to which the sample is
representative of the study population. Obviously, the best way to
ensure that QALYs are accurate for the study population is to
interview each patient in the study population to develop
individual-specific QALY values. Because this is not usually
possible, researchers aim to ensure that the sample is representative
of the population with respect to variables that they suspect will
affect QALY values.
Because the time and resources did not permit it, we were not able
to conduct direct surveys of the patient populations affected by
each of our case study technologies. Instead, we used average
QALY values available from other empirical studies. Table 2-1 lists
available QALYs for a number of health states. When assigning
QALYs for this study, we used the closest health state for which
QALYs were available. If possible, we used QALYs that were
developed especially for the patient population of interest.
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Table 2-1. Comparison of QALY Utility-Weights for Different Health States

Health State

Utility Weight

Full Health

1.00

Life with menopausal symptoms

0.99

Side effects of hypertension treatment

0.95 - 0.99

Study

Torrance and Feeny, 1989
Torrance and Feeny, 1989

Mild angina

0.90

Torrance and Feeny, 1989

Kidney transplant

0.84

Torrance and Feeny, 1989

Chronic lung disease

0.83

O’Brien and Viramontes, 1994

Lower extremity amputation

0.80

DCCTRG, 1993, 1995, 1996

Mechanical equipment to walk

0.79

Torrance and Feeny, 1989

Mild shingles pain

0.73

Wood et al., 1997

Permanent ostomies

0.70

Burckhardt et al., 1993

Moderate angina

0.70

Torrance and Feeny, 1989

Blindness

0.69

DCCTRG, 1993, 1995, 1996

Some physical and role limitation with occasional
pain

0.67

Torrance and Feeny, 1989

Severe menopausal symptoms

0.64

Daly et al., 1993

Home dialysis

0.64

Torrance and Feeny, 1989

Chronic lung disease

0.63

O’Brien and Viramontes, 1994

End-stage renal disease

0.61

DCCTRG, 1993, 1995, 1996

Insulin-dependent diabetes

0.58

Burckhardt et al., 1993

Osteoarthritis

0.52

Burckhardt et al., 1993

Rheumatoid arthritis

0.52

Burckhardt et al., 1993

Fibromyalgia syndrome

0.51

Burckhardt et al., 1993

Severe angina

0.50

Torrance and Feeny, 1989

Severe shingles pain

0.47

Wood et al., 1997

Anxious/depressed and lonely much of the time

0.45

Torrance and Feeny, 1989

Blind or deaf or dumb

0.39

Torrance and Feeny, 1989

Chronic obstructive pulmonary disease

0.38

Burckhardt et al., 1993

Mechanical aids to walk, needs help of another
person to get out, and learning disabled

0.31

Torrance and Feeny, 1989
(continued)
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Table 2-1. Comparison of Utility-Weights for Different Health States (continued)

Health State

Utility Weight

Dead

Study

0.00

No use of arms and legs, blind, unable to attend
school or work, needing help with self care and
getting around, and depressed

<0.00

Torrance and Feeny, 1989

Confined to bed with severe pain

<0.00

Torrance and Feeny, 1989

Unconscious

<0.00

Torrance and Feeny, 1989

Determining the Monetary Value of Changes in WellBeing
The final step in determining the monetary value of the per-patient
change in health outcomes is to assign a monetary value to a
QALY.
Recently, economists have developed empirical methods to
estimate the dollar value of reducing fatal and nonfatal health risks.
We took advantage of previous work in this area, particularly that
of Mauskopf and French (1991) and Moore and Viscusi (1988b).
They developed estimates of the value of a QALY for the average
person based on WTP values for avoiding illness and accidents. 5
First, they determined the loss in QALYs associated with published
WTP estimates. For example, a study by Moore and Viscusi
(1988a) estimated the dollar value of avoiding immediate
premature death based on data on working men with an average
age of 40 years. The expected loss in life-years is 36 years,
assuming a life expectancy of 76 years. If we assume perfect health
until death, then the QALYs lost are also 36 years. Thus, if the
marginal dollar value of a life-year is constant, the dollar value of
one QALY can be estimated by dividing the dollar value of
avoiding premature death by 36. Alternatively, we can apply a
5The values developed by these studies represent average WTP values for a QALY

among the U.S. population. The value that people place on a year of good
health is likely to vary by a number of factors, including income. WTP surveys
can be conducted for the specific population of interest to determine that
population’s value for a QALY. The averages used for this study are widely
used when population-specific values are not available.
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discount rate to the remaining life-years, assuming that life-years in
the near future are more highly valued. Then the WTP estimate is
divided by the total discounted life-years to determine the value of
a QALY.
For this study, we used Moore and Viscusi’s (1988a) estimate of
$5 million for the value of avoiding premature death at age 40.
This is also the mid-point of estimates reviewed by Fisher, Violette,
and Chestnut (1989). Table 2-2 provides alternative values of a
QALY under alternative assumptions regarding the QALY discount
rate. These values are obtained by finding the 36-year annuity
value of a $5 million principal at each discount rate. Thus,
5,000,000
V = 36
1
∑ 1+dt

(2.4)

t=1

where V is the annual QALY value, d is the QALY discount rate,
and t indexes the year.
Table 2-2. Alternative
QALY Values

Discount Rate

QALY Valuea

0%

$138,889

3%

$229,019

5%

$302,173

7%

$383,577

aAssumes that payments are made at the end of the year.

Health economists disagree about the appropriateness of
discounting QALYs. The issue in question is a patient’s time
preference for quality of life and life-years. That is, should a
life-year gained 10 years from now have the same value as one
gained next year? If not, what is the appropriate discount rate?
We followed the recommendations of Lipscomb, Weinstein, and
Torrance (1996) who advise using a 3 percent discount rate and
conducting sensitivity analysis on a range of discount rates. The
choice of a discount rate is discussed in greater detail in
Section 2.6.3.
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2.3.2

Determining the Number of Beneficiaries

The total medical
benefits of a new
technology and the
revenues to private
companies depend
on the speed of the
new technology’s
market penetration.

The total medical benefits of a new technology and the revenues to
private companies depend on the speed of the new technology’s
market penetration. The adoption of a new technology is typically
a function of the benefits of adoption to firms or consumers using
the technology. Typically, firms and consumers do not adopt new
technologies simultaneously; instead, innovations “diffuse” into use
over time (Reinganum, 1989).

Diffusion models
are appropriate for
forecasting the
temporal pattern of
new technology
adoption.

Diffusion models provide a summary statistical description of the
adoption process. Empirical studies support an S-shaped diffusion
curve for the diffusion of new technologies (Mahajan and Peterson,
1985). As shown in Figure 2-8, technological innovations typically
diffuse slowly at first, with few adoptions occurring initially. The
rate of adoption increases as early adopters and other factors, such
as information dissemination and advertising, influence others to
adopt. The rate of adoption declines as the market potential is
approached.

Gradual diffusion is a result of the heterogeneity of firms or
consumers. The expected benefits of adopting a new technology
depend on factors such as firm size, access to information, risk
aversion, and others that differ among decisionmakers. In the case
of medical innovations, the decisionmakers include hospitals,
physicians, and patients who are provided choices between the
defender technology and the new technology. We expect the
heterogeneity of these decisionmakers to result in a gradual
diffusion process rather than simultaneous technology adoption.

The classic diffusion model is the Bass model, or mixed influence
model (Bass, 1969; Mahajan and Peterson, 1985), which contains
two parameters that characterize the diffusion curve. Figure 2-9
illustrates the model and describes the coefficients and their
theoretical interpretation. The coefficient of innovation, p,
represents “external influence,” or adoptions due to the influence of
some external activity, such as professional publications. The
coefficient of imitation, q, represents the influence of word-ofmouth effects, or “internal influence.” Thus, the number of new
adoptions (rate of change in cumulative adoptions) is proportional
to the difference between market potential, M(t), and the number of
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Figure 2-8. The Classic
Diffusion Curve

Cumulative Adoptions

Market
Potential

Time

Figure 2-9. Bass (MixedInfluence) Diffusion
Model

a(t + 1) = [p + q • A(t)/M(t)] [M(t) - A(t)]

Number
of new
adoptions

Number of
potential
adopters
remaining

Coefficient of
imitation or
“internal
influence”

Coefficient of
innovation or
“external influence”

Market
penetration
proportion

A(t) ≥ 0
0 ≤ p ≤ 1 - q, 0 ≤ q ≤ 1 - p

previous adopters, A(t). The proportionality factor
[p + q • A(t)/M(t)] is sometimes interpreted as the probability of
adoption at time t. The Bass model synthesizes the approaches of
Mansfield (1961) and Fourt and Woodlock (1960). Their models
are special cases of the Bass model.
The Bass model is theoretically consistent with our expectations of
the diffusion of biomedical innovations. Upon introduction to the
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market (and after Food and Drug Administration [FDA] approval),
only a few physicians will use new medical innovations because
experience and knowledge about the procedures are limited.
However, as information about the new techniques becomes
available through professional papers, conferences, and word of
mouth, the diffusion rate will increase as more physicians adopt the
innovation. Finally, the rate of adoption will slow down as the total
market potential is approached.6
One important limitation of this model is that the cumulative
number of adopters, A(t), always increases over time. Actually
most technologies begin to lose market share as new technologies
emerge and consumer needs and tastes change. For example, data
from the Drug Mentions files produced by the National Center for
Health Statistics (NCHS) indicate that the rate at which doctors
prescribe new drugs for specific diagnoses has an inverted U-shape;
the peak occurs about 10 to 15 years following FDA approval.7
Ideally, we would forecast not only the rate of penetration of ATPfunded technologies, but also the rate of penetration of
technologies that supersede them. For this study, we assume that
the new technology will be completely superseded by a newer
technology after 10 years.
Implementing the Bass diffusion model requires gathering data on
M(t) and A(t), estimating the model, and using the model estimates
to forecast the number of patients who will be treated with the
technology.
Collecting Model Data
The following data are required to estimate the Bass model:
Z M(t) = potential market size in year t and
Z A(t) = the cumulative number of early adopters in year t.
In our study, M(t) is the total relevant patient population in a given
year.
6Trajtenberg (1990) notes that the government regulatory process has had a

profound impact on the diffusion of CT scanners and that it is difficult to fit it to
a specific functional form. The true diffusion process for these ATP innovations
will become apparent only in retrospect, when actual diffusion data can be
examined.
7Based on an unpublished analysis of the Drug Mentions files data by Frank
Lichtenberg, Columbia University.
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Data for the Bass model
can include observations of
the actual early market
penetration of a technology
or forecasts of market
penetration by technology
experts.

Ideally, ex post data would be available for A(t). For example, if
the technology was introduced in 1992, data from 1992, 1993,
1994, 1995, and 1996 would provide five observations for A(t). In
the absence of ex post data, some forecast of A(t) must be
developed. We obtained these forecasts from company
representatives or from physician interviews. Expert interviews are
commonly used to forecast the penetration of new technologies; in
the case of medical technologies, physicians with clinical and
research experience in the applications of interest are the best
experts. Alternatively, forecasts of A(t) can be constructed by
examining the diffusion pattern of analogous technologies.
Company representatives or professional associations and
institutions (e.g., the American Diabetes Association and the
National Cancer Institute) helped us to identify physician experts
who specialize in the applications of interest, either in clinical
practice, in research, or both.
To familiarize the physicians with the technologies and to ensure
that they were considering all aspects of the technologies in their
forecasts of A(t), we constructed clinical profiles of each
technology. Each profile contained a description of the technology
and information such as expected costs and outcomes compared to
the defender technology. We obtained permission from the
developing companies to provide this profile to physicians and did
not disclose the identity of the developing company. Appendix A
provides examples of profiles we used to apply this methodology to
several tissue engineering projects.
Estimating the Diffusion Model
Ordinary least squares (OLS) regression can be used to estimate a
Bass model:
a(t + 1) = [p+q A(t)/M(t)] [M(t) – A(t)]

(2.5)

where
Z a(t+1) is the number of new adopters in the next year,
Z A(t) is the cumulative number of adopters in year t,
Z M(t) is the total market potential in year t, and
Z A(t+1) = A(t) + a(t+1).
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Rewriting Eq. (2.5) provides the estimated equation:
1
a(t + 1) = p • [M(t) – A(t)] + q • A(t) – M(t) • A(t)2 .

(2.6)

Using data collected from physician interviews and company
representatives, we estimated p and q using OLS. In keeping with
the structure of the Bass model, we suppressed the intercept.
The forecast equation is
1
^
a(t + 1) = ^
p • [M(t) – A(t)] + ^
q • A(t) – M(t) • A(t)2 .

(2.7)

Forecasts of A(t) for Years 2 through 10 were constructed by
inserting estimates of p and q into the equation above. Confidence
intervals of 95 percent can be constructed around forecasts of A(t)
to provide a measure of the uncertainty of the results. However,
note that we used expert forecasts to estimate the model. These
forecasts are subject to unmeasurable error; thus, traditional
measures of forecast error do not fully capture the error associated
with these estimates.

2.4

ESTIMATING CHANGES IN HEALTH CARE
COSTS
Our analysis of the impact of new technologies on the cost of
health care uses the structure of the chronic disease model and the
acute illness and injury model presented in Section 2.3. Recall
that, in each year, the distribution of patients among the health
states differs between the new and defender technologies. Each
health state imposes a treatment cost; the vector c in Figure 2-1
specifies these costs. Thus, the total cost of treating all patients in a
given year is the product of the cost vector and the patient
allocation vector. For year 1,
TCD1 = y’1c and TCN1 = z’1c

(2.8)

where TCD1 is the cost of health care under the defender technology
in year 1 and TCN1 is the cost of health care using the new
technology in year 1.
The cost of treating someone in a given health state can differ
between the new and the defender technologies if the new
technology affects the method of treatment for a given health state.
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Eq. (2.8) includes the costs associated with treating the health states
or health outcomes resulting from each technology, but it does not
include the cost of the treatment itself. Thus, if the cost of using the
new technology is different from the cost of using the defender
technology, we added this cost difference to the model. Where
appropriate, we also incorporated the costs of treating the side
effects and complications of each treatment. Chapter 3 discusses
the specific costs associated with the diseases and illnesses
considered in this study.

2.5

CALCULATING RETURNS TO PRIVATE
COMPANIES
Companies invest in R&D to pursue new technologies because, if
successful, the technology will provide a stream of future profits.
Expected private returns depend on the following factors:
Z probability of technical success;
Z expected investments and costs for
X R&D,
X commercialization, and
X production; and
Z expected revenues.

In this model, the private
return on investment
includes the expected
investments and revenues
of the innovator as well as
other companies that may
play a role in
commercializing and
producing the technology.

In this model, private return on investment includes the investments
and revenues of the innovator as well as other companies that may
play a role in commercializing and producing the technology. This
definition of private returns is somewhat different from the one
commonly used in the literature. Normally, private returns to R&D
refer to the returns to the innovator, while returns to downstream
companies are “spillovers” and are counted as part of social returns
but not private returns.
Companies that receive ATP funding may specialize in one phase
of the innovation process while developing contractual
relationships with other companies that participate in other phases.
Companies that specialize in R&D activities do not incur the costs
of commercialization and production. Their benefits are limited to
licensing fees, royalties, or the sale of patents to other firms that
will commercialize and manufacture the new technology.
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Our model includes the costs and benefits from all three phases in
our definition of private returns regardless of whether the ATPsponsored firm is responsible for all of these activities. The early
stage of many of these ATP projects makes it difficult to predict the
R&D, marketing, and production relationships that will emerge
among our case study companies and, therefore, the distribution of
benefits among them. Thus, our definition of private returns
aggregates the costs and revenues of the initial innovator and other
companies that play a role in commercialization. Provided the
estimates of private return on investment are interpreted correctly
as returns to all private companies participating in R&D,
commercialization, and production, this assumption has no impact
on the empirical results.
Constructing the schedule of expected benefits and costs for the
private sector requires the following information for both the withATP scenario and the without-ATP scenario:
Z R&D investment for each year of the R&D phase,
Z investment in commercialization for each year of the
commercialization phase,
Z annual expenditures on the fixed and variable costs of
production,
Z annual revenue, and
Z probability of technical success.
2.5.1

Determining R&D Investment
We assume that the company’s R&D investment in the ATP project
is equal to its contribution to the ATP project’s total budget—that is,
the total project budget minus the amount funded by ATP.

The private sector’s R&D
investment in the with-ATP
scenario is equal to its
matching funds for the ATP
project. R&D investment
in the without-ATP
scenario is determined by
the model as described in
Section 2.2.1.
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This assumptions reflects a narrow view of private-sector R&D
investment. An alternative views R&D as a production process
whose inputs include the stock of the company’s knowledge
resulting from previous R&D in related projects. Thus, at least a
portion of the R&D invested in previous related projects should be
counted as an investment in the current project.
Nevertheless, we applied the more practical, narrower approach to
determining R&D investment because of the lack of data for
determining the total quantity of R&D invested in a general
research area. This may result in an underestimate of the
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company’s investment in ATP-funded technologies. As a
consequence, the resulting estimates of social and private returns
may be biased upward for some projects, especially those in which
the ATP project builds on accomplishments of previous R&D by the
same company. On the other hand, knowledge spillovers from
these ATP projects to other projects are also likely. In fact, ATP
projects are chosen because of their potential to lead to advances in
science and technology that enable advances in other areas. Our
estimates do not account for these spillover benefits, which bias the
estimates of social and private returns downward.
2.5.2

Determining Costs of Commercialization and
Production
Our model includes costs incurred during the commercialization
phase due to activities such as preparing for regulatory review,
developing marketing networks, building production capacity, and
developing supplier networks. In our model, companies do not
incur these expenses unless the project is technically successful.
The commercialization phase begins at the completion of the ATP
project period and ends when the project is brought to market.
ATP funding recipients may not be able to provide an estimate of
the cost of conducting these activities, particularly if their projects
are still in the R&D phase. In this case, assumptions about the
relationships between these costs and available company
information must be developed.
We derived our assumptions about these costs from industry
profiles. According to a composite balance sheet of the
biotechnology industry, selling, general, and administrative
expenses represent about 37 percent of total revenue (Lee and
Burill, 1996). We used this information to construct a timeline of
commercialization costs. We assume that some of these costs are
fixed and the company incurs them in the commercialization
phase. Another portion is variable and the company incurs them
annually in conjunction with production. If γ represents the portion
of these costs incurred prior to production, the fixed
commercialization costs are
CCF = γ*0.37 *

n

∑ TRt

(2.9)

t=1
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where CCF represents the fixed portion of commercialization costs,
TRt is total revenue in year t, and n is the number of years of
production. If the commercialization phase is longer than 1 year,
we spread the fixed costs over the commercialization phase. For
our case studies of ATP-funded tissue engineering technologies, we
assume that γ = 0.25; thus, 25 percent of total commercialization
costs are fixed and incurred during the commercialization phase;
the remainder occur during the production phase.
Our model also includes the cost of additional research required in
the commercialization phase to bring the technology to market,
such as the costs of conducting the research required for regulatory
review. Several of our case study companies provided estimates of
these costs. For those that could not, we developed an estimate
based on average R&D spending in the industry. For the
pharmaceutical industry, R&D spending accounted for 12.5 percent
of revenue in 1993 (NSF, 1996). Thus, we assume that total
research spending, including the total ATP project budget, equals
12.5 percent of revenue:
n

CCR = 0.125 *  ∑ TRt – RA – RC

(2.10)

t=1

where CCR represents the portion of commercialization costs due
to additional research. RA is public investment of ATP funds to the
project, and RC is the company’s contributions to the ATP budget.
Again, if the commercialization phase is longer than 1 year, we
spread these costs over the entire commercialization phase.
Rather than explicitly
including a fixed cost of
the plant and equipment,
we used a production cost
estimate that incorporates
the cost of capital
depreciation.

We also developed estimates of production costs from industry
data. According to a composite balance sheet of the biotechnology
industry, the ratio of production costs (including capital
depreciation) to the value of shipments is 0.42 (Lee and Burill,
1996). Because the costs included in the numerator of this ratio
include capital depreciation, there is no need to account for the
fixed costs of plant and equipment elsewhere. Thus, we assume
that production costs equal 42 percent of revenue.
Ideally, we can replace these assumptions about the relationship
between revenue and the costs of commercialization and
production with actual data from the companies as it becomes
available. Because these assumptions are based on an aggregate
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balance sheet of the biotechnology industry, they do not reflect
differences among segments of the industry or the specific situation
of the ATP-sponsored companies and their partners. As the
biotechnology industry matures, its aggregate balance sheet may
show some reduction in R&D and commercialization costs while
production costs as a percentage of revenue may increase. How
well these assumptions fit the companies in our case study depends
on their stage of development relative to the industry.
2.5.3

Calculating Revenues
Revenue is equal to the per-unit price multiplied by the quantity
sold. We derived our estimates of the quantity of sales for the
goods embodying each technology from the diffusion model
described in Section 2.4. ATP-funded companies provided an
estimate of the price of the product or service embodying the ATPfunded technology. The companies sometimes based these
estimates on the cost of the defender technology. If the companies’
goal is to provide the product or service at the same or lower cost
than the defender technology, the price of the defender technology
guided their estimate of the expected price.

2.5.4
We used the companies’
own assessment of their
progress toward
demonstrating the
technical feasibility of the
project as a proxy of the
probability of technical
success. We adjusted this
assessment to account for
the percentage of project
R&D that has been
completed.

Estimating the Probability of Technical Success
Assessing the probability of technical success for ATP projects in
tissue engineering is very difficult, especially for projects that are
relatively young. We derived our estimates of the probability of
technical success from the companies’ own assessments of their
progress toward demonstrating the technical feasibility of their ATP
projects, as reported in quarterly and anniversary business reports.
We adjusted their estimates to account for the projects’ expected
completion dates:
Pr = TP/PF

(2.11)

where TP represents the percentage of progress the companies have
made toward demonstrating technical feasibility, and PF is the
percentage of the projects’ calendar time that had elapsed at the
time TP was assessed.8

8Ideally, we would use the percentage of the project budget spent at the time

technical progress was assessed; however, this information was not available.
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In their quarterly and anniversary business reports, companies
report their progress toward demonstrating the feasibility of their
technical goals. The companies report a range (e.g., 0 to
25 percent). We used the midpoint of the range for the value of TP.
We calculated PF as the ratio of the elapsed project time to the total
project period. For example, suppose one of the ATP-funded
companies reported in its business report that it had made 25 to
50 percent progress toward demonstrating technical feasibility.
Also suppose that at the time the company filed the report,
50 percent of the ATP project period had elapsed. Then the
probability of technical success is
0.375
0.5 = 0.75.
This method of estimating the probability of technical success has
important limitations. Even the companies cannot predict whether
they will meet all of their technical goals. Furthermore, our method
of adjusting the company assessments to account for the status of
the projects can result in probabilities greater than one. Clearly, a
more robust method for determining this probability is needed. The
sensitivity of our results to our estimates of the probability of
technical success is reported in Appendix B.
We determined the probability of technical success in the withoutATP scenario by applying the model described in Section 2.2.1.
This model determines the change in the probability of technical
success as a function of the change in R&D spending.

2.6

CALCULATING MEASURES OF ECONOMIC
RETURN
After gathering the data and completing the modeling activities, we
calculated measures of economic return from three perspectives:
the social return on public investment, the social return on public
and private investment, and the private return on private
investment.
Measures of economic return on investments in ATP-funded
technologies can be calculated from the time profile of benefits and
costs to the public and to the private sector in each scenario. We
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used four steps to develop the measures of social and private
returns:
1. Construct the time profile of benefits and costs for the withATP and without-ATP scenarios.
2. Choose measures of economic return.
3. Choose a discount rate.
4. Conduct sensitivity analysis on key parameters.
2.6.1

The relevant time horizon
for evaluating the R&D
investment depends on our
expectations for the
emergence of a new
technology that will
replace the ATP-funded
technology.

Constructing the Time Profile of Benefits and Costs
for Each Scenario
The with-ATP and without-ATP scenarios specify the expected
private and social benefits and costs in each year. The first year of
the scenario is the first year in which benefits or costs are incurred
(e.g., Year 1 of the ATP project funding). The last year of the
scenario is defined as the final year of the production phase.
Determining the last year of the scenario requires speculation about
the emergence of new technologies that may replace the ATPfunded technology. As explained in Section 2.1, we assume that
this occurs 10 years after expected market introduction in the withATP scenario.
The annual net benefit to the private sector is the difference
between annual revenues and annual costs to the innovator and its
partners. The annual net benefit to society is equal to the net
benefit to the private sector, minus ATP funds provided by
taxpayers, plus net benefit to patients, plus net benefit due to
changes in the cost of health care. During the R&D phase, the
expected net benefit to both the private sector and society is the
same as the net benefit. In the years after the R&D phase, the
expected net benefit is the product of the probability of technical
success and the net benefit.
To calculate the social return on public investment, we calculated
the difference between the expected net benefit to society for the
with-ATP scenario and the expected net benefit to society for the
without-ATP scenario for each year:
IENBt = ENBwt – ENBwo
t

(2.12)

where IENBt is the incremental expected net benefit in year t, ENBwt
is the with-ATP expected benefit in year t, and ENBwo
is the
t
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without-ATP expected net benefit in year t. We used the annual
values of IENBt to calculate the social return on public investment.
All the data in our model are expressed in constant (1996) dollars.
We adjusted any data that were denominated in pre-1996 dollars
by applying either the consumer price index (CPI) or, for medical
expenses, the medical care component of the CPI.9
2.6.2
NPV and IRR are
appropriate choices for
measuring public- and
private-sector research
because they have been
widely used to evaluate
public-sector research and
are also commonly used in
the private sector.

Choosing Measures of Economic Return
NPV and IRR are appropriate choices for measuring the net benefits
of ATP projects because they have been widely used to evaluate
public-sector research and can provide comparable estimates.
They are also commonly used in the private sector to estimate the
potential benefits of alternative investment projects.
NPV provides the most straightforward method for evaluating the
economic impact of a project. NPV is
n

NPV =

NBt

∑ (1+r)t

(2.13)

t=1

where NBt is the net benefit (benefit minus cost) in year t, n is the
number of years over which benefits or costs accrue, and r is a
prespecified discount rate. An NPV greater than zero indicates that
the discounted value of the benefits of investing the technology is
greater than the discounted value of the costs. Although NPV is the
most correct measure of the economic value of a project, it does
not allow for comparisons across projects of different sizes.
The correct discount rate to apply to the NPV calculation is the
subject of a great deal of debate, especially for cases in which some
of the benefits are health related. Section 2.6.3 provides a
discussion of the issues relevant to choosing a discount rate. As
described below, the sensitivity of the empirical results should be
tested for their sensitivity to the discount rate assumption.
The IRR is another commonly used measure of the economic
benefits from an investment. The IRR is the interest rate that forces
9Cutler et al. (1996) assert that the medical care CPI overstates inflation in medical

care costs. However, we believe that some of the shortcomings of the medical
care CPI (e.g., lack of adjustment for changes in quality) are mitigated by our
explicit accounting for changes in the patient’s benefits from new treatment
technologies.
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the NPV of the project’s expected net benefits to be 0. Thus, to
calculate the IRR, we set Eq. (2.13) to zero and solve for r.

We considered the
IRR’s bias toward
earlier payoff
projects by
calculating both a
rate of return and an
NPV for each
project.

An IRR that refers to the costs and benefits to the company
receiving ATP funding and its partners is called the private rate of
return (PRR). An IRR that refers to the benefits and costs to all
stakeholders is called the social rate of return (SRR). The IRR can
be interpreted as a percentage yield occurring over a defined period
of time. One benefit of the IRR over NPV is that it does not require
selection of a discount rate. However, we do need to compare the
IRR to an appropriate discount rate or to an alternative project to
decide whether the project is socially desirable.
The IRR suffers from several potential shortcomings for evaluating
investments in technologies. These shortcomings, which have been
discussed by Tassey (1996), include its bias toward projects that
provide benefits earlier in the study period and its failure to
consider explicitly the reinvestment rate of interim receipts. We
considered the IRR’s bias toward earlier payoff projects by
calculating both a rate of return and an NPV for each project.
A potential solution to the IRR’s failure to consider the reinvestment
rate of interim receipts is to use the “adjusted” IRR, or AIRR. The
AIRR was defined by Ruegg and Marshall (1990) as the annual
compound percentage yield from a project over the study period,
taking into account the rate for reinvestment in interim receipts.
Calculating the AIRR requires choosing a reinvestment rate.
However, it may be conceptually faulty to assume that the returns
from medical innovations can be reinvested. A large portion of
these benefits are benefits to patients who enjoy a better quality of
life than they would in the absence of these new innovations. It
seems inappropriate to assume that these benefits, which are
embodied in patients’ well-being, can be reinvested. Thus, we
chose not to calculate the AIRR.
We calculated social return on public investment and social return
on investment using both NPV and PRR for each project. In
addition, we calculated composite measures of NPV and IRR. We
calculated the composites by summing the total expected net
benefits and costs for each year for all the projects:
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7

NBt =

∑ NBj,t

(2.14)

j=1

Because the expected net
benefit is used to calculate
NPV, and because all
benefits and costs have
been converted to constant
dollars, a riskless real
discount rate should be
used to determine the NPV.

2.6.3

where j indexes the project. Then we substituted Eq. (2.14) into
Eq. (2.13) to calculate the NPV and IRR for all projects taken
together.
The composite NPV and IRR combine the benefits and costs from
all projects. The first year of benefits or costs from any project is
1992; the final year is 2011. Thus, the composite benefits and costs
occur over a 20-year time period. The composite NPV is not equal
to the sum of the individual project NPVs because no single project
has benefits and costs over all 20 years.
Choosing a Discount Rate
We consulted several sources to consider the merits of alternative
discount rates. As discussed in OMB Circular A-94 and in Gold et
al. (1996), OMB recommends discounting all costs and benefits in a
cost-benefit analysis at the real rate of 7 percent, which, according
to OMB Circular A-94, “approximates the marginal pretax rate of
return on an average investment in the private sector in recent
years” (p. 9).
However, for discounting costs to government (e.g., in a costeffectiveness analysis) OMB recommends using “the real treasury
borrowing rate on marketable securities of comparable maturity to
the period of analysis.” The rates most recently published by OMB
for this purpose range from 2.1 percent for 3-year projects to
2.8 percent for 30-year projects. Their rationale for using this rate
for a cost-effectiveness analysis is that these analyses seek to find
the lowest-cost way for government to achieve some predesignated
objective.
The basic difference between these two OMB recommendations
relates to risk. The 7 percent assumption was developed by OMB
as an average rate that theoretically combines the riskless rate,
which they recommend for discounting costs to society in costeffectiveness analysis, with a risk-adjusted rate, which is normally
used to discount private investments that have high opportunity
costs and high risks. Thus, if we did not adjust private costs for risk
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(if we were discounting a stream of uncertain costs and benefits),
we might want to use the 7 percent recommended by OMB.
However, the Panel on Cost Effectiveness in Health and Medicine
has examined OMB’s recommendations, as well as the
recommendations of scores of empirical and theoretical researchers
in health benefits analysis, and has recommended the following:
Z first convert all uncertain costs and benefits into “certainty
equivalents,” expressed in real terms, and
Z discount at a selected riskless real discount rate (Gold et al.,
1996).
Assuming risk neutrality, the certainty equivalent is equal to the
real expected net benefits, which we have calculated by
multiplying the real net benefits by the probability of technical
success.
Risk neutrality is a common assumption when quantifying medical
benefits (Gold et al., 1996). It is convenient operationally because
it implies that the certainty equivalent of benefits is equal to the
expected value. This implies that patients are indifferent between
two events with the same expected value. We do not know the
actual risk preferences of the patients affected by these
technologies. Because we did not have the resources necessary to
explore the risk preferences of the specific populations of interest in
this study, we followed the conventional practice and assumed risk
neutrality.
The riskless rate recommended by the Panel on Cost Effectiveness
in Health and Medicine is 3 percent (Gold et al., 1996). This is
based on the recommendations of a number of researchers,
including Viscusi (1995).
The Panel also recommends the following:
Z discounting costs and benefits at the same rate and
Z conducting sensitivity analysis at 5 percent because many
other studies have used 5 percent as their base case.
In our analysis of ATP projects in tissue engineering, we followed
the Panel’s recommendations. We
Z assumed risk neutrality and developed the certainty
equivalent by multiplying the net returns by the probability
of success,
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Z discounted costs and benefits at the same rate,
Z discounted social and private returns at the same rate (since
they have been risk-adjusted),
Z used the 3 percent discount rate, and
Z conducted sensitivity analysis for discount rates of 1 and
5 percent.
2.6.4

Conducting Sensitivity Analysis
Because many of the variables in a model of the returns on
investment in ATP-funded medical technologies are measured with
considerable uncertainty, it is important to test the sensitivity of our
results to specific parameter values. Sensitivity analysis can be
conducted in a variety of ways. The results can simply be
calculated for a range of values for each of the parameters of
interest. Alternatively, Monte Carlo simulation, using a program
such as @RISK, allows the analyst to incorporate measures of
uncertainty of the parameters to generate the probability
distribution functions for the results.
We tested our results with respect to changes in the following
parameters:
Z discount rate,
Z per-patient treatment costs and QALYs,
Z probability of technical success,
Z commercialization cost parameters,
Z R&D cost parameters,
Z production cost parameters, and
Z product price.
Appendix B contains the results of these sensitivity analyses.

2.7

METHODOLOGICAL CHALLENGES AND
LIMITATIONS
Implementing the methodology described in this report is
challenging. Analysts face a number of difficulties regarding
modeling and data collection in each of the implementation steps.
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2.7.1

Characterizing New and Defender Technologies
A significant challenge is choosing the applications to study.
Choosing to analyze the most immediate and probable application
is the most practical approach and probably provides the most
reliable data. However, ignoring the later applications probably
underestimates the project’s benefits.

Existing or prospective
studies of project spillovers
may provide a general
guideline for forecasting
the return on investment
from later applications of
ATP-funded technologies.

A potential approach to this problem may be to draw from existing
or prospective studies of project spillovers. An empirical analysis
of trends in the return on investment in the application of an
enabling technology as it ages may provide a general guideline for
forecasting the return on investment for later applications. For
example, a retrospective study of the medical applications resulting
from the discovery of imaging technology might show that the
return on investment in each application rise at first, then decline as
the enabling technology ages and is replaced by a new discovery.
Until this type of information is available, the best approach to
capturing return on investment from future applications in the
absence of data is to describe the applications qualitatively, as we
have for the seven tissue engineering projects. A discussion of their
potential returns in relation to the application that is studied can
also provide some perspective on the potential unmeasured returns.
For example, we studied the tumor imaging application of the
discovery of a new molecule. While tumor imaging is the most
likely commercial success in the short run, the potential of this
molecule to assist in discouraging tumor growth has potential
implications that go far beyond its potential as a diagnostic tool.

2.7.2

Modeling Medical Benefits
The most challenging task in modeling medical benefits is
quantifying the benefits of new technologies to patients. The
methodology described in this report uses QALYs to measure the
change in a patient’s welfare due to changes in their health status.
However, this method is limited by the insensitivity of QALYs to
small or short-term changes in a patient’s health status. This
prevented us from calculating the full health benefits of some
technologies.

2-43

A Framework for Estimating the National Economic Benefits of ATP Funding of Medical Technologies

QALY measures are not
sensitive enough to capture
small or short-term changes
in health states. Although
the WTP method provides
a comprehensive and
theoretically consistent
alternative, it is also the
most difficult to implement.

2.7.3

The alternative is to collect WTP estimates for each change in
health status. Although WTP provides the most comprehensive and
theoretically consistent measure of the value of health outcomes, it
is also the most difficult and expensive to implement. In the
absence of WTP estimates of the value of utility losses associated
with each of the outcomes relevant to the applications of our
technologies, we would need to collect primary data from
individuals to assess their WTP values. This approach is often not
an option given the time and resources available for a study. Its use
must be dictated by the importance of the most accurate health
benefits information, given the other limitations of the analysis.
Forecasting Market Penetration
While the Bass model is a generally accepted model for forecasting
the diffusion of new technologies, it has one important drawback
for studying ATP-funded enabling technologies. The cumulative
number of adopters predicted by the Bass model is strictly
increasing over time. Yet the market penetration of technologies
may fall after it peaks as new technologies emerge and consumer
needs and tastes change. Thus, a diffusion model is needed that
accounts for the future emergence of technologies that will replace
the ATP-funded technology. One way to think of such a model is
that it actually forecasts the diffusion of two technologies: the ATPfunded technology and its replacement. Clearly, knowledge of
these potential replacements would be limited. It would be helpful
to develop data about the likely pattern of obsolescence of ATPfunded technologies.

2.7.4

Estimating Company Costs and Revenues
Estimating company costs and revenues requires information about
the expected costs of R&D, production, and commercialization.
This information is extremely difficult to collect. Many of these
projects are years from commercialization, and many of the
companies will license these technologies rather than produce and
market them. Even if companies can provide estimates of these
costs, they may not because they are concerned about the
confidentiality of data such as product price and production costs.
Although industry balance sheets and other secondary data can be
used to develop assumptions about these costs, these assumptions
may be misleading because they do not account for the specific
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circumstances of each company. Furthermore, the biotechnology
industry is very young. As the industry matures and becomes more
profitable, the ratios between sales and these costs will probably
change.
It may be useful to refine our techniques for interviewing company
representatives to improve our estimates of these costs. For
example, if the company produces other products, we may be able
to infer some information about costs for developing the ATP
technology from the history of the development of other products.
Similarly, we may be able to consider the historical costs of
commercialization and production of an existing product that uses
a current process technology and serves similar markets.
2.7.5

Calculating Social and Private Returns
Constructing a without-ATP scenario is the most challenging task in
calculating social and private returns. Because the without-ATP
case is the counterfactual, we must rely on the company’s
conjectures about what they might have done in the absence of an
ATP grant and on a model that predicts the results of that behavior.
Better information about how companies respond to such funding
could improve our models and our estimates of the without-ATP
scenario.
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Tissue Engineering
Case Studies
One of the objectives of this project was to illustrate the
methodology described in Chapter 2 by applying it to seven ATPfunded projects in tissue engineering. Another objective was to
estimate the social return on public investment in the seven ATP
projects chosen for the case studies. This chapter describes in
detail how we applied the methodology described in Chapter 2 to
each of the seven case studies. It also reports the results of the
analysis and discusses the limitations of each case study. Finally,
we offer conclusions about the suitability of the methodology, the
expected social and private return on investment in tissue
engineering technologies, and the role of ATP in improving those
returns.

3.1

CASE STUDY APPLICATIONS
ATP asked RTI to apply the methodology described in Chapter 1 to
a single application of each of seven multiple-application tissue
engineering projects funded from 1990 to 1996. Chapter 1 briefly
describes these seven projects, and Table 1-1 provides summary
information.
At the request of the ATP staff, we spent a greater share of our effort
and resources modeling and collecting data for the first four
projects listed in Table 1-1. ATP based their selection of these indepth case studies on the likelihood that key data would be
available either from the companies or from other sources. For
these projects, we used a more detailed medical benefits modeling
strategy, spent more time searching for secondary data in the
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medical literature, and collected more data for the diffusion
forecasts.
We consulted a number of sources for data and information,
including
Z interviews with company representatives,
Z ATP proposals and progress reports,
Z interviews with physicians,
Z medical databases and journals, and
Z publicly available company and industry information.
Sources of medical outcome and cost data are listed in Table 3-1.
Table 3-1. Sources of Outcome and Cost Data

ATP Project

Source of Outcome Data

Stem Cell Expansion

Boogaerts and Demuynck (1994)
Champlin (1996)
Faucher et al. (1994)
Hillner, Smith, and Desch (1993)

Boogaerts and Demuynck (1994)
Champlin (1996)
Faucher et al. (1994)
Hillner, Smith, and Desch (1993)

Biopolymers for Tissue
Repair

Sinisaari et al. (1996)
Rokkanen et al. (1996)

AHCPR (1996)
Böstman (1994)
Levin and Condit (1996)
Shaw and Lawton (1995)
Tiel-van Buul et al. (1995)

Living Implantable
Microreactors

Eastman et al. (1993)
DCCTRG (1996)
DCCTRG (1995)

AHCPR (1996)
Eastman et al. (1993)
Ray et al. (1996)
DCCTRG (1996)
DCCTRG (1995)

Proliferated Human Islets

Eastman et al. (1993)
DCCTRG (1996)
DCCTRG (1995)

AHCPR (1996)
Eastman et al. (1993)
Ray et al. (1996)
DCCTRG (1996)
DCCTRG (1995)

Biomaterials for Clinical
Prosthesis

Vangsness et al. (1995)
Harner et al. (1996)
Jackson, Corsetti, and Simon (1996)
Mohtadi (1993)
Marks and Mohtadi (1996)

None

Gene Therapy Applications

Kosary et al. (1995)
Buccheri and Ferrigno (1995)

Virgo et al. (1996)

Universal Donor Organs

Evans (1993)
UNOS (1996)
UNOS (1997)

Evans (1993)
Votapka et al. (1995)
AHCPR (1996)
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Some of the information we used in our model was taken from
confidential sources such as company interviews and reports. To
honor our confidentiality agreement with these companies, we do
not discuss this information.
3.1.1

Human Stem Cell and Hematopoietic Expansion
Systems
Aastrom Biosciences Inc.’s ATP project is developing a CPS to be
used in stem cell therapy to make the collection of stem cells easier
and more convenient to the donor or patient. Stem cell therapy is
often used to enable cancer patients to endure high-dose or
multicycle chemotherapy or radiation therapy. The stem cells are
removed from the patient prior to the therapy and replaced
afterwards to restore the patient’s hematopoietic system. Table 3-2
summarizes the assumptions of our analysis of this project.
Timeline of R&D Costs and Benefits
Our model assumes that the relevant time horizon for this project is
1992 to 2009. The 2-year R&D period begins in 1992. Aastrom
Biosciences expects that its CPS will enter the market in 2000.
Thus, the commercialization phase begins in 1994 and ends in
1999. The production phase lasts 10 years, beginning in 2000 and
ending in 2009.
Aastrom estimates that ATP funding accelerated the project by 1 to
2 years. Using the conservative estimate of 1 year of acceleration,
the without-ATP scenario includes an R&D phase that lasts 3, rather
than 2, years. The commercialization phase begins in 1995 and the
production phase begins in 2001. However, because the window
of market opportunity ends in 2009, the production phase in the
without-ATP scenario is only 9 years.
Impact of ATP on Social Returns

ATP funding accelerated
this project by 1-year and
increased the probability of
technical success by
9 percent.

ATP awarded Aastrom $1,220,000 in matching funds. Aside from
the 1-year acceleration effect discussed above, ATP funding also
affected the expected probability of success for this project. Recall
that the change in the probability of technical success due to ATP
funding depends on how ATP funding affects the total spending in
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Table 3-2. Model Assumptions for “Human Stem Cell and Hematopoietic Expansion Systems”

Timeline of Costs and Benefits

With ATP

Without ATP

Year 1 of R&D phase

1992

1992

Year 1 of commercialization phase

1994

1995

Year 1 of production phasea

2000

2001

Final year of market window

2009

2009

Impact of ATP
ATP matching funds

$1,220,000

Acceleration

1 year

Probability of success
Elasticity of marginal benefits curve

-0.5

Total project R&D

$2,734,000 with ATP; $2,034,520 without ATP

Probability of success

9 percent higher in the with-ATP scenario

Scope effects

None reported

Medical Benefits Per Patient
Application

Stem cell harvest and transplant, especially as used
in high-dose chemotherapy and radiation

Defender technology

PBPC collection

Patient population

Patients undergoing stem cell harvest and transplant
in the U.S.
Z Reduces the probability of reintroducing tumor
cells in some patients
Z Reduces donor time and discomfort
Z Eliminates mobilization drugs and their side
effects
665 in 2000; 17,251 by 2009 (See Table 3-3)

Differences in health outcomes
(Not quantified)

Number of Beneficiaries
Changes in Health Care Costs

Will reduce the number of care episodes, procedure
time, and needle sticks required to harvest a
sufficient quantity of stem cells. The cost of CPS
equipment and consumables will partially offset
these savings

Private Company Costs and Benefits
Private spending in R&D phase

$1,514,000 with ATP; $2,034,520 without ATP

Commercialization cost

37 percent of revenue

Production cost

42 percent of revenue

aRTI’s

estimate is based on company projections of time required for clinical trials. This estimate applies only to the
U.S. market.
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the R&D phase. This depends on the elasticity of the marginal
benefits function. Our conversations with Aastrom officials
indicated that although ATP funding was important to the project
Aastrom would have proceeded with the project even in the
absence of ATP funding. Thus, we assume that the marginal
benefits function was relatively inelastic, with an elasticity of -0.5.
Using this elasticity and Eq. (2.2), we estimate that in the absence
of ATP funding total spending in the R&D phase would have
totaled $2,034,520, rather than $2,734,000, which was spent in
the with-ATP scenario. Applying this change in spending to
Eq. (2.3), we estimate a 9 percent increase in the probability of
technical success in the with-ATP scenario over the without-ATP
scenario.
Aastrom reported no impact on the scope of the project. However,
Aastrom did indicate that the ATP funding helped position them to
obtain other sources of funding. This “halo effect” of ATP funding
may have affected Aastrom’s cost of capital, their total R&D
spending, and the probability of technical success. We did not
explicitly quantify this effect; thus, we have probably
underestimated the impact of ATP on the benefits of this
technology.
Medical Benefits to Patients
Application. The Aastrom CPS will be used to culture and grow
bone marrow cells to be used for transplant. In the future, the CPS
may be used to grow other cell types, potentially useful in various
therapies, such as human gene therapy and adjuvant therapy for
T-cell-related disorders like AIDS. However, its most immediate
applicationthat examined for this studyis to transplant bone
marrow cells.
We compared the costs
and benefits of using the
Aastrom CPS to those of
using PBPC.

Defender Technology. Aastrom officials told us that the currently
preferred method for harvesting stem cells is peripheral blood
progenitor cell collection (PBPC), which has replaced traditional
bone marrow harvest because it is less costly and painful.
Under PBPC, the patient is given drug injections to encourage the
mobilization of stem cells from the bone marrow into the
peripheral blood over a week or more. The mobilized cells are
then collected by connecting the patient to an apheresis device via
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intravenous needles or a surgically placed catheter. The patient’s
or donor’s blood cells are collected, and the therapeutic volume of
stem and progenitor cells is separated from it. Then the blood is
returned to the patient. The donor must undergo this procedure for
2 to 3 days, for 4 to 6 hours per day.1 Researchers are trying to
reduce the amount of time required for this procedure to a single
protracted session. Specialized laboratory testing is conducted on
each day of the procedure to determine whether a sufficient
quantity of the desired cells has been collected.
Differences in Health Outcomes. Using the CPS will be
considerably simpler for the donor than using PBPC. In a brief
outpatient procedure, the donor will receive a local anesthetic, and
a small aspirate of bone marrow will be taken from the hip. No
drugs or procedures will be required to prepare the patient for this
procedure prior to the time of the aspirate.
In addition, the CPS method is considerably simpler for the donor
than PBPC. Rather than undergoing a series of apheresis sessions
preceded by drug therapy for cell mobilization, the patient will
receive a local anesthetic, and a single aspirate of bone marrow
will be taken from the hip.
We did not explicitly model differences in long-term health
outcomes between the CPS and PBPC. Aastrom officials indicated
that if the Aastrom CPS is technically successful (e.g., the cells
produced in an Aastrom CPS engraft as quickly as the cells
collected by PBPC), patients’ long-term health outcomes will be
similar. However, they did mention two factors that may affect a
small portion of patients using the CPS rather than PBPC:
Z reduced probability that cancerous cells will be extracted
with the stem cells and reintroduced to the patient and
Z elimination of the drugs used to mobilize stem cells under
the PBPC procedure.

1JNCI News indicates that the procedure requires two to four sessions of 3 to 5

hours each. Physicians we interviewed indicated that there is a trend toward
fewer, longer procedures.
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The acute illness
and injury model
probably
underestimates the
benefits to patients
of the Aastrom CPS
compared to the
PBPC method.

The acute illness and injury model probably underestimates the
benefits to patients of the Aastrom CPS compared to the PBPC
method. We were not able to explicitly incorporate the benefits of
either CPS’ potential health effects or its impact on patient
convenience and comfort into our model. Empirical data on the
changes in health risk are not available; furthermore, QALYs are not
sensitive enough to quantify the impact of differences in pain or
discomfort for short periods of time. However, we did explain
these factors to physicians who provided diffusion estimates. The
physicians confirmed that these factors will probably not have
significant consequences on the health outcomes of most patients,
although they may influence the popularity of the method with
physicians and therefore the diffusion rate.
Number of Beneficiaries
Patients receiving autologous or allogeneic stem cell transplants in
the U.S. are eligible to benefit from this technology. In 1996, this
population totaled 12,000 according to the International Bone
Marrow Transplant (IBMT) registry (1997). According to Aastrom,
this number will grow as high-dose chemotherapy and radiation
therapy become more popular treatments for the relevant forms of
cancer. If we use the current rate of increase as cited by the IBMT
(1997) registry, this number will increase to 16,000 by the year
2000 and to 25,000 by the year 2009.

Our market penetration
model predicts that
Aastrom’s CPS will be used
for 665 patients in its first
year. Its market will grow
to 17,251 by 2009.

Table 3-3 shows the expected total number of eligible patients from
2000 to 2009. It also shows the results of our analysis of the
expected market penetration of the Aastrom CPS. We need the
market penetration estimation methodology described in
Section 2.3.2 to calculate the estimates in Table 3-3. We
interviewed three physicians to obtain input for the diffusion
model. Appendix A provides their names and affiliations, the
clinical profile we used to inform them about the technology, the
interview guide, and the raw data we collected.
Using the data we collected from the experts, we estimated the
Bass diffusion model according to the procedures described in
Section 2.3.2. The Bass model provided the parameter estimates
for the forecast equation (Eq. [2.7]). We used these parameters to
estimate the number of patients who will be treated using the CPS
for each year in the production phase.
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Table 3-3. Expected
Market Penetration of
Aastrom’s CPS

Number Using CPS
Year

Eligible Patients

With ATP

Without ATP

2000

16,000

665

0

2001

17,000

1,060

665

2002

18,000

1,674

1,060

2003

19,000

2,606

1,674

2004

20,000

3,976

2,606

2005

21,000

5,890

3,976

2006

22,000

8,384

5,890

2007

23,000

11,334

8,384

2008

24,000

14,424

11,334

2009

25,000

17,251

14,424

Changes in Health Care Costs
Publicly available information from Aastrom indicates that the CPS
will reduce the resources required to harvest stem cells. Aastrom
officials and physicians we interviewed verified that the cost of
PBPC is between $12,000 and $20,000; we used the midpoint,
$16,000, in our comparison of the cost of PBPC and the procedure
using CPS. The cost of CPS equipment and consumables will
partially but not completely offset these savings. Aastrom’s
estimate of these costs is confidential information.
Estimating Private Return on Investment
R&D Costs. Aastrom’s contribution to the cost of the ATP project
was $1,514,000. As explained above, we estimate that in the
absence of ATP funding Aastrom would have spent $2,034,520 on
this project.
Commercialization and Production Costs. Aastrom could not
provide an estimate of the costs of commercialization or production
of their CPS instruments and consumables. Thus, we used data
from the biotechnology industry described in Chapter 2 to assume
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that commercialization costs would be 37 percent of total revenue
and that production costs would be 42 percent of revenue.
Summary
Our model assumes that the Aastrom CPS will enter the U.S. market
in 2000, following a 6-year commercialization phase and a 2-year
R&D phase. In the absence of ATP funding, Aastrom estimates
product introduction would be delayed by 1 year. ATP funding
also led to an increase in the total R&D spent on the project,
increasing the probability of technical success by 9 percent.
If it is technically successful, the Aastrom CPS will replace the
PBPC method for patients undergoing stem cell harvest and
transplant. This technology will reduce the discomfort associated
with the procedure, may reduce the probability of reintroducing
tumor cells to some patients, and may reduce the risks of some side
effects. This treatment will also be less expensive than the average
cost of PBPC. Because we were not able to quantify the medical
benefits of this technology, our analysis of the medical benefits
focused on the reduction in cost.
Based on physician interviews and model forecast, we expect that
the Aastrom CPS will be used to treat over 600 patients in its first
year of production and over 17,000 patients in 2009.
Aastrom and its partners in commercialization and production will
incur commercialization and production costs, which we assume
will be 37 percent and 42 percent of total revenue, respectively.
Our analysis probably underestimates the benefits of this
application of Aastrom’s technology. We were not able quantify
the benefits of the following factors:
Z possible decreases in the probability of reintroducing cancer
into some patients,
Z the benefit to the patient of reducing the inconvenience and
discomfort of the procedure, and
Z the potential benefits of eliminating mobilization drugs.
In addition, we only considered the U.S. population in estimating
the number of patients who will benefit from this technology. The
European market will probably lead to greater revenues for Aastrom
and its partners.
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3.1.2

Structurally New Biopolymers Derived from Alpha-L
Amino Acids
Integra LifeSciences Corporation received ATP funding to develop a
novel synthetic polymer technology to create a cache of new
bioabsorbable polymers for use in biomedical implants. Integra will
develop the resulting new polymers into prototype orthopedic
devices in collaboration with the Hospital for Joint Diseases.
Table 3-4 summarizes the assumptions of our analysis of this project.
Timeline of R&D Costs and Benefits
Our model assumes the relevant time horizon for this project is
1994 to 2009. Integra LifeSciences begins its 3-year ATP project in
1994; the R&D phase is 1994 through 1996. Integra expects that its
bioabsorbable fracture fixation materials will enter the market in
2000. Thus, the commercialization phase begins in 1997 and ends
in 1999. The production phase lasts 10 years, beginning in 2000
and ending in 2009.
Integra estimates that ATP funding accelerated the project by at
least 10 years. In our model, the R&D phase in the without-ATP
scenario lasts 13, rather than 3, years. The commercialization
phase begins in 2007. In the absence of ATP funding, the
production phase would not have begun until after the market
window had closed. Thus, we assume that without ATP this
product would never enter the production phase.
Impact of ATP on Social Returns

ATP funding accelerated
this project by 10 years,
increased the probability of
technical success by
171 percent, and expanded
the scope of the project.
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ATP awarded Integra $1,999,000 in matching funds. Aside from the
10-year acceleration effect discussed above, ATP funding also
affected the expected probability of technical success for this
project. Our conversations with Integra officials indicated that ATP
funding was crucial to the success of this project. Although Integra
would have pursued the technology even in the absence of ATP
funds, they would have funded the project at a much lower annual
rate. Other projects would have taken prominence. Thus, we
assume that their marginal benefits function was relatively elastic,
with an elasticity of -2. Using this elasticity and Eq. (2.2), we
estimate that in the absence of ATP funding total spending in the
R&D phase would have totaled $89,124 rather than $2,468,000,
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Table 3-4. Model Assumptions for “Structurally New Biopolymers Derived from Alpha-L Amino
Acids”

Timeline of Costs and Benefits

With ATP

Without ATP

Year 1 of R&D phase

1994

1994

Year 1 of commercialization phase

1997

2007

Year 1 of production phase

2000

N/A

Final year of market window

2009

N/A

Impact of ATP
ATP matching funds

$1,999,000

Acceleration

At least 10 years

Probability of success
Elasticity of marginal benefits curve

-2

Total project R&D

$2,468,000 with ATP; $89,124 without ATP

Probability of success

171 percent higher in the with-ATP scenario

Scope effects

Significant but not quantified

Medical Benefits Per Patient
Application

Bioabsorbable fracture fixation devices (pins, screws,
rods, plates)

Defender technology

Metal fixation devices

Patient population

Patients with nonweight-bearing fractures of the
shoulder, elbow, wrist, hand, knee, and ankle
Z Reduces stress shielding and secondary fractures
due to screw holes

Differences in health outcomes
(Not quantified)

Z Eliminates removal surgery
Z Reduces potential for tissue abrasion or device
loosening and migration
Number of Beneficiaries

8,173 in 2000; 34,889 by 2009 (See Table 3-6)

Changes in Health Care Costs

Eliminates need for second surgery in some patients,
but material costs are higher.

Private Company Costs and Benefits
Private spending in R&D phase

$469,000 with ATP; $89,124 without ATP

Commercialization cost

37 percent of revenue

Production cost

42 percent of revenue
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which was spent in the with-ATP scenario. Applying this change in
spending to Eq. (2.3), we estimate a 171 percent increase in the
probability of technical success in the with-ATP scenario over the
without-ATP scenario.
Integra reported that ATP funding also affected the scope of the
project. The funding allowed Integra to attract talented scientists
who will explore the technology’s applications in a number of areas
other than fracture fixation, including additional orthopedic
applications such as dental and maxillofacial fixation devices and
weight-bearing plates, screws, and rods. These applications would
open the technology to a greater number of orthopedic patients.
Although we did not quantify the impact of ATP on the project’s
scope, this had no impact on our results. In the without-ATP
scenario, production is delayed by 10 years; thus, the model
attributes 100 percent of the net benefits of this project to ATP
funding. The scope effects do not create any additional differences
between the with-ATP and the without-ATP scenarios.
Medical Benefits to Patients
Integra representatives
stress that the early
applications of this
technology are only a small
fraction of the potential
uses of this product.

Application. This platform technology has broad applications in
orthopedics (fracture fixation, cartilage and ligament repair); wound
care; cardiovascular repair; and drug delivery. However, in the
near term, Integra is focusing on the orthopedic fracture fixation
market to demonstrate the material’s properties and generate
revenue. The first fracture fixation applications—those examined
for this study—will be nonweight-bearing pins and screws to repair
fractures of the shoulder, elbow, wrist, hand, knee, and ankle.
Defender Technology. Because current bioabsorbable fixation
devices have not achieved widespread acceptance to date, the
defender technology remains metal fixation devices such as pins,
rods, plates, and screws. These devices are surgically placed after
reduction of the fracture to maintain alignment and provide stability
for the fracture segments. A small proportion of these devices
(10 percent at Integra’s estimate) are later removed at a second
surgery after complete healing.2 Removal is most common in the
ankle area where the threat of abrasion is highest because of the
2Our interviews with physicians indicate that the removal rate is much higher in

children. Our model analyzes the adult and pediatric markets separately.
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limited soft tissue coverage in this region. Stress shielding is also a
significant concern and motivator for removal. Regions that are
more difficult to access surgically are least likely for secondary
device removal. Depending on fracture location, metal fixation
devices can also have an adverse effect on the growth and maturity
of bones in children; thus, the use of bioabsorbable devices may
have special merit in children.

Although Integra
believes their new
material will
improve fracture
healing compared to
metal fracture
fixation devices,
there are currently
no human clinical
trial data to quantify
these impacts.

Differences in Health Outcomes. We were not able to model any
differences in health outcomes between Integra’s technology and
the defender technology. Although Integra believes their new
material will improve fracture healing compared to metal fracture
fixation devices, there are currently no human clinical trial data to
quantify these impacts. One recent study compared metal fixation
devices to currently available bioabsorbable devices using several
randomized trials (Böstman, 1996). This study found no significant
difference between the ultimate results of treating these fractures
with currently available (not Integra’s) bioabsorbable fixation
devices and metallic fixation devices. However, these results are
not directly relevant to Integra’s product, because Integra’s material
is different than the material used in currently available
bioabsorbable devices.
Integra has developed data indicating that compared to currently
available bioabsorbable fixation devices the Integra devices reduce
the infection rate. However, these data are not relevant to our
model because we are comparing the Integra devices to metallic
devices.
We were able to quantify what will probably be the most important
impact of this material in this application: the economic benefits of
eliminating removal surgery. This surgery is often performed when
metal pins and screws are used, especially when the patient is a
child. As explained below, we used the acute illness and injury
model to quantify differences in the health care costs of treating a
fracture using conventional metal fixation devices and Integra’s
fixation devices, including the elimination of the second surgery.
While some risk and discomfort to the patient are probably
associated with the second surgery, we were not able to capture
these effects.
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Number of Beneficiaries
We divided the patient population into two groupsadults and
childrenbecause the impact of Integra’s fracture fixation devices
will be different for these two groups. Because removal surgery is
more common in children, elimination of this surgery will affect
these populations differently. Thus, it was important to model the
market penetration of Integra’s technology separately for children
and adults.
Table 3-5 shows the expected number of adult and child patients
who incur the type of injuries we are considering in this model.
Table 3-6 shows the total number of eligible patients and the
expected number of patients to be treated with the Integra product
in the with-ATP and without-ATP scenarios. We developed these
estimates of market penetration using the methodology explained in
Section 2.3.2. We interviewed three physicians to obtain input for
the diffusion model. Using these data, we estimated the Bass
diffusion model and used the forecast equation (Eq. [2.7]) to
determine the expected number of patients treated with the Integra
materials for each year in the production phase for each
population.
Changes in Health Care Costs
Table 3-7 lists the costs of procedures and materials relevant to our
analysis of the impact of Integra’s technology on health care costs.
We obtained data regarding the hospital charges for most of the
procedures of interest from the HCUP-3 Nationwide Inpatient
Sample for 1992 Hospital Inpatient Stays (AHCPR, 1996). We
inflated these charges to 1996 prices using the CPI index for
medical care from the Statistical Abstract and used the standard
hospital cost-to-charge ratio of 0.5 to determine costs. To estimate
the charges for some removal surgeries we used the ratio of
removal surgery costs to initial surgery costs for each procedure
given in Böstman (1996).
To calculate the average per-patient change in cost, we considered
the difference in the removal rates for the two therapies. According
to the physicians we interviewed, metal fixation devices require
removal surgery in 90 percent of the procedures performed on
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Table 3-5. Number of
Patients with Injuries
Repairable with Integra’s
Fracture Fixation
Materials

Number of Patients
Adulta,b

Injury Type
Shoulder or elbow

Childa,b

Annual Change

1,350

825

None

Wrist and hand

18,000

9,300

None

Knee

11,700

9,000

None

Ankle

9,000

14,800

None

Total

40,050

33,825

None

aCompany and physician interviews
bNational Hospital Discharge Survey (1994)

Table 3-6. Number of
Patients Treated with
Integra’s Bioabsorbable
Fracture Fixation
Products

Table 3-7. Costs of
Materials and Procedures
for Fracture Fixation

Number Using Integra Product
Year

Eligible Patients

With ATP

Without ATP

2000

73,875

8,173

0

2001

73,875

13,286

0

2002

73,875

20,007

0

2003

73,875

26,980

0

2004

73,875

31,977

0

2005

73,875

34,158

0

2006

73,875

34,744

0

2007

73,875

34,863

0

2008

73,875

34,885

0

2009

73,875

34,889

0

Procedure

Cost

Source

Shoulder or elbow

$3,738

AHCPR (1996)

Wrist and hand

$3,620

AHCPR (1996)

Knee

$9,066

AHCPR (1996)

Ankle

$4,990

AHCPR (1996)

$852

Böstman (1996)

Wrist and hand

$1,148

Böstman (1996)

Knee

$2,176

Böstman (1996)

Ankle

$1,018

AHCPR (1996)

Surgery to insert metal pins and screws

Surgery to remove metal pins and screws
Shoulder or elbow

Metal pins and screws

$10

Physician interview
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children and 10 percent of the procedures performed on adults.
Based on conversations with physicians, we estimate that the
removal rate for both children and adults may be about 1 percent
using Integra’s bioabsorbable devices. Thus, to calculate the
average cost of treatment using the new and old technologies, we
took a weighted average of the total procedure cost, including
materials, and, when required, removal surgery. The average
reduction in per-patient costs is $691.
Estimating Private Return on Investment
R&D Costs. Integra’s contribution to the cost of the ATP project
was $469,000. As explained above, we estimate that in the
absence of ATP funding Integra would have spent $89,124 on this
project.
Commercialization and Production Costs. Integra could not
provide an estimate of the costs of commercialization or production
of their fracture fixation products. Thus, we used data from the
biotechnology industry described in Chapter 2 to assume that
commercialization costs would be 37 percent of total revenue and
that production costs would be 42 percent of revenue.
Summary
Our model assumes that Integra’s bioabsorbable fracture fixation
products will enter the U.S. market in 2000, following a 3-year
commercialization phase and a 3-year R&D phase. In the absence
of ATP funding, Integra estimates that the R&D phase would have
been extended by at least 10 years. ATP funding also led to an
increase in the total R&D spent on the project, increasing the
probability of technical success by 171 percent.
Assuming technical success, Integra’s materials will replace metal
pins and screws for fracture fixation in patients with fractures to the
shoulder, elbow, wrist, knee, and ankle. Using these bioabsorbable
implants will eliminate the surgery that is required in many cases to
remove metal pins and screws. Although this technology may also
have significant effects on healing of these fractures, we were not
able to quantify these effects.
Based on physician interviews and the diffusion model forecast, we
expect that these materials will be used to treat over 8,000 patients
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in the first year of production and almost 35,000 patients in 2009.
The average per-patient cost of treating these fractures will fall by
$691 (in 1996 dollars).
Integra will receive revenue from sales of its bioabsorbable fracture
fixation products. Its costs include the R&D costs associated with
the ATP project and commercialization and production costs,
which we assume will be 37 percent and 42 percent of total
revenue, respectively.

This model is
limited by its failure
to consider other
applications of this
technology and its
failure to account
for health effects.

3.1.3

The main limitation of this model is that it considers only the very
first application of Integra’s technology. Integra expects that other
orthopedic applications, including additional orthopedic
applications, wound care, cardiovascular repair, and drug delivery,
will follow soon after this initial application.
The second limitation of this model is its failure to account for any
differences in health outcomes between Integra’s bioabsorbable
fixation devices and metal fixation devices. Although no data
currently support the estimation of these benefits, these data may
become available as Integra proceeds with its animal models and
human trials. At that time, it would be helpful to add health effects
to this model.
Disease Treatment Using Living Implantable
Microreactors
BioHybrid Technologies, Inc., is developing the capability to
implant specific cells into the human body that produce hormones
or other bioactive agents that the patient cannot produce or is not
producing in sufficient quantity. BioHybrid’s approach is to encase
the transplanted cells in microspheres to isolate them from the
immune system. These “microreactors” have pores large enough to
permit glucose; nutrients; electrolytes; oxygen; and relatively small
bioactive species, like insulin, to pass but are small enough to
block the larger immunocytes and other relatively large molecules
involved in transplant rejection. Isolating the implanted cells from
the immune system opens up the possibility of using cells from
sources other than the recipient, for treatment of diseases such as
diabetes. Table 3-8 summarizes the assumptions of our analysis of
the project.
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Table 3-8. Model Assumptions for “Disease Treatment Using Living Implantable
Microreactors”

Timeline of Costs and Benefits

With ATP

Without ATP

Year 1 of R&D phase

1994

1994

Year 1 of commercialization phase

1997

1999

Year 1 of production phase

2000

2002

Final year of market window

2009

2009

Impact of ATP
ATP matching funds

$4,263,000

Acceleration

2 years

Probability of success
Elasticity of marginal benefits curve

-0.5

Total project R&D

$8,525,000 with ATP; $6,027,730 without ATP

Probability of success

11 percent higher in the with-ATP scenario

Scope effects

None reported

Medical Benefits Per Patient
Application

Diabetes

Defender technology

Daily insulin injections

Patient population

All Type I diabetics; insulin-dependent Type II
diabetics

Differences in health outcomes

Reduces the probability of retinopathy, nephropathy,
and neuropathy as noted in the Diabetes Control and
Complication Trial (DCCT) study (DCCTRG, 1996)

Number of Beneficiaries

65,498 in 2000; 1,171,047 by 2009 (See Table 3-11)

Changes in Health Care Costs

Annual procedure costs increase but costs of treating
health effects of diabetes fall

Private Company Costs and Benefits
Private spending in R&D phase

$4,262,000 with ATP; $6,027,730 without ATP

Commercialization cost

37 percent of revenue

Production cost

42 percent of revenue

Timeline of R&D Costs and Benefits
In our model, the relevant time horizon for this project is 1994 to
2009. BioHybrid’s 3-year ATP project begins in 1994; the R&D
phase is 1994 through 1997. (BioHybrid has recently been
approved for a 2-year no cost project extension.) BioHybrid
expects that its product will enter the U.S. market in 2000. Thus,
the commercialization phase begins in 1997 and ends in 1999.
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The production phase lasts 10 years, beginning in 2000 and ending
in 2009.
BioHybrid estimates that ATP funding accelerated the project by
2 years. In our model, the R&D phase in the without-ATP scenario
lasts 4, rather than 2, years; the commercialization phase begins in
1999 and the production phase begins in 2002. However, because
the window of market opportunity ends in 2009, the production
phase in the without-ATP scenario is only 8 years.
Impact of ATP on Social Returns
ATP awarded BioHybrid $4,263,000 in matching funds. Aside
from the 2 years of project acceleration discussed above, ATP
funding also increased the expected probability of technical
success for this project. We discussed the impacts of ATP funding
with BioHybrid officials who indicated that although ATP funding
was important to securing private funding on the project BioHybrid
would have proceeded with the project even in the absence of ATP
funding. Thus, we assume that the marginal benefits function was
relatively inelastic, with an elasticity of –0.5. Using this elasticity
and Eq. (2.2), we estimate that in the absence of ATP funding total
spending in the R&D phase would have totaled $6,027,730, rather
than $8,525,000, which was spent in the with-ATP scenario.
Applying this change in spending to Eq. (2.3), we estimate an
11 percent increase in the probability of technical success in the
with-ATP scenario compared to the without-ATP scenario.

ATP funding helped
BioHybrid attract
the private-sector
funding needed for
the ATP match and
the additional
funding needed to
bring the product to
market.

BioHybrid reported no impact on the scope of the project;
however, they did indicate that the ATP funding helped attract the
private-sector funding for the ATP match and the additional funding
that will be required to bring the product to market. This “halo
effect” of ATP funding may have affected BioHybrid’s cost of
capital, their total R&D spending, and their probability of technical
success. We did not explicitly quantify this effect; thus, we have
probably underestimated the impact of ATP on the benefits of this
technology.
Medical Benefits to Patients
Application. BioHybrid’s technology has the potential to be
applied to a number of therapeutic applications, including
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hemophilia, Parkinson’s disease, Alzheimer’s disease, and hepatic
failure. However, the most immediate applicationthe one
considered for this studyis for diabetic patients who are unable to
produce insulin to control blood glucose.
BioHybrid’s technology
will replace daily insulin
injections in diabetic
patients.

Defender Technology. This technology would be used in place of
multiple daily insulin injections.
Differences in Health Outcomes. To receive the BioHybrid
implants, patients will undergo an outpatient procedure under local
anesthetic. Encapsulated islet cells will be injected into the
peritoneal cavity under ultrasound control. Because the
transplanted islet cells have a finite life, the patient will receive an
injection once or twice a year. The dose and frequency of
treatment have not yet been finalized but will be determined during
the planned clinical trials.
If successful, the transplants will allow patients to achieve close to
normal glycemic control, virtually eliminating many of the risks of
long-term complications of diabetes, including retinopathy,
nephropathy, and renal disease. To quantify the impact of these
health impacts, we used the chronic disease model described in
Chapter 2. We found much of the data required for the model in
the results of a carefully controlled study of intensive insulin
therapy on the long-term health outcomes of diabetic patients, the
Diabetes Control and Complication Trial (DCCT). This study
demonstrated that intensive insulin therapy would lead to tight
glycemic control (DCCTRG, 1993; DCCTRG, 1995; DCCTRG,
1996). BioHybrid believes that the control provided by its
technology will be at least as effective as intense insulin therapy.
Thus, if BioHybrid is technically successful, our estimates of the
long-term health impacts of its technology are conservative.

We examined the
technology’s impact on the
three primary
complications of diabetes:
retinopathy, nephropathy,
and neuropathy.

Health States. Our model includes three diseases—retinopathy,
nephropathy, and neuropathy—which are the primary health
complications of diabetes. For each of these diseases, a series of
health states describes the seriousness of the disease. The DCCT
defined these health states (DCCTRG, 1993). They are listed in
Table 3-9.
Each of the health states is associated with a QALY and a cost. The
cost includes the personnel, drug, equipment, and establishment
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Table 3-9. Annual Health
States, QALYs, and Cost
for the Diabetes Model

Cost

QALY

Retinopathy Model
No retinopathy

$0

1.00

Background retinopathy

$0

1.00

Proliferative retinopathy

$0

1.00

Macular edema

$0

1.00

$1,911

0.69

Normoalbuminuria

$0

1.00

Microalbuminuria

$0

1.00

Albuminuria

$0

1.00

$46,207

0.61

No neuropathy

$0

1.00

Neuropathy

$0

1.00

$31,225

0.80

Blindness
Nephropathy Model

End-stage renal disease (ESRD)
Neuropathy Model

Lower extremity amputation
Source: DCCTG (1993, 1995, 1996).

cost of treating these disease states. The cost and QALY estimates
listed in Table 3-9 were based on those reported by the DCCT study
(DCCTRG, 1993; DCCTRG, 1995; DCCTRG, 1996). Note that no
estimates are provided for intermediate health states.
Transition Probabilities. The transition probabilities indicate the
probability of moving from one health state in one year to another
health state in the next year. We developed the transition
probabilities for nephropathy, neuropathy, and retinopathy based
on the DCCT study (DCCTRG, 1993; DCCTRG, 1995; DCCTRG,
1996). The transition probability matrixes for the three models are
found in Table 3-10.
Switching Probabilities. At the end of each year, part of the patient
cohort will be switched from the defender technology to the new
technology. The market diffusion forecast provides these switching
probabilities.
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Table 3-10. Transition Matrixes for the Diabetes Model: Conventional Treatment

No retinopathy

No
Retinopathy

Background
Retinopathya

1 – P1

P1 =
f(α=2.4862,
β=0.008)

Background
retinopathy

1 – P2

Proliferative
retinopathy

Proliferative
Retinopathya

Macular
Edema

Blindness

0.03

0.01

0.97

0.03

P2 =
f(α=1.8976,
β = 0.004)
0.96

Macular edema
Blindness

1
Normoalbuminuria

Normoalbuminuria

Microalbuminuria

Albuminuria

1 – P1 – P2

Death
P2 = 1.2 * diseasefree mortality rate

Microalbuminuria

0.94 – P3

Albuminuria

0.06
0.95 – P4

ESRD

Death

No neuropathy

ESRD

P3 = 1.4 * diseasefree mortality rate
0.05

P4 = 1.7 * diseasefree mortality rate

1 – P5

P5 = Age-specific
ESRD mortality
rate
1

No
Neuropathy

Neuropathy

0.98

0.02

Neuropathy

0.99

Lower extremity
amputation

Lower
Extremity
Amputation
0.01
1

entries represent the probability of moving between health state i and health state j as a function of α and β.
The function is as follows:

aThese

P = 1 −

3-22

e − βt

α

−β t − 1
e ( )

α

Chapter 3 — Tissue Engineering Case Studies

Table 3-10. Transition Matrixes for the Diabetes Model: New Treatment (continued)

No retinopathy

No
Retinopathy

Background
Retinopathya

1 – P1

P1 =
f(α=1.487,
β=0.018)

Background
retinopathy

1 – P2

Proliferative
retinopathy

Proliferative
Retinopathya

Macular
Edema

Blindness

0.02

0.01

0.97

0.03

P2 =
f(α=1.651,
β = 0.007)
0.97

Macular edema
Blindness

1
Normoalbuminuria

Normoalbuminuria

Microalbuminuria

Albuminuria

1 – P1 – P2

Death
P2 = 1.2 * diseasefree mortality rate

Microalbuminuria

0.94 – P3

Albuminuria

0.06
0.95 – P4

ESRD

Death

No neuropathy

ESRD

P3 = 1.4 * diseasefree mortality rate
0.05

P4 = 1.7 * diseasefree mortality rate

1 – P5

P5 = Age-specific
ESRD mortality
rate
1

No
Neuropathy

Neuropathy

0.99

0.01

Neuropathy

0.99

Lower extremity
amputation

Lower
Extremity
Amputation
0.01
1

entries represent the probability of moving between health state i and health state j as a function of α and β.
The function is as follows:

aThese

P = 1 −

e − βt

α

−β t − 1
e ( )

α

3-23

A Framework for Estimating the National Economic Benefits of ATP Funding of Medical Technologies

Number of Beneficiaries
Although there are many
undiagnosed diabetics in
the U.S., we do not include
them in our patient cohort
because they will not be
treated.

The relevant patient population is Type I and insulin-dependent
Type II diabetics because they depend on daily insulin injections.
As shown in Table 3-11, there will be approximately 2,044,550
diagnosed insulin-dependent diabetics in the U.S. in 2000. Our
model follows the progression of this cohort of diabetics from the
time the new technology is introduced (2000) through the end of
their lives.

Table 3-11. Expected Market Penetration for BioHybrid’s Diabetes Treatment

Number Using BioHybrid Technology
Year

Eligible Patientsa

With ATP

Without ATP

2000

2,044,550

65,498

0

2001

2,044,550

110,468

0

2002

2,044,550

183,271

65,498

2003

2,044,550

295,888

110,468

2004

2,044,550

457,310

183,271

2005

2,044,550

661,608

295,888

2006

2,044,550

874,437

457,310

2007

2,044,550

1,041,811

661,608

2008

2,044,550

1,134,485

874,437

2009

2,044,550

1,171,047

1,041,811

aTotal eligible patients from ADA web site (1996) and Adams and Marano (1995). These numbers have been adjusted

for the expected number of new diagnoses and deaths from 1996 to 2000.

Table 3-11 also shows the results of our analysis of the expected
market penetration of BioHybrid’s encapsulation technology. We
developed these estimates of market penetration using the
methodology explained in Section 2.3.2. We interviewed three
physicians to obtain input for the diffusion model.
Using these data, we estimated the Bass diffusion model and the
forecast equation (Eq. [2.7]) to determine the expected number of
patients receiving BioHybrid’s technology for each year in the
production phase.
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Changes in Health Care Costs
Each of the health states in the model is associated with an annual
cost. The difference between the cost of treating a patient using
daily insulin injections and BioHybrid’s technology depends on
both the cost of treatment (daily insulin injections or BioHybrid
implants) and the cost of treating the complications of diabetes,
which are defined by the health states shown in Table 3-9. As
noted earlier, the cost estimates listed in Table 3-9 are based on
those reported by the DCCT study (DCCTRG, 1993; DCCTRG,
1995; DCCTRG, 1996). The per-patient lifetime increase in health
care costs is $42,996.
Estimating Private Return on Investment
R&D Costs. BioHybrid’s contribution to the cost of the ATP project
was $4,262,000. As explained above, we estimate that in the
absence of ATP funding BioHybrid would have spent $6,027,730
on this project.
Commercialization and Production Costs. BioHybrid could not
provide an estimate of the costs of commercialization or
production. Thus, we used data from the biotechnology industry
described in Chapter 2 to assume that commercialization costs
would be 37 percent of total revenue and that production costs
would be 42 percent of revenue.
Summary
Our model examines the costs and benefits of the development of
BioHybrid’s diabetes treatment technology from 1994 to 2009. In
the with-ATP scenario, the R&D phase lasts 3 years, the
commercialization phase lasts 3 years, and the production phase
lasts 10 years. In the without-ATP scenario, the R&D phase lasts
5 years, and the production phase lasts only 8 years.
ATP funding accelerated the R&D phase of the project by 2 years,
increased the level of total R&D spending by about $2.5 million
and increased the probability of technical success by 11 percent.
BioHybrid’s technology will be used in the treatment of diabetes in
lieu of daily insulin injections. The treatment, if technically
successful, will provide glycemic control at least as effective as that
studied in the DCCT. Thus, we used data from that study to model
the health impacts of this technology.
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Based on the predictions of the experts we interviewed and our
market diffusion model, we expect that in its first year of
production, this technology will be used to treat over 65,000
patients; by 2009, it will be used to treat over one million diabetics
annually. Although the costs of treating diabetes will rise, the costs
of treating its complications will fall as the complications are
reduced by the treatment.
In the with-ATP scenario, BioHybrid invests $4,262,000 in R&D for
this project; our model predicts that without the ATP grant they
would have invested over $6 million. Our model assumes that
BioHybrid and its partners in commercialization and production
will spend about 37 percent and 42 percent of revenue on
commercialization and production, respectively.
This model does not take into account the following factors:
Z patients diagnosed after 2000 whom we did not include in
the fixed patient cohort;
Z the change in quality of life for the patient from eliminating
insulin injections;
Z the improved health outcomes that may occur over and
above what was found in the DCCT; and
Z other health effects associated with diabetes that were not
modeled by the DCCT, such as cardiovascular effects.
In addition, we could not find estimates of QALYs or costs for the
intermediate health states of diabetes (see Table 3-9). The DCCT
only estimates costs and QALYs for the end-stage diseases.
Because these end-stage conditions occur late in life, most of the
benefits of the diabetes model occur late in a patient’s life.
Consequently, the benefits are sensitive to the discount rate,
especially because costs occur in each year, while benefits occur
late in life.
3.1.4

Treatment of Diabetes by Proliferated Human Islets
in Photocrosslinkable Alginate Capsules
VivoRx, Inc., is developing a new treatment for diabetes that will
consist of transplanting human islets that have been encapsulated in
immunoprotective membrane consisting of a novel material. This
material protects the cells from the host’s immune response. This
technology has potential applications for liver disease, thyroid
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VivoRx has tested the
effectiveness of its diabetes
treatment using islet cells
from human cadaver
pancreata. The success of
these tests has encouraged
VivoRx to take the next
step in making this
treatment widely available:
providing proliferated
human islets for transplant.

disease, Parkinson’s disease, and Alzheimer’s disease. However,
the most immediate applicationthat examined for this studyis
for the treatment of diabetes. It will eliminate the need for daily
insulin injections and will enable patients to achieve tight glycemic
control, reducing the risk of the common complications of diabetes.
The objective of VivoRx’s ATP project is to make this therapy
widely available by producing a source of human islet cells.
VivoRx is developing the culture conditions and methods for
proliferating human islets. They are simultaneously perfecting the
polymers and biomaterials that are required to achieve
immunoprotection and biocompatibility for the encapsulation
technology. Table 3-12 summarizes the assumptions of our
analysis of the project.
Timeline of R&D Costs and Benefits

The relevant time
horizon for this
project is 1995 to
2008.

In our model, the relevant time horizon for this project is 1995 to
2008. VivoRx’s 3-year ATP project begins in 1995; the R&D phase
of this project is 1995 through 1997. VivoRx expects that its
product will enter the market in 1999. Thus, the
commercialization phase occurs in 1998. The production phase
lasts 10 years, beginning in 1999 and ending in 2008.
VivoRx estimates that ATP funding accelerated the project by 3 to 5
years. Using the median of this range (4 years), the R&D phase in
the without-ATP scenario lasts 7, rather than 3, years. The
commercialization phase occurs in 2002 and the production phase
begins in 2003. The window of market opportunity is fixed; the
production period in the without-ATP scenario lasts only 6 years.
Impact of ATP on Social Returns
ATP awarded VivoRx $2,000,000 in matching funds. Aside from the
acceleration effect discussed above, we modeled how ATP funding
affected the expected probability of technical success for this project.
We asked VivoRx officials about how they would have proceeded in
the absence of ATP funding. They indicated that although ATP
funding was important to securing private funding on the project
VivoRx would have proceeded with the project even in the absence
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Table 3-12. Model Assumptions for “Treatment of Diabetes by Proliferated Human Islets in
Photocrosslinkable Alginate Capsules”

Timeline of Costs and Benefits

With ATP

Without ATP

Year 1 of R&D phase

1995

1995

Year 1 of commercialization phase

1998

2002

Year 1 of production phase

1999

2003

Final year of market window

2008

2008

Impact of ATP
ATP matching funds

$2,000,000

Acceleration

4 years

Probability of success
Elasticity of marginal benefits curve

-0.5

Total project R&D

$16,925,000 with ATP; $15,893,570 without ATP

Probability of success

2 percent higher in the with-ATP scenario

Scope effects

None reported

Medical Benefits Per Patient
Application

Diabetes

Defender technology

Daily insulin injections

Patient population

All Type I diabetics; insulin-dependent Type II
diabetics

Differences in health outcomes

As noted in the DCCT study (DCCTRG, 1996), about
0.6 QALY per patient over their lifetime

Number of Beneficiaries

63,711 in 1999; 1,007,470 by 2008

Changes in Health Care Costs

Annual procedure costs increase but costs of
treating health effects of diabetes fall

Private Company Costs and Benefits
Private spending in R&D phase

$14,925,000 with ATP; $15,893,570 without ATP

Commercialization cost

37 percent of revenue

Production cost

42 percent of revenue

of ATP funding. Thus, we assume that the marginal benefits function
was relatively inelastic, with an elasticity of –0.5. Using this
elasticity and Eq. (2.2), we estimate that in the absence of ATP
funding total spending in the R&D phase would have totaled
$15,893,570, rather than $16,925,000, which was spent in the withATP scenario. Applying this change in spending to Eq. (2.3), we
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estimate a 2 percent increase in the probability of technical success
in the with-ATP scenario compared to the without-ATP scenario.
Medical Benefits to Patients
Application. Although the proliferation of human islet cells will
lead to advances in the treatment of many diseases, the most
immediate applicationthat considered for this studyis to
replace daily insulin injections in diabetic patients.
Defender Technology. This technology would be used in place of
multiple daily insulin injections.
Differences in Health Outcomes. The application will involve an
outpatient procedure and a local anesthetic. Proliferated,
encapsulated human islet cells are injected into the peritoneal
cavity. The procedure will be repeated once per year or perhaps
once every 2 years to replenish the cells. The dose and frequency
of treatment have not yet been finalized but will be determined
during the current Phase I/Phase II trials.
If successful, the procedure will allow patients to achieve close to
normal glycemic control, virtually eliminating many of the risks of
long-term complications of diabetes, including retinopathy,
nephropathy, and renal disease. Because the expected long-term
health effects and the patient population are the same as for
BioHybrid’s technology, we used the same model and data to
quantify the health impacts of this technology. VivoRx officials
noted that it is appropriate to use the long-term health impacts
reported in the DCCT to analyze the benefits of VivoRx’s
technology. Thus, the health states, the QALYs and costs
associated with them, and the transition probabilities required for
the model are the same as those used for the BioHybrid project.
We derived the switching probabilities for each year from the
market penetration analysis discussed below.
Number of Beneficiaries
The relevant patient population is Type I and insulin-dependent
Type II diabetics. As shown in Table 3-13, there will be
approximately 1,955,000 diagnosed insulin-dependent diabetics in
the U.S. in 1999. Our model follows the progression of this cohort
of diabetics from 1999 through the end of their lives.
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Table 3-13 shows the expected total number of patients eligible to
receive this treatment from 1999 to 2008. It also shows the results
of our analysis of the expected market penetration of the VivoRx
diabetes treatment. We developed these estimates of market
penetration using the methodology explained in Section 2.3.2. We
interviewed three physicians to obtain input for the diffusion
model. Using these data, we estimated the Bass diffusion model
and the forecast equation (Eq. [2.7]) to determine the expected
number of patients receiving VivoRx’s technology for each year in
the production period.
Table 3-13. Expected Market Penetration for the VivoRx Diabetes Treatment Technology

Number Using VivoRx Technology
Year

Eligible Patients

With ATP

Without ATP

1999

1,955,000

63,711

0

2000

1,955,000

122,647

0

2001

1,955,000

202,286

0

2002

1,955,000

305,295

0

2003

1,955,000

430,677

63,711

2004

1,955,000

571,339

122,647

2005

1,955,000

713,520

202,286

2006

1,955,000

840,452

305,295

2007

1,955,000

939,509

430,677

2008

1,955,000

1,007,470

571,339

Changes in Health Care Costs
Each of the health states is associated with an annual cost. The
difference between the cost of treating a patient using daily insulin
injections and VivoRx’s technology depends on both the cost of
treatment (daily insulin injections or VivoRx implants) and the cost
of treating the complications of diabetes, which are defined by the
health states shown in Table 3-9. The cost estimates listed in
Table 3-9 are based on those reported by the DCCT study
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(DCCTRG, 1993; DCCTRG, 1995; DCCTRG, 1996). The perpatient lifetime increase in health care costs is $129,627.
Estimating Private Return on Investment
R&D Costs. VivoRx’s contribution to the cost of the ATP project was
$14,925,000. As explained above, we estimate that in the absence
of ATP funding VivoRx’s investment costs would have risen to
$15,893,570; however, the total R&D funding would have fallen.
Commercialization and Production Costs. We used data from the
biotechnology industry described in Chapter 2 to assume that
commercialization costs would be 37 percent of total revenue and
that production costs would be 42 percent of revenue.
Summary
Our model examines the costs and benefits of developing VivoRx’s
diabetes treatment technology from 1995 to 2008. In the with-ATP
scenario, the R&D phase lasts 3 years, the commercialization phase
lasts 1 year, and the production phase lasts 10 years. In the
without-ATP scenario, the R&D phase lasts 7 years, and the
production phase lasts only 6 years.
ATP funding accelerated the R&D phase of the project by 4 years,
increased the level of total R&D spending by over $1 million, and
increased the probability of technical success by 2 percent.
VivoRx’s technology will be used in the treatment of diabetes in
lieu of daily insulin injections. The treatment, if technically
successful, will provide glycemic control at least as effective as that
studied in the DCCT. Thus, we used data from that study to model
the health impacts of this technology.
Based on the predictions of the experts we interviewed and our
market diffusion model, we expect that in its first year of
production, this technology will be used to treat over 63,000
patients. By 2008, it will be used to treat over one million diabetics
annually. Although the costs of treating diabetes will rise, the costs
of treating its complications will fall as the complications are
reduced by the treatment.
In the with-ATP scenario, VivoRx invests $14,925,000 in R&D; our
model predicts that without the ATP grant they would have invested
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almost $16 million. Our model assumes that VivoRx and its
partners in commercialization and production will spend about
37 percent and 42 percent of revenue on commercialization and
production, respectively.
Because we used the same health benefits model for VivoRx’s
technology as we did for BioHybrid’s, our estimates suffer from the
same limitations, including the failure to consider
Z patients diagnosed after 1999 whom we did not include in
the fixed patient cohort;
Z the change in quality of the patient’s life from eliminating
insulin injections;
Z the improved health outcomes that may occur over and
above what was found in the DCCT;
Z other health effects associated with diabetes, such as
cardiovascular effects; and
Z the differences in cost on health effects of intermediate
stages of each disease.
In addition, we did not consider the potential interaction between
the VivoRx technology and the BioHybrid technology. Instead, we
analyzed each technology in the absence of the other. If both
technologies are technically successful, they may compete for
market share. It is difficult to forecast how this competition might
affect private and social returns.
3.1.5

Fabrication of Clinical Prosthesis from Biomaterials
The objective of Tissue Engineering’s ATP project was to further the
development of its new class of biomaterials. These biomaterials
can be developed into prostheses that provide templates that
mobilize the body’s own cells and induce them to rebuild lost
tissue, gradually replacing the prosthesis itself. With ATP funding,
Tissue Engineering furthered the development of its basic ADMAT,
or animal derived extracellular matrix. It can produce ADMAT in a
variety of forms, has characterized the necessary properties of the
ADMAT substrate to promote cell growth and differentiation, has
characterized ADMAT for immunogenicity, and has developed cell
banks to support five types of proposed cell-incorporating
prostheses. Table 3-14 summarizes the assumptions of our analysis
of the project.
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Table 3-14. Model Assumptions for “Fabrication of Clinical Prostheses from Biomaterials”

Timeline of Costs and Benefits

With ATP

Without ATP

Year 1 of R&D phase

1993

1993

Year 1 of commercialization phase

1996

1998

Year 1 of production phase

2001

2003

Final year of market window

2010

2010

Impact of ATP
ATP matching funds

$1,999,000

Acceleration

2 years

Probability of success
Elasticity of marginal benefits curve

-0.01

Total Project R&D

$4,127,000 with ATP; $4,099,750 without ATP

Probability of success

1 percent higher in the with-ATP scenario

Scope effects

None reported

Medical Benefits Per Patient
Application

Repair of the anterior cruciate ligament (ACL)

Defender technology

Allogeneic banked tissue or autologous graft from
patella tendon

Patient population

Patients undergoing surgery for ACL repair

Differences in health outcomes
(Not quantified)

May reduce failure rates associated with both
allogeneic banked tissue and autologous graft, risk
of contamination associated with allogeneic tissue,
and reduce morbidity compared to autologous graft

Number of Beneficiaries

9,000 in 2001; 71,773 by 2010 (See Table 3-15)

Changes in Health Care Costs

None

Private Company Costs and Benefits
Private spending in R&D phase

$2,128,000 with ATP; $4,099,750 without ATP

Commercialization cost

37 percent of revenue

Production cost

42 percent of revenue

Timeline of R&D Costs and Benefits
Our model traces the benefits and costs of Tissue Engineering’s ATP
project from 1993 to 2010. The ATP project begins in 1993; the
R&D phase of this project is 1993 to 1995. Tissue Engineering
expects that its product will enter the U.S. market in 2001. Thus,
the commercialization phase begins in 1996 and ends in 2000.
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The production phase lasts 10 years, beginning in 2001 and ending
in 2010.
Tissue Engineering estimates that ATP funding accelerated the
project by 2 years. The R&D phase in the without-ATP scenario
lasts 5, rather than 3, years. The commercialization phase begins
in 1998 and the production phase begins in 2003. However, the
window of market opportunity is fixed; the production period is
2 years shorter in the without-ATP scenario.
Impact of ATP on Social Returns
ATP awarded Tissue Engineering $1,999,000 in matching funds.
Aside from the acceleration effect discussed above, ATP funding
also had a very small impact on the probability of technical success
for this project. We asked Tissue Engineering officials about how
they would have proceeded in the absence of ATP funding. They
indicated that the absence of ATP funding would have made no
difference in their funding decisions. Thus, we assume that their
marginal benefits function was very inelastic, with an elasticity of
–0.01. Using this elasticity and Eq. (2.2), we determined that in the
absence of ATP funding, total spending in the R&D phase would
have totaled $4,099,750, rather than $4,127,000, which was spent
in the with-ATP scenario. This results in a 1 percent increase in the
probability of technical success in the with-ATP scenario compared
to the without-ATP scenario.
Tissue Engineering reported no impact on the scope of the project;
however, they did indicate that the ATP funding was important for
peer recognition of their work.
Medical Benefits to Patients
ADMAT can be used for
vascular grafts, ligament
and tendon repair, and
periodontal and similar
reconstruction.

Application. ADMAT can be used to enhance collagen scaffolds
for vascular grafts, ligaments, tendons, periodontal tissue, and
similar reconstructions. ADMAT alone can be used as a matrix on
which “glandular” cells such as insulin-producing cells, nerve cell
precursors, thyroid cells, and others can grow and function. At the
time of our survey, a likely early commercial application was
thought to be reconstruction of ligaments, tendons, and articular
cartilage. A specific sub-class of those therapies is the application
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of ADMAT to repair the anterior cruciate ligament (ACL), which is
the application modeled for this project.
Defender Technology. Two technologies are currently in use for
surgical repair of the ACL: graft from cadaver tissue and autologous
graft from the patient’s patella tendon or hamstring. Many patients
do not undergo surgical repair.
Differences in Health Outcomes. ACL repair currently suffers from
a number of problems. Cadaver tissue is limited and carries a risk
of viral infection. Autologous grafts often cause graft site morbidity,
which may limit the patient’s use of the area from which the graft
was taken.
We spoke with several doctors who specialize in ACL repair and
reviewed many papers on ACL repair procedures. These sources
indicated that eliminating the risk of viral infection and graft site
morbidity in patients undergoing ACL repair would certainly
increase a patient’s quality of life. Currently, a QALY instrument
developed by Dr. Nicholas G.H. Mohtadi at the University of
Calgary is being tested to determine the relative quality of life of
patients before and after ACL surgery (Mohtadi, 1993). This
research, which is being conducted by Dr. Mohtadi and his
colleague Dr. P.H. Marks at the University of Toronto, will provide
significant insight into the potential health benefits of eliminating
complications of ACL repair (Marks and Mohtadi, 1996).
Until these estimates are available, we have only qualitative data to
determine the potential gain from removing the complications of
ACL surgery. Based on our conversations with a number of
physicians, we assume that with the new technology a person
would gain 0.025 QALY points per year (e.g., their QALYs would
change from 0.90 to 0.925). For a person who lives 40 years past
the time of surgery, this translates into 0.58 additional QALYs using
a 3 percent discount rate.
Number of Beneficiaries
The patient population for Tissue Engineering’s technology consists
of the patients undergoing surgery for ACL repair. Jack Parr, of
Wright Medical, a firm partnering with Tissue Engineering in
marketing this application, estimated this population at 100,000
annually.
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Table 3-15 shows the expected total number of patients eligible to
receive this treatment from 2001 to 2010. It also shows the results
of our analysis of the expected market penetration of the Tissue
Engineering technology. We developed these estimates of market
penetration using the methodology explained in Section 2.3.2.
Because this was not one of our in-depth case studies, we obtained
input for the diffusion model from one expert, a representative from
Wright Medical.
Table 3-15. Expected
Market Penetration for
the Tissue Engineering’s
ADMAT Material for
Repairing the ACL

Number Using ADMAT
Year

Eligible Patients

With ATP

Without ATP

2000

100,000

9,000

0

2001

100,000

19,493

0

2002

100,000

30,293

9,000

2003

100,000

40,629

19,493

2004

100,000

49,780

30,293

2005

100,000

57,277

40,629

2006

100,000

62,996

49,780

2007

100,000

67,102

57,277

2008

100,000

69,914

62,996

2009

100,000

71,773

67,102

Using these data, we estimated the Bass diffusion model and the
forecast equation (Eq. [2.7]) to determine the expected number of
patients receiving Tissue Engineering’s technology for each year in
the production period.
Changes in Health Care Costs
The additional cost of the
ADMAT material will be
outweighed by the savings
resulting from eliminating
the costs of obtaining the
graft from a cadaver or
from the patient’s patella
tendon.
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We assume that the cost of repairing an ACL with the material
provided by Tissue Engineering would be the same as current
methods. Although the new technology requires the purchase of
the ADMAT material developed by Tissue Engineering, other costs
associated with the defender technology, such as obtaining the
graft material from a cadaver or from another site on the patient,
will be eliminated. According to a representative of Wright

Chapter 3 — Tissue Engineering Case Studies

Medical, these savings will at least outweigh the cost of the
ADMAT material. Thus, there are no changes in health care costs
in this model.
Estimating Private Return on Investment
R&D Costs. Tissue Engineering’s contribution to the cost of the
ATP project was $2,128,000. As explained above, we estimate that
in the absence of ATP funding Tissue Engineering would have spent
$4,099,750 on this project.
Commercialization and Production Costs. Tissue Engineering
could not provide an estimate of the costs of commercialization or
production of the ADMAT material for use in repairing the ACL.
Thus, we used data from the biotechnology industry described in
Chapter 2 to assume that commercialization costs would be
37 percent of total revenue and that production costs would be
42 percent of revenue.
Summary
We evaluated the benefits and costs of Tissue Engineering’s ATP
project from 1993 to 2010. In the with-ATP scenario, the R&D
phase lasts 3 years, the commercialization phase lasts 5 years, and
the production phase lasts 10 years. In the without-ATP scenario,
the R&D phase is 2 years longer and the production phase is 2
years shorter.
Tissue Engineering stated that ATP funding accelerated the project
by 2 years but had little impact on the level of funding or the scope
of the project. Based on these qualitative remarks, our model
estimated a 1 percent increase in the probability of technical
success due to ATP funding.
If technically successful, Tissue Engineering’s ADMAT material will
replace allogeneic and autologous grafts for patients undergoing
surgery for ACL repair. The reduction in failure rates, reduced risk
of contamination, and reduced morbidity will increase the quality
of life for these patients. The cost of treating these patients will not
substantially change.
Based on the predictions of a company representative and our
market penetration model, we expect that ADMAT will be used to

3-37

A Framework for Estimating the National Economic Benefits of ATP Funding of Medical Technologies

repair the ACL in 9,000 patients in its first year to market, and
about 72,000 patients in 2010.
Tissue Engineering and its partners in commercialization and
production will receive revenue from the sale of ADMAT. Tissue
Engineering spent 2,128,000 in R&D on the ATP project. In our
model, they will incur commercialization and production costs of
37 and 42 percent of these revenues, respectively.
The primary weakness of this model is the unavailability of clinical
data to verify the qualitative estimates of the impact of this
technology on patients’ quality of life.
3.1.6

Application of Gene Therapy to Treatment of
Cardiovascular Diseases
The objective of Progenitor, Inc.’s, ATP project was to develop a
supply of transplantable endothelial cells from precursor stem cells
that can be genetically engineered or otherwise modified for
specific medical purposes. Progenitor originally envisioned that
one application target would use these cells to repair damaged
vascular tissue, with the most immediate application being the
treatment of damage associated with coronary angioplasty. Other
potential medical application areas originally identified by
Progenitor were cancer treatments and bone development.
In the course of its research, Progenitor made an important
discovery that provided an opportunity to strengthen the goals and
activities related to cancer treatments. Progenitor believes that
eventually this discovery will lead to a new treatment for solid
tumor cancers. However, its most immediate application is the
diagnosis, location, and staging of soft tissue metastases. The
resulting improvement in diagnostic techniques will allow for more
aggressive, effective cancer therapy at an earlier stage of metastasis,
improving patients’ prognosis. Table 3-16 summarizes the
assumptions of this analysis of the project.
Timeline of R&D Costs and Benefits
We modeled the benefits and costs of Progenitor’s ATP project from
1995 to 2011. The 3-year ATP project begins in 1995; the R&D
phase is 1995 to 1997. Progenitor expects that its product will
enter the U.S. market in 2002. Thus, the commercialization
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Table 3-16. Model Assumptions for “Application of Gene Therapy to Treatment of
Cardiovascular Disease”

Timeline of Costs and Benefits

With ATP

Without ATP

Year 1 of R&D phase

1995

1995

Year 1 of commercialization phase

1998

2000

Year 1 of production phase

2002

2004

Final year of market window

2011

2011

Impact of ATP
ATP matching funds

$1,996,000

Acceleration

2 years

Probability of success
Elasticity of marginal benefits curve

-0.5

Total project R&D

$2,795,000 with ATP; $1,494,390 without ATP

Probability of success

20 percent higher in the with-ATP scenario

Scope effects

Some effects reported but not quantified

Medical Benefits Per Patient
Applicationa

Diagnosis, location, and staging of soft tissue
metastases from lung cancera

Defender technology

Standard diagnostic techniques

Patient population

Lung cancer patients

Differences in health outcomes

Improve diagnosis of cancer metastasis; sensitivity
and selectivity of diagnosis will be at least 85%

Number of Beneficiaries

17,350 in 2002; 124,508 by 2011 (See Table 3-17)

Changes in Health Care Costs

Procedure will be performed in conjunction with
current techniques, adding to the cost of diagnosis;
extending patient’s life also adds to lifetime health
care costs

Private Company Costs and Benefits
Private spending in R&D phase

$799,000 with ATP; $1,494,390 without ATP

Commercialization cost

37 percent of revenue

Production cost

42 percent of revenue

aThe technology will apply to all tissue metastases; we examined only lung cancer metastases as an illustration of the

potential benefits on a portion of the applicable patient population.

3-39

A Framework for Estimating the National Economic Benefits of ATP Funding of Medical Technologies

phase begins in 1998 and ends in 2001. The production phase
lasts 10 years, beginning in 2002 and ending in 2011. Progenitor
estimates that ATP funding accelerated the project by 2 years. The
R&D phase in the without-ATP scenario lasts 5, rather than 3, years.
The commercialization phase begins in 2000 and the production
phase begins in 2004. However, the window of market opportunity
is fixed; the production period is 2 years shorter in the without-ATP
scenario.
Impact of ATP on Social Returns
ATP funding accelerated
the project by 2 years,
increased total R&D
spending by about
$1.3 million, and increased
the probability of technical
success by 20 percent.

ATP awarded Progenitor $1,996,000 in matching funds. Aside from
the acceleration effect discussed above, ATP funding also had an
important impact on the probability of technical success for this
project. Progenitor indicated that in the absence of ATP funding
they would have proceeded with the project, although it would
have had a lower priority, resulting in lower annual funding and the
delay mentioned earlier. Thus, we assume that their marginal
benefits function was relatively inelastic, with an elasticity of –0.5.
Using this elasticity and Eq. (2.2), we determined that in the
absence of ATP funding total spending in the R&D phase would
have totaled $1,494,390, rather than $2,795,000, which was spent
in the with-ATP scenario. This results in a 20 percent increase in
the probability of technical success in the with-ATP scenario
compared to the without-ATP scenario.
Progenitor stated that the ATP funding allowed them to explore
endothelial cells in greater depth than they might have otherwise
been able to. However, they were not able to state specifically
how this affected the scope of the project. Thus, we were not able
to model these scope effects in terms of changes in the applications
or patient populations.
Medical Benefits to Patients
Application. Progenitor believes that eventually this technology will
lead to a new treatment for solid tumor cancers. However, its most
immediate application is the diagnosis, location, and staging of soft
tissue metastases. The resulting improvement in diagnostic
techniques will allow for more aggressive, effective cancer therapy
at an earlier stage of metastasis, improving patients’ prognosis. We
chose to illustrate the potential benefits of Progenitor’s product by
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Progenitor’s first
application of its discovery
will be the diagnosis,
location, and staging of soft
tissue cancer metastases.
The resulting improvement
in diagnosis of these
metastases will allow more
effective cancer therapy.

showing its impact on the diagnosis and treatment of lung cancer.
The technology will be embodied in a diagnostic kit. The kit will
be used to conduct an imaging procedure that will be used in
conjunction with technetium bone scans.
Defender Technology. Currently no technologies image soft tissue
adequately to diagnose metastasis at a very early stage. Thus,
Progenitor’s product will not replace any current technologies but
will supplement the current diagnostic techniques.
Differences in Health Outcomes. Progenitor’s technology will
improve the detection of metastasis once cancer has been
diagnosed. We used the acute illness and injury model to develop
a cancer diagnosis model to estimate the value of improved
diagnosis of cancer metastasis.
Ideally, we would develop a Markov model for demonstrating the
benefits of improved cancer diagnosis. In each year after being
diagnosed with cancer, a patient has a probability of transitioning
into another health state. The improved diagnosis provided by the
Progenitor product would decrease the probability of progressing
into more advanced health states because the correct diagnosis
would lead to more appropriate treatment. Because the Progenitor
project was not one of our in-depth case studies and because time
for collecting data was limited, we opted for a simpler model, as
illustrated in Figure 3-1.
The patient population includes all lung cancer patients. We
allocated this population among localized, regional, and distant
metastasis, using data on the incidence of different stages of cancer
at diagnosis. For each stage of cancer, the defender technology
provides probability, p, that the metastasis will be diagnosed
correctly, while Progenitor’s technology provides improved
probability of correct diagnosis, p′. Metastases that are detected
can be treated appropriately; left undetected, these metastases will
progress to a more advanced stage before they are treated, costing
the patient additional life-years. For example, if patients with
regional metastasis are diagnosed correctly, we assume their 5-year
survival rate is equal to Y2, the 5-year survival rate for regional
metastasis. If they are misdiagnosed, we assume their metastasis
progresses, so we assigned them a 5-year survival rate for distant
metastasis (Stage 3) of Y3.
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Figure 3-1. Cancer Diagnosis Model
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expected 5-year survival rate, distant metastasis (Stage 3)
expected 5-year survival rate, distant metastasis (Stage 4)

We obtained data about the incidence of cancer, the initial
allocation of patients among different stages of cancer, and
expected life-years by stage of disease from SEER Cancer Statistics
Review, 1973-1992 (Kosary et al., 1995). We obtained data
regarding the sensitivity of standard metastasis detection techniques
(CT scans) from Buccheri and Ferrigno (1995). Progenitor provided
an estimate of the expected sensitivity of their product.
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Number of Beneficiaries
The patient population for this application of Progenitor’s
technology is all lung cancer patients. Table 3-17 shows the
expected total number of patients eligible to receive this procedure
from 2002 to 2011. It also shows the results of our analysis of the
expected market penetration of Progenitor’s product.
Table 3-17. Expected
Market Penetration for
Progenitor’s Tumor
Imaging Technology

Number Using Progenitor’s
Technology
Year

Eligible Patients

With ATP

Without ATP

2002

173,500

17,350

0

2003

174,021

43,505

0

2004

174,543

69,817

17,350

2005

175,066

87,533

43,505

2006

175,591

96,575

69,817

2007

176,118

96,865

87,533

2008

176,647

97,156

96,575

2009

177,176

97,447

96,865

2010

177,708

97,739

97,156

2011

178,241

98,033

97,447

Representatives of Progenitor were able to provide a 10-year
forecast of market penetration; therefore, we did not use the Bass
model to estimate market penetration for this technology.
Appendix A contains the raw data we collected from company
representatives.
Changes in Health Care Costs
Because Progenitor’s technology will not replace a defender
technology, but will augment existing diagnostic techniques, the
cost of the diagnostic procedure represents an increase in the cost
of treating a patient with lung cancer. In addition, some of the
benefits derived from extending a patient’s life are offset by the cost
of caring for that person during these additional years. The perpatient increase in lifetime health care costs is about $452. We
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obtained data on the average annual cost of treating lung cancer
patients from Virgo et al. (1996).
Estimating Private Return on Investment
R&D Costs. Progenitor’s contribution to the cost of the ATP project
was $799,000. As explained above, we estimate that in the
absence of ATP funding, Progenitor would have invested
$1,494,390 on this project.
Commercialization and Production Costs. Progenitor could not
provide an estimate of the costs of commercialization or production
of its product; it plans to license the technology to another
company that will conduct these activities. Thus, we used data
from the biotechnology industry described in Chapter 2 to assume
that commercialization costs would be 37 percent of total revenue
and that production costs would be 42 percent of revenue.
Summary
We evaluated the costs and benefits of Progenitor’s ATP project
from 1995 to 2011. In the with-ATP scenario, the R&D phase lasts
3 years, the commercialization phase lasts 4 years, and the
production phase lasts 10 years. In the without-ATP scenario, the
R&D phase is 2 years longer while the production phase is 2 years
shorter.
ATP funding accelerated the project by 2 years. Using our model
of the impact of the cost of funding on total R&D and the
probability of technical success, we estimate that ATP funding
increased the total R&D effort by about $1.3 million and the
probability of technical success by 20 percent.
Although this technology has a number of applications, the one
examined for this case study is the diagnosis, location, and staging
of soft tissue metastases from many kinds of cancer. To illustrate
the potential impact of this technology on one patient population,
we modeled the health benefits to lung cancer patients. By
improving the diagnosis of metastasis, this technology will lead to
more aggressive and effective treatment of lung cancer, improving
patients’ survival rate.
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The procedure will add to the total cost of diagnosis because it will
be performed in conjunction with currently used diagnostic
techniques. Extending a patient’s life also adds to the lifetime costs
of their health care.
Based on Progenitor’s estimates, our model assumes that
Progenitor’s technology will be used for over 17,000 diagnoses in
its first year of production; by 2011, it will be used for over 98,000
diagnoses.
Progenitor and its partners in commercialization and production
will earn revenues from the sale of diagnostic kits that will embody
the Progenitor technology. Aside from R&D expenses, they will
also incur commercialization and production costs, which, in our
model, are 37 and 42 percent of revenue, respectively.
The accuracy of this model would be improved by using a Markov
model and populating it with data regarding the probability of
transitioning from one health state to the next, the cost of treating
patients in each health state, and the QALYs associated with each
health state. In addition, we considered only the sensitivity of
diagnostic methods (the probability that a positive result is correct).
We did not consider the impact of false positive diagnoses. If
Progenitor’s new diagnostic technique improves the specificity of
cancer diagnosis, this may also contribute to social benefits to the
extent that incorrect positive diagnoses lead to costly unnecessary
treatment and cause patients pain and suffering. Finally, we have
considered only one type of cancer; however, if successful, this
product will improve diagnosis of soft tissue metastasis for many
kinds of cancer.
3.1.7

Universal Donor Organs for Transplantations
The objective of Alexion Pharmaceuticals’ ATP project is to
develop transgenic animals that will provide a source of organs for
xenogeneic transplants. In most cases, xenogeneic transplants fail
because of hyperacute rejection (HAR), which causes graft failures
within minutes to hours. To address this problem, Alexion is
developing animals that express key human genes to eliminate the
HAR response. Alexion plans to develop organs for human
transplant, called UniGraft organs, from transgenic pigs.
Table 3-18 summarizes the assumptions of our analysis of the
project.
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Table 3-18. Model Assumptions for “Universal Donor Organs for Transplantation”

Timeline of Costs and Benefits

With ATP

Without ATP

Year 1 of R&D phase

1995

1995

Year 1 of commercialization phase

1998

1999

Year 1 of production phasea

2002

2003

Final year of market window

2011

2011

Impact of ATP
ATP matching funds

$1,999,000

Acceleration

1 year

Probability of success
Elasticity of marginal benefits curve

-0.5

Total project R&D

$3,203,000 with ATP; $1,963,770 without ATP

Probability of success

16 percent higher in the with-ATP scenario

Scope effects

None reported

Medical Benefits Per Patient
Applicationb

Standard heart disease treatment while awaiting
transplant

Defender technology

Heart transplants

Patient populationa

Patients who can benefit from a heart transplant but
cannot receive one because supply is inadequate

Differences in health outcomes

A large percentage of patients die while awaiting
heart transplants; immediate availability of organs
will improve survival rate because patients will not
have to wait for organs; reduces deaths of patients
awaiting organs

Number of Beneficiaries

1,200 in 2002; 8,675 by 2011 (See Table 3-19)

Changes in Health Care Costs

Recipients of UniGraft hearts incur the same costs as
a human transplant recipient; annual treatment costs
for transplant patients are higher; lifetime treatment
costs rise due to increased life expectancy

Private Company Costs and Benefits
Private spending in R&D phase

$1,204,000 with ATP; $1,963,770 without ATP

Commercialization cost

37 percent of revenue

Production cost

42 percent of revenue

aAlexion believes that ultimately the market may expand beyond traditional heart transplant candidates.
bUniGraft organs will be developed for hearts, kidneys, lungs, and islets. Our analysis considers heart transplants only.
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Timeline of R&D Costs and Benefits
Our model assumes the relevant time horizon for this project is
1995 to 2011. Alexion’s 3-year ATP project begins in 1995; the
R&D phase is 1995 to 1997. Alexion expects that its product will
enter the U.S. market in 2002. Thus, the commercialization phase
begins in 1998 and ends in 2001. The production phase lasts 10
years, beginning in 2002 and ending in 2011.
Alexion estimates that ATP funding accelerated the project by 1 to
2 years. Using the conservative estimate of 1 year, the R&D phase
in the without-ATP scenario lasts 4, rather than 3, years. The
commercialization phase begins in 1999 and the production phase
begins in 2003. However, the window of market opportunity is
fixed; the production period is 1 year shorter in the without-ATP
scenario.
Impact of ATP on Social Returns
ATP awarded Alexion $1,999,000 in matching funds. Aside from
the acceleration effect discussed above, ATP funding also had an
important impact on the probability of technical success for this
project. Alexion representatives indicated that in the absence of
ATP funding they would have proceeded with the project, although
it would have progressed more slowly. Thus, we assume that their
marginal benefits function was relatively inelastic, with an elasticity
of –0.5. Using this elasticity and Eq. (2.2), we determined that in
the absence of ATP funding total spending in the R&D phase would
have totaled $1,963,770, rather than $3,203,000, which was spent
in the with-ATP scenario. This results in a 16 percent increase in
the probability of technical success in the with-ATP scenario
compared to the without-ATP scenario.
Medical Benefits to Patients
Application. Although Alexion’s technology may enable the
xenogeneic transplant of hearts, kidneys, lungs, and islets, we
modeled the medical and economic benefits of transplanted
xenogeneic hearts only. This analysis illustrates the potential
benefits of xenogeneic transplants for other organs.
Defender Technology. We assume that Alexion’s UniGraft hearts
will be used for patients who would otherwise not be able to obtain
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a heart transplant because of a shortage of donor organs. Thus, the
defender technology is standard heart disease treatment while
awaiting a heart transplant.
Differences in Health Outcomes. Wider use of organ transplants
could offer many patients significant improvement in the quality
and duration of their lives while improving the cost-effectiveness of
treatment. Patients with prolonged waiting times are at risk for endorgan deterioration, have an increased risk of transplant failure, or
may die before a donor organ becomes available (Mehta et al.,
1995).
To estimate the health effects of the availability of xenogeneic
hearts, we examined the life expectancy of patients who are
candidates for heart transplants. We assume that xenogeneic heart
transplant patients will have the same survival rate as human heart
transplant recipients. This is Alexion’s benchmark for technical
success. Therefore, the per-patient change in QALYs for patients
receiving UniGraft hearts is equal to the expected life-years for
heart transplant patients minus the expected life-years for patients
who are treated with standard heart disease therapy but do not
receive a transplant. We used data from Evans (1993) and the
United Network for Organ Sharing (UNOS, 1996; 1997) to
determine the change in life expectancy.
Number of Beneficiaries
We defined the patient population for this technology very
conservatively. We assume that the relevant population is patients
who are placed on the heart transplant waiting list maintained by
the UNOS but who do not receive a heart. This definition is
narrow because Alexion believes that if xenogeneic organs are
available the criteria for being placed on the waiting list will be
relaxed, increasing the eligible population. We chose to make a
more conservative assumption because we cannot predict what
these relaxed criteria might be and how many patients might
qualify under them.
Table 3-19 shows the expected total number of patients eligible to
receive this treatment from 2002 to 2011. It also shows the results
of our analysis of the expected market penetration of UniGraft
hearts. We developed these estimates of market penetration using
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Table 3-19. Expected
Market Penetration of
UniGraft Hearts

Market Penetration
Year

Eligible Patientsa

With ATP

Without ATP

2002

11,998

1,200

0

2003

11,998

2,361

1,200

2004

11,998

3,610

2,361

2005

11,998

4,852

3,610

2006

11,998

5,982

4,852

2007

11,998

6,919

5,982

2008

11,998

7,631

6,919

2009

11,998

8,132

7,631

2010

11,998

8,465

8,132

2011

11,998

8,675

8,465

aWe

used a very broad definition of heart transplant candidates that includes all
patients who could benefit from a heart transplant below age 65 but cannot
receive one because organs are unavailable (AHA, 1996).

The immediate availability
of UniGraft organs would
change the use of organ
transplantation by
Z eliminating long
waiting times for
donor organs and the
associated negative
medical effects,
Z

allowing surgeries to
be scheduled
optimally,

Z

eliminating the cost of
maintaining a
recipient in the
hospital while
awaiting a donor
organ, and

Z

eliminating the need
to keep a donor alive
on life support.

the methodology explained in Section 2.3.2. Company
representatives provided market penetration estimates for the first 5
years. Using these data, we estimated the Bass diffusion model and
the forecast equation (Eq. [2.7]) to determine the expected number
of patients receiving UniGraft hearts for each year in the production
period.
Changes in Health Care Costs
We assume that the cost of a heart transplant using a xenogeneic
heart will be the same as the cost of a heart transplant using a
human donor. This is a very conservative assumption. Alexion
believes that the availability of xenogeneic organs will decrease
costs of transplants by
Z eliminating the need to keep donors on life support,
Z reducing hospitalization during recipient waiting time, and
Z transplanting organs to recipients and scheduling surgeries
more effectively.
As with the cancer diagnosis model, the improvements in life-years
will be partially offset by the cost of caring for a person who has
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had a transplant. We assume that the lifetime cost of treating a
patient who receives a UniGraft heart is equal to their expected
life-years times the annual cost of treatment after transplant, plus
the cost of the transplant procedure. The lifetime treatment cost for
a patient who does not receive a UniGraft heart is equal to the
annual cost of treating a patient before transplant times their
expected life-years. For patients who receive Unigraft hearts,
lifetime health care costs rise because the expected life-years, the
annual cost of treatment, and the procedure costs are all higher for
UniGraft transplant patients. We used data from Votapka et al.
(1995) to determine the annual cost of treating a patient before and
after heart transplant. We used data from AHCPR (1996) to
determine the cost of a heart transplant. The per-patient increase in
lifetime health care costs is $102,661.
Estimating Private Return on Investment
R&D Costs. Alexion’s contribution to the cost of the ATP project
was $1,204,000. As explained above, we estimate that in the
absence of ATP funding Alexion would have spent $1,963,770 on
this project.
Commercialization and Production Costs. Alexion could not
provide an estimate of the costs of production and
commercialization. These activities will be handled by Alexion’s
partner in commercialization and production. Thus, we used data
from the biotechnology industry described in Chapter 2 to assume
that commercialization costs would be 37 percent of total revenue
and that production costs would be 42 percent of revenue.
Summary
In the with-ATP scenario, Alexion’s 3-year ATP project begins in
1995. The R&D phase is 3 years, the commercialization phase is 4
years, and the production phase is 10 years. In the without-ATP
scenario, the R&D phase lasts 1 year longer and the production
phase is 1 year shorter.
ATP funding led to a 1-year acceleration of the project. It also
induced an increase in total R&D spending of over $1.2 million,
leading to a 16 percent increase in the probability of technical
success.
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Alexion’s transgeneic UniGraft organs will probably be developed
for hearts, kidneys, lungs, and islets. To illustrate the potential
benefits of the development of these organs, we developed a model
of its impact on heart transplants. In our model, these hearts will
be used for patients who are awaiting a heart transplant but cannot
receive one because of a shortage of donor organs. The defender
technology is the standard heart disease treatment while awaiting a
donor organ. We modeled the health benefits of the availability of
UniGraft organs by comparing the expected life-years of patients
receiving heart transplants with those who do not.
We defined the patient population conservatively as the patients
who are placed on the heart transplant waiting list but do not
receive a heart. Using information from company representatives
our diffusion model estimates that 1,200 patients will receive
Unigraft hearts in the first year of production; 8,674 patients will
receive UniGraft hearts in the year 2009.
We assume that the cost of transplanting a UniGraft heart will be
the same as the cost of a human heart transplant. The annual cost
of treatment for a heart patient that has received a transplant is
higher than a pre-transplant patient. Furthermore, increases in life
expectancy increase the lifetime treatment costs for those patients
receiving UniGraft hearts.
Alexion and its partners in commercialization and production will
receive revenues from the sale of UniGraft hearts and incur R&D,
commercialization, and production costs. We assume that
commercialization and production costs will be 37 percent and
42 percent of revenue, respectively.
This model has a number of limitations. First, it considers only
heart transplants, although, if successful, Alexion may develop
other organs as well. Second, the relevant population is defined
conservatively, according to current guidelines for acceptance of a
patient on the transplant waiting list. Finally, we assume that only
patients who cannot get a human heart will be candidates for a
UniGraft heart; thus, the model does not consider the potential
savings from xenogeneic transplants as compared to human donor
transplants.
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3.2

CASE STUDY RESULTS
Each of the technologies discussed in Section 3.1 offers unique
benefits to society and specific challenges to modeling their
potential economic benefits. This section reports the results of our
analysis of each project and discusses why they differ among the
seven projects. It also discussed the limitations of each analysis.

3.2.1

The composite social
return on public investment
represents the returns on all
of the projects taken
together.

Private and Social Return on Investment in ATP
Tissue Engineering Projects
Table 3-20 shows the expected social return on public investment
for each of the ATP projects examined in this study and for all of
the projects taken together (the composite). These projects
demonstrate a wide range of NPV and SRR. As a group, they
provide over $35 billion in social return on public investment and
an SRR of 116 percent over 20 years. These results imply that the
ATP funding invested in these projects provides an expected net
benefit of over $35 billion dollars to the nation.

Table 3-20. Expected Social Return on Public Investment:
ATP Tissue Engineering Projects for a Single Preliminary Application

ATP Project

Project
Time Horizon

NPV
(1996$ millions)

IRR
(%)

Stem Cell Expansion

1992 to 2009

$47

21%

Biopolymers for Tissue Repair

1994 to 2009

$98

51%

Living Implantable Microreactors

1994 to 2009

$17,750

148%

Proliferated Human Islets

1995 to 2008

$1,297

34%

Biomaterials for Clinical Prosthesis

1993 to 2010

$15,058

128%

Gene Therapy Applications

1995 to 2011

$945

111%

Universal Donor Organs

1995 to 2011

$783

92%

Compositea,b,c,d

1992 to 2011

$34,258

116%

aThe

composite measure of return is based on a sum of expected benefits and costs in each year across all projects.

bThe

time period for the composite measure includes all years from all the individual project periods.

cThe

composite NPV is not a simple sum of individual NPV because the time periods are different.

dThe

composite IRR is not an average of the individual project IRRs because IRR is not additive.
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Table 3-21 shows how the expected social return on public
investment compares to the expected social return on investment
for each project. This comparison provides a perspective on the
importance of ATP funding in catalyzing the social return on
investment. As demonstrated by the composite return, ATP funding
is responsible for inducing about 31 percent of the total social
returns from all of these projects over 20 years. For the individual
projects, the effect of ATP on social returns ranges from a low of
24 percent to 100 percent of social returns.
Table 3-21. Social Return on Investment and Social Return on Public Investment:
ATP Tissue Engineering Projects for a Single Preliminary Application

Expected Social Return
on Investment
Time
Horizon

NPV
(1996$ millions)

Stem Cell Expansion

1992 to 2009

$134

20%

$47

21%

Biopolymers for Tissue Repair

1994 to 2009

$98

51%

$98

51%

Living Implantable Microreactors

1994 to 2009

$74,518

149%

$17,750

148%

Proliferated Human Islets

1995 to 2008

$2,252

36%

$1,297

34%

Biomaterials for Clinical Prosthesis 1993 to 2010

$32,855

118%

$15,058

128%

ATP Project

IRR
(%)

Expected Social Return
on Public Investment
NPV
(1996$ millions)

IRR
(%)

Gene Therapy Applications

1995 to 2011

$2,411

106%

$945

111%

Universal Donor Organs

1995 to 2011

$2,838

91%

$783

92%

Compositea

1992 to 2011

$109,229

115%

$34,258

116%

aSee

notes to Table 3-20 for an explanation of the derivation of the composite measure of return.

Social return on investment in these projects vary with respect to
the number of patients that will be treated, the value of the health
benefits of the new technology, the changes in health care costs,
and the probability of technical success. For example, the two
projects, “Living Implantable Microreactors” and “Proliferated
Human Islets” are very similar in many respects. They have similar
medical benefits to the same patient population. The main
differences between these two projects are the probability of
technical success, as reported by the companies, and the changes
in health care cost. BioHybrid Technologies, Inc., projects a lower
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annual cost for the islet transplant procedure and a higher
probability of technical success.
The two projects “Biopolymers for Tissue Repair” and “Biomaterials
for Clinical Prosthesis” further demonstrate the sources of
differences among projects. The size of the market for these two
technologies is similar. However, for “Biomaterials for Clinical
Prosthesis,” market penetration during the production phase is
expected to be more complete. Furthermore, while we did develop
an estimate of the reduction in health care costs for “Biopolymers
for Tissue Repair,” we were not able to quantify any health benefits
for patients because we could not find any relevant health outcome
data. By comparison, we did quantify a substantial per-patient
health benefit for “Biomaterials for Clinical Prosthesis” because we
were able to collect information regarding the potential health
benefits.
Table 3-22 demonstrates how ATP funding induced increases in
social returns. Recall that in our model, ATP might affect the
development of medical technologies by accelerating the
technology’s development, increasing the probability of success (by
stimulating additional R&D investment), or widening the
technology’s applications (scope). Table 1-4 shows the magnitude
of these impacts for each project. ATP funding accelerates the
projects by 1 to 10 years, increases the probability of success by 1
to 171 percent, and wideness the scope of two projects.
The acceleration effect has a much greater impact on the social
return on public investment than the probability effect. Table 3-23
demonstrates the relative impact of the acceleration effect on the
social return on public investment. To determine the impact of the
acceleration effect only, we calculated the social return on public
investment assuming that the probability of technical success in
both scenarios is the same as it is in the with-ATP scenario. Then
we compared the NPV considering both the probability and
acceleration effects to the NPV considering the acceleration effect
only. The table shows that the acceleration effect is responsible for
81 percent of the social return on public investment.
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Table 3-22. Impact of ATP Funding on the Development of Medical Technologies for Seven
Tissue Engineering Projects

ATP Project
Stem Cell Expansion
Biopolymers for Tissue Repair

Project
Accelerationa
(years)

Increase in the
Probability of
Technical Success
(percent)

1 to 2

Widening of Technology
Applicationsb
(scope effects)

9%

None reported

At least 10

171%

Significant but not
quantified

2

11%

None reported

3 to 5

2%

None reported

Biomaterials for Clinical Prosthesis

2

1%

None reported

Gene Therapy Applications

2

20%

Some effects reported but
not quantified

Universal Donor Organs

1

16%

None reported

Living Implantable Microreactors
Proliferated Human Islets

aThis is the number of years of acceleration reported by the ATP-funded companies. When they reported a 2-year

range, we assume the lower number for our analysis. For “Proliferated Human Islets,” we used the middle number,
4 years, for our analysis.
bOur model allows conceptually for a widening of scope effect of ATP. In practice, for the applications examined in

this study, there was little or no impact in all but one case, which we did not quantify.

Table 3-23. Impact of Acceleration Effect on Social Return on Public Investment

NPV (1996$ millions)
ATP Project

Acceleration and
Probability Effects

Acceleration
Effect Only

Acceleration,
Percent of Total

Stem Cell Expansion

$47

$38

82%

Biopolymers for Tissue Repair

$98

$98

100%

$17,750

$11,528

65%

$1,297

$1,278

99%

$15,058

$15,022

100%

Gene Therapy Applications

$945

$642

68%

Universal Donor Organs

$783

$458

58%

$34,258

$27,759

81%

Living Implantable Microreactors
Proliferated Human Islets
Biomaterials for Clinical Prosthesis

Compositea
aSee

notes to Table 3-20 for an explanation of the derivation of the composite measure of return.
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The results
demonstrate that by
accelerating R&D
and increasing the
probability of
technical success,
ATP can have an
important impact on
the social return on
investment.

Clearly, ATP provided the greatest leverage for social returns for the
second project, “Biopolymers for Tissue Repair.” ATP accelerated
the benefits from this project by at least 10 years, had a significant
impact on the probability of success, and affected the scope of the
project.3 According to company officials, in the absence of ATP
funding, the company might not have developed this technology at
all or might have developed it so slowly that the market opportunity
for this technology would have passed before it was ready for
commercialization. Although the impact of ATP on social returns
was less dramatic for the remaining projects, it is clear that these
two potential sources of ATP’s impact on the R&D process have
provided important increases in social returns.
Table 3-24 shows the composite private returns for all of the ATP
projects in tissue engineering.4 The private returns for all projects
are significantly lower than their social returns. Although the
composite NPV is about $1.5 billion, the individual expected NPV
varies widely from over $1 billion to less than zero. Individual
PRRs (not reported) range from about 14 percent to less than zero.

Table 3-24. Composite Private Returns:
ATP Projects in Tissue Engineering for a Single Preliminary Applicationa

Project returns
Increment attributable to ATP
aSee

NPV (1996$ millions)

IRR (%)

$1,564

12%

$914

13%

notes to Table 3-20 for an explanation of the derivation of the composite measure of return.

From the data we had available for this study, we estimated
expected NPV for four of the seven ATP projects in tissue
engineering is positive; thus we expect the ATP-sponsored
companies and their partners in commercialization and production
to earn profits on the development, commercialization, and sales of
these technologies. However, because we have modeled these

3Although we were not able to quantify the scope effects, this does not affect the

results because the 10-year acceleration of benefits virtually attributes all
benefits of the technology to ATP funding.
4Although the model calculated the private returns on each project, they are not
disclosed to preserve the confidentiality of the companies.
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activities together, we do not know how these profits will be
distributed among the companies.
Three of the seven projects have negative expected private NPV,
implying that the ATP-sponsored companies and their partners in
commercialization and production will suffer a loss from the
development of these applications of these technologies. However,
this result is not surprising given the limitations of our analysis.
Recall that the applications considered in this study are only the
first of many possible applications of ATP-funded technologies.
Although three of the seven projects show an expected negative
NPV, ATP-sponsored companies base their investment decisions on
the potential long-term profitability of these technologies in all of
their applications. Thus, investments in future application will
probably may be more profitable because of the spillovers between
the first and future applications.
The substantial differences
between private and social
returns for these projects
provide a rationale for
encouraging private-sector
investment through the
ATP program.

ATP funding has a dramatic impact on the private return on
investment in some projects. Although the magnitude of ATP’s
contribution to private returns varies by project, our estimate of the
total contribution to NPV is about $914 million, which is about
58 percent of the total. This means that ATP’s funding stimulates
additional private-sector investment and research that yield returns
that will be significantly higher than they would be without ATP
funding.
Two of the companies reported that ATP funding helped them
attract other forms of capital. To the extent that this “halo effect”
reduced their cost of capital, ATP funding may have had an
additional impact on private returns that we did not measure. In
Section 3.3, we discuss how we could extend our model to capture
these impacts.
The wide disparity between social and private returns indicates the
importance of ATP’s incentives to the private sector to pursue these
technologies. Because the social returns far outweigh the returns to
the companies developing, commercializing, and producing these
technologies, the private sector is less likely to fund these kinds of
high-risk projects. Hence, ATP funding serves to provide the
incentives needed to stimulate the private sector’s investments in
these activities.
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3.2.2

Sources of Project Variations
Tables 3-20 through 3-22 demonstrate a wide variation in the social
return on public investment and in the social return on investment,
in terms of both the NPV and the IRR. Some of the characteristics
of projects that provide a relatively higher expected social return on
investment have the following characteristics:
Z Broad application. Technologies that apply to more
patients and diffuse more quickly throughout the patient
population have a greater expected social return on
investment.
Z Significant health benefits. Technologies that lead to more
significant improvements in the health of patients over and
above the defender technology will have a greater expected
social return on investment.
Z Cost-effectiveness. Technologies that offer health care
improvements at relatively lower costs provide greater
expected social return on investment.
Z Higher probability of technical success. Technologies with
a greater expected probability of technical success have a
higher expected social return on investment.
The impact of ATP funding on the magnitude of social returns also
varies from one project to the next. The primary factors affecting
these differences include the following:
Z ATP’s impact on project timing. The number of years by
which ATP funding accelerates the R&D phase of the
project has an important impact on social returns.
Conditions that lead to high estimates of the acceleration
effect from ATP funding are the absence of alternative
capital sources and the risk of the project, as perceived by
the company and its potential sources of capital.
Z ATP’s impact on R&D funding and the probability of
technical success. The impact of ATP funding on the total
R&D investment has an important effect on the social return
on public investment because it affects the project’s
expected probability of technical success. The impact of
ATP funding depends on the company’s motivation and
ability to pursue the project in the absence of ATP funds.
For all but two projects, ATP stimulated increases in R&D
investment sufficient to make a significant difference in the
probability of technical success. In addition, ATP funding
may have further reduced the company’s cost of capital by
helping them to attract other sources of private funding. We
did not quantify this impact of ATP funding.
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Z ATP’s impact on project scope. If ATP funding encourages
the company to pursue additional applications and patient
populations, the social return on the public investment will
increase. Our study investigated only one application of
each of the technologies studied. We did not explicitly
model any scope effects for the projects we examined. The
scope effects may be evident in the number of applications
for which the technology is eventually used.
3.2.3

Methodological Limitations
The results of this study are subject to a number of methodological
limitations and assumptions that may affect the results. Some of the
limitations of our analysis include
Z analyzing only a single application of each technology,
Z omitting the value of some medical benefits that could not
be quantified,
Z failing to quantify ATP’s impact on a company’s ability to
attract other sources of capital, and
Z basing assumptions about costs and benefits on the
expectations of informed individuals.
Single-Application Analysis
This study analyzes only one preliminary application for each
project. Because these technologies provide basic scientific
platforms for many applications, their long-term impact may be
much greater than suggested here, as companies apply their
discoveries to a wide variety of medical applications. In addition,
the knowledge generated by these initial applications may lead to
advances in unrelated areas by other companies.
Limitations of the Health Benefits Models
The models we used to quantify the health benefits of each
technology have limitations that might affect the results of the
study. As shown in Table 3-25, some analyses included only a
portion of the entire population of patients that might benefit from
the technology. In other cases, we did not consider all of the
potential health benefits of the technologies, usually because data
to support these estimates were not available. Similarly, some of
the cost savings associated with the technologies may be
underestimated because of our inability to quantify them.
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Table 3-25. Limitations of the Health Benefits Models

ATP Project

Patient Population

Benefits per Patient

Human Stem Cell and
Hematopoietic Expansion
Systems

Does not consider
the European
market

Does not consider
decreases in the probability of
reintroducing cancer,
benefits due to convenience, or
potential benefits of eliminating
mobilization drugs

Structurally New
Biopolymers Derived from
Alpha-L Amino Acids

Considers only the
first application of
this technology

Does not account for differences Price of new device
in healing rates
subject to uncertainty

Disease Treatment Using
Living Implantable
Microreactors

Considers only
Does not account for changes in
patients diagnosed QALYs for intermediate health
as diabetics by the states
first year of
commercialization

Does not account for
changes in cost for
intermediate health
states

Treatment of Diabetes by
Proliferated Human Islets
in Photocrosslinkable
Alginate Capsules

Same as above

Same as above

Same as above

Fabrication Using Clinical
Prosthesis from
Biomaterials

Considers only
patients who
currently undergo
ACL repair

Estimate of QALY change is
speculative

Assumes that the cost
of using the new
material would be the
same as current
technologies

Application of Gene
Therapy to Treatment of
Cardiovascular Diseases

Includes only lung
cancer patients

Cannot capture the QALY
impacts of health states other
than death

Does not consider the
cost impact of
eliminating false
positive diagnoses

Universal Donor Organs
for Transplantations

Considers only the
market for heart
transplants;
considers only
patients eligible
under current
criteria

Cannot capture the QALY
impacts of health states other
than death

Does not consider
potential savings of
xenogeneic transplants
compared to human
transplants
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Our method for quantifying the health benefits of a disease may
also tend to underestimate the total benefits. The economic burden
of a disease is usually divided into three components: direct
medical costs, indirect costs, and intangible costs. Direct medical
costs are the costs of medical treatment. Indirect costs are the
societal costs associated with the loss in productivity due to illness
and unpaid caregiver time. Intangible costs are due to the patient’s
pain and suffering.
Because we measured the health benefits of these technologies in
terms of QALYs, our estimates capture how ATP-funded
technologies change both the direct medical costs and the
intangible costs of a disease. However, they may not capture
changes in the indirect costs. Improvements in the health of a
patient population with a particular illness or injury may reduce the
indirect costs of the disease, allowing those receiving an improved
treatment to lead more productive lives. These benefits to society
may not be captured by QALYs.
Health economists disagree about whether QALYs actually do
capture changes in indirect costs. While the standard assumption is
that QALYs do not capture indirect costs, some health economists
argue that QALY estimates do include these costs. Assuming that
the standard assumption is correct, if we were able to fully capture
the changes in indirect costs due to these technologies, our
estimates of the social returns to investment in some of these
technologies would be higher.
ATP’s Impact on Availability of Capital
Two companies in our study reported that ATP funding influenced
their ability to attract private funding. This “halo effect” may have
reduced the companies’ cost of capital. Conceptually, reducing the
companies’ cost of capital would affect the cost of R&D in the same
way ATP funding affects it. That is, as the cost of R&D effort falls,
the level of effort rises, increasing the probability of technical
success. Although we did not quantify the benefits of this
mechanism of ATP impact, we could modify our methodology to
incorporate this effect as explained below.
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Data Limitations
Because none of these technologies have yet reached the
commercial marketthough several are in clinical trialsthe
results of this analysis are based, in part, on the expectations of the
innovators and other informed individuals. We do not know at this
time whether these expectations will be realized. However, the
methodology we employed can be used to update our estimates as
better data on the actual costs and benefits of the technologies
become available.
We examined the sensitivity of our results to our assumptions about
some of the most uncertain parameters in our model. The results of
the sensitivity analyses are reported in Appendix B. We examined
the sensitivity of social returns to the following parameters:
Z discount rate,
Z per-patient treatment costs and QALYs, and
Z probability of technical success.
We examined the sensitivity of private returns to several key
parameters:
Z discount rate,
Z commercialization cost percentage,
Z production cost percentage,
Z product price, and
Z probability of technical success.
We found that the results are fairly sensitive to the predictions
about the technologies’ costs and effectiveness by doctors and
company representatives. As these technologies develop, estimates
of their costs and effectiveness may change dramatically, or their
technical success may prove impossible. As better information
becomes available, we should consider adjusting these estimates to
incorporate more accurate forecasts of these costs and benefits.

3.3

CONCLUSIONS AND POTENTIAL
IMPROVEMENTS
The objectives of this project were to
Z develop a methodology for estimating the expected social
economic return on public investment in ATP-funded
projects with medical applications,
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Z illustrate this methodology by applying it to seven ATPfunded projects in tissue engineering,
Z estimate the social return on public investment in these
seven ATP projects, and
Z provide insight regarding the factors that affect the social
return on public investment in ATP-funded projects with
medical applications.
This section offers conclusions about the suitability of this
methodology for estimating the private and social return on
investment in medical and other technologies and ways this
methodology might be improved. It also discusses our conclusions
with respect to the social and private returns on investments in
each of the case study technologies and offers observations about
why these results differ among the case studies.
3.3.1

Developing, Applying, and Improving the Methodology
To address the specific methodological challenges of modeling and
estimating the economic return on investment in new medical
technologies, we extended the currently accepted framework for
calculating private and social returns. We incorporated nonmarket
methods for valuing the benefits of these technologies to patients.
We illustrated this methodology by applying it to seven ATP-funded
projects in tissue engineering.
Applicability of this Methodology
This methodology is useful for analyzing ATP-funded medical
technologies, particularly under the following conditions:
Z One or several primary applications are apparent.
Z The health outcome and resource cost differences between
the new and defender technologies can be quantified (e.g.,
because some clinical trials or other studies have produced
the required data).
Z The impact of changes in health outcomes on patients’ wellbeing has been quantified by other studies (e.g., QALYs for
health outcomes or health states are available).
Z The market potential for the new technology is apparent.
Z The technology is sufficiently close to commercialization to
enable company representatives to project the costs of
commercialization and production.
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Aside from medical
technologies, this
methodology is also
applicable to other
situations in which
the technology
affects goods and
services whose
values are not
adequately reflected
in market prices.
For example,
technologies that
improve
environmental
quality or reduce
the crime rate
provide benefits that
are not priced in the
market.

ATP funding may reduce
the cost of R&D effort by
reducing the cost of other
sources of funding. We
could improve the model
by incorporating empirical
estimates of these
differences in cost to
demonstrate how they
further encourage R&D
effort and improve the
probability of technical
success.
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Aside from medical technologies, this methodology is also
applicable to other situations in which the technology affects goods
and services whose values are not adequately reflected in market
prices. For example, technologies that improve environmental
quality or reduce the crime rate provide benefits that are not priced
in the market. Nonmarket valuation methods are required to value
these kinds of social benefits. As in this study, valuation of these
social benefits requires determining the beneficiaries’ willingness to
pay for these improvements.
Potential Methodological Improvements
The methodology we developed and applied in this study might be
improved in several ways. These potential improvements involve
Z improving our model of the impact of ATP funding on
company investment behavior,
Z forecasting the impact of distant applications, and
Z modeling the decline in market penetration.
Modeling the Impact of ATP Funding on Company Investments.
Constructing a without-ATP scenario is the most challenging task in
calculating social and private returns. Because the without-ATP
case is the counterfactual, we must rely on the company’s
conjectures about what they might have done in the absence of an
ATP grant. Clearly, better information about how companies
respond to ATP grants could improve our estimates of the withoutATP scenario.
First, ATP needs to understand how companies react to changes in
the real cost of R&D. ATP seeks to identify projects that would not
be funded to the same degree by the private sector. Information
about how a company’s size, scope, ownership structure, age, and
R&D portfolio affect its R&D investment decisions could shed some
light on these issues. An ex post empirical analysis of the private
return on investment in projects funded with alternative sources of
funds could identify points on the marginal benefits curve relating
the cost of R&D to its returns.
Second, ATP needs to understand exactly how its funding affects
the cost of R&D. In this study, we assume that in the absence of
ATP the cost of an R&D dollar is equal to $1, and that with ATP the
cost of an R&D dollar is the ratio of the company’s ATP match to
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the total project budget. But the difference between the price of
R&D in the with-ATP scenario versus without-ATP scenario
depends on the cost of alternative funding. ATP funding may
reduce the cost of R&D effort not only by subsidizing the project’s
budget, but also by helping the company attract other sources of
funding and reducing the cost of capital. If companies could
provide an empirical estimate of the impact of ATP funding on the
cost of capital, it could be incorporated into the model, and we
could demonstrate how these decreases in the cost of capital further
encourage company R&D and improve the probability of technical
success.
Existing or prospective
studies of project spillovers
may provide a general
guideline for forecasting
the return on investment in
later applications of ATPfunded technologies.

Forecasting Impacts of Distant Applications. Analyzing the most
immediate and probable application of an ATP project provides the
most reliable data regarding its potential impacts. However,
ignoring the later applications probably underestimates the project’s
benefits.
The challenge of collecting data regarding these distant applications
can be significant. Because the expected benefits lie farther into
the future, all of the data required to calculate social returns,
including the size of the expected patient population, the
appropriate defender technology, and the costs of health care
resources, become more and more uncertain. Data regarding
expected private returns may be even more difficult to gather, since
the companies will be very reluctant to forecast spending on R&D,
commercialization, and production for applications that are
relatively remote.
A potential approach to this problem may be to draw from existing
or prospective studies of project spillovers. An empirical analysis
of trends in the returns to the application of an enabling technology
as it ages may provide a general guideline for forecasting the
returns from later applications. For example, a retrospective study
of the medical applications resulting from the development of
ultrasound techniques might show that the return on investment in
each successive application of the techniques rise at first, then
decline as the enabling technology ages and is replaced by a new
technique. Analyzing this pattern could help ATP determine how
many distant applications should be examined to capture the
majority of the returns.
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We know very little about
how quickly the value of
new medical technologies
depreciates through the
emergence of treatments
and technologies that
render them obsolete.

Improving Market Penetration Forecasts. While the Bass model is
a generally accepted model for forecasting the diffusion of new
technologies, it has one important drawback for studying ATPfunded enabling technologies. The cumulative number of adopters
predicted by the Bass model is strictly increasing over time. Yet
technologies depreciate over time as new technologies emerge and
consumer needs and tastes change. Thus, a diffusion model is
needed that accounts for the future emergence of technologies that
will replace the ATP-funded technology. One way to think of such
a model is that it actually forecasts the diffusion of two
technologies: the ATP-funded technology and its replacement.
Our ability to determine what these replacement technologies
might be and their pattern of diffusion limits our ability to
implement the double-diffusion method outlined above. However,
we could develop empirical data about the likely pattern of
obsolescence of ATP-funded technologies by analyzing the
diffusion patterns of existing medical technologies. For example,
we could examine the diffusion patterns of two drugs introduced at
different times but with the same application. The objective of this
analysis would be to examine the factors that affect how quickly a
new technology is superseded by an even newer technology.

3.3.2

Summary of Social Returns from Seven ATP Projects
in Tissue Engineering
If successful, these technologies and their applications will improve
the quality of life for thousands of people every year. Among the
technologies we examined, the medical benefits include
Z a less painful, invasive, and expensive system for
transplanting bone marrow cells;
Z a bioabsorbable fracture fixation device that will eliminate
the need for removal surgery and improve healing of
fractures;
Z a virtual cure for the negative health effects of diabetes;
Z a system for making donor organs more widely available;
Z a diagnostic technique that improves the detection of
cancer metastasis, which increases the effectiveness of
cancer treatment; and
Z a material that will improve the effectiveness of ligament
repair.
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Our analysis of the social and private benefits of these technologies
yields the following findings:
Z The expected social return on ATP public investment in
these technologies, or the increment to social returns
attributable to ATP funding, is estimated at $34 billion in
net present value.
Z The expected social rate of return on ATP public investment
in these technologies is estimated at an annual rate of
116 percent.
Z The expected total social return on public and private
investment in these technologies is estimated at $112 billion
in net present value, or an annual rate of 115 percent.
Z The expected total private return on investment in these
technologies to ATP-award companies and their partners in
commercialization and production is estimated at
$1.6 billion in net present value, or an annual rate of
12 percent. Of the $1.6 billion in net present value of
private returns, $914 million is estimated to be attributable
to ATP funding.
Z To the extent that the technologies will yield applications in
addition to those we investigated, it is likely that public and
private returns on these projects will be higher.
These results illustrate two important points about the role of ATP
in funding these technologies:
Z ATP plays a significant role in increasing the expected
social and private returns on these projects.
Z The social returns far outweigh the benefits to the private
sector. Private companies will therefore tend to underinvest
in these technologies compared to what would be optimal
from society’s perspective. The wide disparity between
social and private returns indicates the importance of ATP’s
incentives to the private sector to pursue these technologies.
Three factors affect the social return on public investment in
projects with medical applications:
Z the number of years by which ATP funding accelerates the
R&D phase of the project,
Z the impact of ATP funding on the probability of technical
success, and
Z the impact of ATP funding on the scope of the project.
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Appendix A
Market Diffusion
Interview Materials,
Summaries, and
Results

This appendix contains materials used to complete the forecasts of
technology penetration for each of the seven tissue engineering
projects we analyzed in this study. For the four in-depth case
studies listed in Table 1-1, we conducted more in-depth case
studies than for the remainder of the projects. For the in-depth case
studies, we interviewed physicians to obtain data for the Bass
diffusion model, as explained in Section 2. For the remainder of
the companies, we collected diffusion estimates for the Bass model
from the companies’ representatives.

A.1

INTERVIEW MATERIALS
Figures A-1 through A-4 contain the clinical profiles we developed
and provided to physicians prior to the interviews. We did not
identify the company, either on the profile or during the interview.
Figure A-5 is a sheet of questions that we sent to the physicians
along with the clinical profile. It was designed to prepare the
physicians to answer our questions. Figure A-6 contains the
informal interview guide that we used while interviewing the
physicians over the telephone.
Table A-1 provides information about the physicians we
interviewed. These physicians were recommended to us as experts
in the treatment of the relevant diseases by ATP-sponsored
companies, by associations such as the American Diabetes
Association, or by other physicians.

A.2

DATA COLLECTED
Table A-2 contains the data that we collected from the physicians
and company representatives for input to the model. For some of the
projects, the physicians identified and provided market penetration
estimates for a number of different populations. In these cases, we
divided the eligible population into these segments and developed
weighted averages for input to the Bass diffusion model. For
example, for the project “Biopolymers for Tissue Repair,” the total
eligible population was 73,875; 33,825 adults and 40,050 children.
Expert 1 forecasted a market cap of 25 percent for adults and
75 percent for children as his estimate for the market cap. Therefore,
we used 38,494 as his forecast of the market cap for this technology.
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Figure A-1. Clinical Profile for “Human Stem Cell and Hematopoietic Expansion Systems”

Many patients with dose-sensitive cancers are treated with high-dose chemotherapy and/or
radiation. To enable the patient to survive this treatment, patients are treated with stem cell
therapy to repair the damage to their hematopoietic system. In many cases, the stem cells are
harvested from the patient prior to the myelotoxic treatment or from a donor via peripheral blood
progenitor cell (PBPC) collection. PBPC requires the use of mobilization drugs that may have
side effects for the patient or donor.
Assume that a new method for stem cell harvest is now available. This new method involves
extracting a small quantity of bone marrow (a single aspirate) in a doctor’s office under local
anesthesia. The aspirate is placed in a Cell Production System (CPS) which is fully automated for
growing stem cells outside the human body. This method may reduce the probability that
certain tumor cells will be reintroduced via the graft.
Please examine the clinical profile below and think about the current stem cell harvest
techniques versus the new treatment we described above. Then, answer the questions on the
following page.
Expected cost of new treatment per
patient, including all resources
required for stem cell harvest:

No more than $12,000.

Likely alternative treatment and
treatment cost:

Peripheral blood progenitor cell (PBPC) mobilization. $12,000$20,000

Risks/side-effects:

No drugs or procedures required to prepare the patient for the
procedure prior to the time of the aspirate.

Ease of use:

It is very easy to use and requires limited training.

Expected outcomes of new
treatment compared to likely
alternative treatment:

May reduce tumor cells in a graft by 10- to 70-fold versus the
conventional methods.
Other differences noted below.
Cell
Source

Care
Episodesa

Procedure
Time (Hours)

Needle
Sticksb

PBPC mobilization
and collectionc

21

39

22

CPSd

2

1-3

4-10

Note: The numbers in the table include all procedures associated with stem cell procurement and
administration.
aIncludes all outpatient, inpatient, and home care episodes.
bIncludes bone marrow aspirates, blood samples, catheter placements, and subcutaneous
injections.
cBased on an average of three rounds of apheresis following cell mobilization injections.
dBased on data accumulated during confidential company’s pre-clinical research and trials.
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Figure A-2. Clinical Profile for “Structurally New Biopolymers Derived from Alpha-L Amino
Acids”

Currently, fractures of the shoulder, elbow, wrist and hand, knee, and ankle are fixed with
metallic devices. Some fractures are also fixed with bioabsorbable materials. Assume that new
devices—pins and screws made from a newly developed bioabsorbable material—have just
become available. The new bioabsorbable material is made from a novel synthesis of tyrosine
that avoids the problems associated with acids produced by the breakdown of existing
bioabsorbable polymers. Also, the new pins and screw are stiffer than the current bioabsorbable
alternative. The primary application for the pins and screws is orthopedic repair (fracture
fixation).
The new bioabsorbable pins and screws are intended for use in the following types of fractures:
Z shoulder (distal clavicle, acromion, glenoid rim, proximal humerus)
Z elbow (humeral condyles or capitellum, olecranon, radial head or neck)
Z wrist and hand (distal radius, carpal and metacarpal bones)
Z knee (femoral and tibial condyles, patella)
Z ankle (uni or bimalleolar, and severe with syndesmotic disruption)
Source: Böstman, O., E. Hirvensalo, E. Partio, P. Törmälä, and P. Rokkanen. 1991. “Impact of the Use of
Absorbable Fracture Fixation Impacts on Consumption of Hospital Resources and Economic
Costs.” The Journal of Trauma 31(10):1400-1403.

Please examine the clinical profile below and think about the current treatment for fracture
fixation versus the new bioabsorbable treatment described above. Then, answer the questions
on the following page.
Expected cost of new treatment per
patient:

Surgery cost identical to defending treatment.
Material cost expected to be $50-$150 per pin or
screw.

Likely alternative treatment and treatment
cost:

Surgery with metallic fixation devices (pins and
screws): $8-$20 per device.

Expected outcomes of new treatment
compared to likely alternative treatment:

Z Reduction in stress shielding and secondary
fractures due to screw holes
Z Elimination of removal surgery
Z Reduced potential for tissue abrasion or device
loosening and migration

A-3

A Framework for Estimating the National Economic Benefits of ATP Funding of Medical Technologies

Figure A-3. Clinical Profile for “Disease Treatment Using Living Implantable Microreactors”

Currently, most insulin-dependent diabetics are treated with daily insulin injections. Assume that
a new treatment has just become available that uses porcine pancreatic transplant cells encased
in microspheres to achieve tight glycemic control in insulin-dependent diabetics. The cells permit
glucose, nutrients, electrolytes, oxygen, and bioactive products to pass but block immunocytes
involved in transplant rejection. As the cells cease to function, the patient will require a booster
injection of new cells. The cells are intended for treatment of all Type I diabetics and Type II
diabetics who require daily insulin injections.
Please examine the clinical profile below and think about the current treatment for insulindependent diabetics versus the new treatment described above. Then, answer the questions on
the following page.
Expected cost of new treatment per
patient:

$12,000 for initial implant and $6,000/year for booster
implants, which are required once or twice a year.

Likely alternative treatment and
treatment cost:

Daily insulin injections: $1,666/year

Expected outcomes of new treatment:

The new treatment will achieve equal or superior
outcomes as realized in the Diabetes Control and
Complications Trial (DCCT). The DCCT demonstrated
the benefits of tight glycemic control for insulindependent diabetics. Results of the trial showed:
Z 76% reduced risk of eye disease
Z 50% reduced risk of kidney disease
Z 60% reduced risk of nerve disease
Z 35% reduced risk of cardiovascular disease

Other benefits:

Z Improved quality of life
Z Reduces glucose monitoring to once a week
Z Eliminates daily insulin injections
Z Automatic insulin response to glucose
Z No immunosuppression required
Z Simple to administer

Ease of use:

A-4

Procedure will be an injection under ultrasound
control, similar to amniocentesis; done on an
outpatient basis. Requires a simple syringe.
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Figure A-4. Clinical Profile for “Treatment of Diabetes by Proliferated Human Islets in
Photocrosslinkable Alginate Capsules”

Currently, most insulin-dependent diabetics are treated with daily insulin injections. Assume that
a new treatment has just become available that uses proliferated insulin-secreting human islet
cells combined with a unique encapsulation technology to help patients achieve tight glycemic
control. The encapsulation technology ensures adequate immunoprotection and
biocompatability with the human body. The cells are intended for treatment of Type I diabetics
and Type II diabetics who require daily insulin injections. This new treatment eliminates the
need for daily insulin injections.
Please examine the clinical profile below and think about the current treatment for insulindependent diabetics versus the new treatment described above. Then, answer the questions on
the following page.
Expected cost of new treatment per
patient:

$10,000-$15,000 per year

Likely alternative treatment and
treatment cost:

Daily insulin injections: $1,666/year

Expected outcomes of new treatment:

The new treatment will achieve similar outcomes as
realized in the Diabetes Control and Complications
Trial (DCCT). The DCCT demonstrated the benefits of
tight glycemic control for insulin—dependent
diabetics. Results of the trial showed:
Z 76% reduced risk of eye disease
Z 50% reduced risk of kidney disease
Z 60% reduced risk of nerve disease
Z 35% reduced risk of cardiovascular disease

Other benefits:

Z Improved quality of life
Z Reduces glucose monitoring to once a week
Z Eliminates daily insulin injections
Z Automatic insulin response to glucose
Z No immunosuppression required
Z Simple to administer

Ease of use:

Product is injectable, an in-office treatment. Patient is
placed under local anesthesia, sits for 3 hours, and
then goes home. Patient makes a monthly visit to the
doctor for monitoring. Treatment is once a year or
once every two years.
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Figure A-5. Questions about the Clinical Profile

1. In thinking about the application that this therapy is intended for according to the profile
you just read, what group of patients do you believe will be eligible to receive the
treatment?
Please list by group, defining each group. For example, one group might consist of “Type
II diabetic patients currently requiring daily insulin injections.” Use as many groups as
necessary.
Group A:

Group B:

Group C:

2. Given that Group A is eligible for this treatment, what percentage of patients in this group
do you think will actually receive the treatment?
Please provide this percentage for each of the first 5 years that the treatment is available.
Group A:
______%
(year 1)

______%
(year 2)

______%
(year 3)

______%
(year 4)

______%
(year 5)

______%
(year 1)

______%
(year 2)

______%
(year 3)

______%
(year 4)

______%
(year 5)

______%
(year 1)

______%
(year 2)

______%
(year 3)

______%
(year 4)

______%
(year 5)

Group B:

Group C:
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Figure A-6. Physician Interview Guide

This interview is part of a study that RTI is doing for the National Institute of Standards
and Technology (NIST). NIST has asked us to talk with clinical experts about the
expected market acceptance of a number of new biotechnologies.
Introduction
1. First, can you please tell me about your particular affiliation?
a. research organization, hospital or clinic, private or group practice,
government, etc.
b. type of patient base you see (if appropriate)
c. number of years you have been in your present position, current title
d. your affiliation with the biotechnology company
Estimating the Eligible Population
Please examine the clinical profile of the treatment, including the target patient profile
and the expected costs and outcomes of the treatment.
1. In thinking about the application that this therapy is intended for according to the
profile we sent you, what group or groups of patients do you believe are eligible to
receive the treatment?
ê describe patient cohorts (e.g., by age, severity of disease, type of disease,
receiving a certain treatment, etc.)
ê Would these patients all be eligible for the defending treatment as we have
defined it on the profile?
2. Do you think the population of eligible patients will change over time, or will the
number of eligible patients remain constant over the next 10 years? How will it
change?

(continued)
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Figure A-6. Physician Interview Guide (continued)

Potential Barriers to Market Penetration and Market Penetration

1. What do you view as some of the barriers to this treatment’s widespread use? For
example,
ê physicians
ê insurance companies
ê patients
ê hospitals
ê costs

2. Who do you think will be most influential in determining whether this treatment
becomes widely used or not (e.g., physicians, hospitals and managed care
formularies, insurance companies, patients)?

3. Given that patients in group A (as you have defined it) are eligible for this
treatment, and taking into account the barriers we just discussed, what percentage
of the patients in group A do you think will actually receive the treatment?
Please provide this percentage for each of the first 5 years that the treatment is
available.
______% ______% ______% ______% ______%
(year 1)
(year 2)
(year 3)
(year 4)
(year 5)
4. Given that patients in group B (as you have defined it) are eligible for this
treatment, and taking into account the barriers we just discussed, what percentage
of the patients in group B do you think will actually receive the treatment?
Please provide this percentage for each of the first 5 years that the treatment is
available.
______% ______% ______% ______% ______%
(year 1)
(year 2)
(year 3)
(year 4)
(year 5)
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Table A-1. Physicians Interviewed for Each Case Study Company

Company
Aastrom
Biosciences, Inc.

VivoRx, Inc./
BioHybrid
Technologies, Inc.

Physician

Vocation or Title

Hospital or Work
Affiliation(s)

Location

Nature of Work

A-9

Feb. 6, 1997

Dr. Sam
Silver

Director of Adult Bone
Marrow Transplants

University of Michigan
Hospital

Ann Arbor, MI

60% patient contact
20% administrative
20% clinical research

Feb. 20, 1997

Dr. Randy
Broun

Clinical Associate Professor
of Medicine

The Jewish Hospital of
Cincinnati, University
of Cincinnati, and
private practice

Cincinnati, OH

80% patient contact
20% other

Feb. 25, 1997

Dr.
Richard
Champlin

Chairman ad interim, Dept.
University of Texas
of Hematology and Chief,
M.D. Anderson Cancer
Section of Blood and Marrow Center
Transplantation

Houston, TX

Not covered in
interview

Feb. 7, 1997

Dr. Barry
Eppley

Plastic and Oral Surgeon

Indiana University
Medical Center

Indianapolis,
IN

95% patient contact
5% lab and clinical
research

Feb. 10, 1997

Dr.
Richard
Freidman

Professor of Orthopedic
Surgery

Medical University of
South Carolina

Charleston, SC

80% clinical
20% research and other

Feb. 12, 1997

Dr. Robert
Bucholz

Professor and Chairman of
Orthopedic Surgery

University of Texas
Southwestern Medical
Center

Dallas, TX

90% patient contact
10% clinical research

Feb. 11, 1997

Dr. John
Buse

Director, Diabetes Center

University of North
Carolina-Chapel Hill

Chapel Hill,
NC

70% patient contact
30% clinical research
and administrative

Mar. 7, 1997

Dr. John
Deller

Endocrinologist

The Heart Institute of
Rancho
the Desert—Eisenhower Mirage, CA
Medical Center

95% patient contact
5% other

Mar. 11, 1997

Dr. Ann
Brown

Assistant Professor of
Medicine, Endocrinology;
Medical Director, Diabetes
Education Program

Duke University
Medical Center

50% clinical
20% research
30% administrative

Durham, NC
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Integra
LifeSciences

Date of
Interview
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Table A-2. Data Collected from Physician and Company Interviews

Percentage of Population Receiving Treatment
Eligible Population

Year 1

Year 2

Year 3

Year 4

Year 5

Market Cap

4%

10%

15%

25%

—

—

10%

20%

25%

30%

40%

—

Autologous BMTs

1%

5%

10%

10%

10%

100%

Multiple-course cancer therapy

1%

5%

10%

20%

20%

20%

Cord blood transplants

1%

10%

20%

50%

50%

100%

Chemotherapy + autologous stem cell
support

3%

8%

15%

25%

35%

—

Chemotherapy + cord blood support

3%

8%

15%

20%

20%

100%

Dose intensive therapy

3%

8%

15%

25%

40%

100%

Chemotherapy and allogeneic stem
cell support

3%

8%

15%

20%

20%

100%

Adults (five fracture sites)

1%

3%

5%

10%

15%

25%

Pediatric (all fractures)

2%

6%

10%

20%

30%

75%

Adults (five fracture sites)

25%

40%

55%

70%

75%

75%

Adults

10%

10%

10%

20%

20%

20%

Pediatric

10%

10%

10%

10%

10%

10%

Type I diabetics

1%

5%

10%

10%

10%

10%

10% Type II diabetics

1%

10%

15%

15%

15%

15%

Type I children under 10 years of age

2%

2%

2%

5%

10%

100%

Type I over puberty and with
complications

20%

25%

30%

40%

50%

100%

Type I over puberty with no
complications

10%

10%

10%

20%

30%

100%

Type II insulin-dependent with
disease for ≥10 years

2%

2%

2%

5%

10%

100%

Type I diabetics

3%

7%

15%

30%

50%

95%

Type II diabetics (ins-dep.) < age 50

1%

2%

4%

20%

25%

25%

Stem Cell Expansion
Autologous BMTs
Multicyclic chemotherapy

Biopolymers for Tissue Repair

Living Implantable Microreactors

(—) denotes missing value.
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Table A-2. Data Collected from Physician and Company Interviews (continued)

Percentage of Population Receiving Treatment
Eligible Population

Year 1

Year 2

Year 3

Year 4

Year 5

Market Cap

Proliferated Human Islets
Type I diabetics

1%

5%

10%

10%

10%

10%

10% Type II diabetics

2%

10%

15%

20%

20%

20%

Type I children under 10 years of age

2%

2%

2%

5%

10%

100%

Type I over puberty and with
complications

20%

25%

30%

40%

50%

100%

Type I over puberty with no
complications

10%

10%

10%

20%

30%

100%

Type II insulin-dependent with
disease for ≥10 years

2%

2%

2%

5%

10%

100%

Type I diabetics

3%

7%

15%

30%

50%

95%

Type II diabetics (ins-dep.) < age 50

1%

2%

4%

20%

25%

25%

9%

20%

30%

40%

50%

75%

Gene Therapy Applications

10%

25%

40%

50%

55%

55%

Universal Donor Organs

10%

20%

30%

40%

50%

75%

Biomaterials for Clinical Prostheses

(—) denotes missing value.

A.3

KEY FINDINGS FROM INTERVIEWS
We highlight key findings from the physician interviews by project.
Stem Cell Expansion
Z In addition to autologous bone marrow transplants (BMTs),
physicians believed this procedure would be useful for
patients receiving multicyclic subablative chemotherapy
and umbilical cord stem cell transplants.
Z Two physicians stated that there are technical barriers to
using this treatment for allogeneic transplants due to graft
rejection, graft versus host disease, and the inability to
restore blood cells to the level they need to be.
Z Barriers to this treatment’s market success cited by
physicians interviewed include the cost of capital
equipment for health maintenance organizations (HMOs),
hospitals, and BMT centers; the ease of training; and
physicians’ belief in the procedure’s reliability to grow stem
cells. One physician said that a disadvantage of the
treatment is that once the cell expansion has started, the
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cells will have to be used on a given date and cannot be
“saved” until a later date, in the event that a patient is
unable to undergo the transplant.
Z Physicians and CEOs of hospitals and managed care
organizations were cited as being most influential in
determining whether the treatment will become widely
used.
Z Physicians stated that the possibility of reducing tumor cells
in a graft will be extremely important in determining the
treatment’s market acceptance; however, this factor will not
be important in terms of modeling health outcomes.
Biopolymers for Tissue Repair
Z Physicians noted the differences between the pediatric
orthopedic market and the adult orthopedic market. The
pediatric market has a high removal rate for pins
(95 percent) because physicians are reluctant to leave pins
in growing bone. However, the removal rate for adults is
closer to 10 to 15 percent.
Z One physician said that the only adult population this
would be applicable for is healthy adult patients with lowload nondiaphyseal fractures.
Z Barriers to this treatment that were cited included
physicians’ concern, even if it is misinformation, about
possible reactions to bioabsorbable materials versus inert
metals; the ability to use bioabsorbables mechanically as
easily as metals are used; the fact that biodegradable
devices may not have the same degree of interfragmental
compression; and the higher cost of bioabsorbable
materials.
Z One surgeon said that surgeons will be most influential in
determining whether these devices become widely used if
they find the devices comparable to the metal devices.
Living Implantable Microreactors
Z Physicians believed that the eligible population is identical
to that for VivoRx’s technology.
Z The biggest barriers cited to this treatment’s widespread use
are the fact that human and porcine islets are good reservoirs
for retroviruses, and the long-term effects of porcine
retroviruses are not known. Cost was also cited as a barrier.
Proliferated Human Islets
Z Physicians confirmed that the eligible populations for this
treatment are Type I diabetics and 10 percent of Type II
diabetics (those who are insulin-dependent). The only
group not eligible for this treatment is women who are
pregnant or considering getting pregnant.
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Z One physician believes that children and young adults who
are beyond puberty and have already shown some
complications related to diabetes will be the ideal group for
both VivoRx’s and BioHybrid’s treatments, since the
medical community will do anything to prevent further
complications in such young patients.
Z One physician stated that if we can clone human cells,
these should be better than porcine cells; however, there is
a big reservoir of porcine cells, so availability should not be
an issue.
Z The biggest barriers cited to this treatment’s widespread use
include
ê cost, which far exceeds current diabetes therapy,
especially for young parents with young (less than 10
years of age) diabetic children;
ê availability of tissue for transplantation;
ê the government, which may be overly restrictive in
regulating the number of patients able to receive either
therapy (VivoRx or BioHybrid);
ê pharmaceutical companies that are large producers of
insulin and insulin-related products;
ê concerns about unrecognized malignant cell
transmission; and
ê long-term immunological effects of this type of
transplantation.
Z Physicians predicted that the American Diabetes
Association and professional endocrine societies will be
influential in determining how widespread this treatment
becomes. One physician believed it will be primarily
patient-driven, because many patients will be willing to pay
more for improving lifestyles (i.e., reduction in glucose
monitoring).

A.4

RESULTS OF MODEL ESTIMATES
Table A-3 summarizes the results of our diffusion modeling. The
forecasted estimate is the quantity of patients used in the model for
estimating returns. The “high” and “low” columns are the end
points of the 95 percent confidence intervals for the forecasts.
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Table A-3. Summary Results

Number of Patients
95% Confidence Interval
ATP Project
Human Stem Cell and Hematopoietic Expansion
Systems in Tissue Engineering

Structurally New Biopolymers Derived from
Alpha-L-Amino Acids

Disease Treatment Using Living Implantable
Microreactors

A-14

Year

Forecast
Estimate

High

Low

1

665

665

665

2

1,060

1,162

958

3

1,674

2,002

1,373

4

2,606

3,371

1,953

5

3,976

5,477

2,750

6

5,890

8,424

3,823

7

8,384

11,996

5,224

8

11,334

15,537

6,986

9

14,424

18,318

9,098

10

17,251

20,172

11,489

1

8,173

8,173

8,173

2

13,286

13,889

12,683

3

20,007

21,525

18,500

4

26,980

29,056

24,763

5

31,977

33,494

29,942

6

34,158

34,718

33,002

7

34,744

34,874

34,289

8

34,863

34,889

34,715

9

34,885

34,890

34,840

10

34,889

34,890

34,876

1

65,498

65,498

65,498

2

110,468

130,376

90,560

3

183,271

252,047

124,436

4

295,888

460,182

169,546

5

457,310

755,608

228,401

6

661,608

1,043,557

303,100

7

874,437

1,175,873

394,507

8

1,041,811

1,187,567

501,178

9

1,134,485

1,187,113

618,454

10

1,171,047

1,187,135

738,431
(continued)
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Table A-3. Summary Results (continued)

Number of Patients
95% Confidence Interval
ATP Project
Treatment of Diabetes by Proliferated Human
Islets in Photocrosslinkable Alginate Capsules

Fabrication of Clinical Prosthesis from
Biomaterials

Application of Gene Therapy to Treatment of
Cardiovascular Diseasesa

Year

Forecast
Estimate

High

Low

1

63,711

63,711

63,711

2

122,647

175,059

70,234

3

202,286

339,115

78,109

4

305,295

552,472

87,592

5

430,677

779,403

98,978

6

571,339

958,064

112,598

7

713,520

1,053,241

128,820

8

840,452

1,087,586

148,042

9

939,509

1,097,188

170,678

10

1,007,470

1,099,607

197,136

1

9,000

9,000

9,000

2

19,493

22,777

16,209

3

30,293

37,258

23,397

4

40,629

50,442

30,376

5

49,780

60,631

36,974

6

57,277

67,321

43,050

7

62,996

71,152

48,506

8

67,102

73,145

53,292

9

69,914

74,124

57,400

10

71,773

74,591

60,862

1

17,350

2

43,505

3

69,817

4

87,533

5

96,575

6

96,865

7

97,156

8

97,447

9

97,739

10

98,033
(continued)
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Table A-3. Summary Results (continued)

Number of Patients
95% Confidence Interval
ATP Project

Year

Forecast
Estimate

High

Low

Universal Donor Organs for Transplantations
1

1,200

1,200

1,200

2

2,361

2,638

2,084

3

3,610

4,203

3,020

4

4,852

5,705

3,968

5

5,982

6,949

4,883

6

6,919

7,832

5,726

7

7,631

8,379

6,464

8

8,132

8,684

7,082

9

8,465

8,843

7,579

10

8,675

8,923

7,964

aWe did not estimate a model for this project because the company representative gave us a 10-year forecast.
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Appendix B
Sensitivity Analysis

This appendix describes the sensitivity of our estimates of the social
return on public investment, the social return on investment, and
the private return on investment to changes in key parameters.

B.1

SENSITIVITY OF SOCIAL RETURNS
We examined the sensitivity of the social return on public
investment and the social return on investment to the following
parameters:
Z discount rate,
Z per-patient treatment costs and QALYs, and
Z probability of technical success.

B.1.1

Sensitivity to the Discount Rate
Changing the discount rate has a complex effect on the social NPV.
First, if the technology has a QALY impact, it affects the total
number of QALYs gained per patient, since QALYs that occur later
in life are discounted. Second, it affects the value of a QALY, as
explained in Section 2. Finally, it affects the rate at which the
expected net benefits are discounted.
Table B-1 shows the value of the social NPV when the discount rate
is 5 percent and 1 percent. The composite social returns on all
projects are about 40 percent lower than baseline at a 5 percent
discount rate and about 75 percent higher than baseline at a
1 percent discount rate. For most projects, decreasing the discount
rate increases the NPV of social returns. For one project,
“Proliferated Human Islets,” the social benefits are negative at a
5 percent discount rate because at this rate the discounted value of
the lifetime health-related benefits per patient is less than the
discounted lifetime cost of treatment. Because the per-patient net
benefits are negative for this project, the impact of ATP on the
return on investment from this project is also negative, because the
with-ATP scenario includes more patients. The increase in the
discount rate decreases the value of improvements in the quality of
life, which occur late in life relative to the cost of treatment.
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Table B-1. Social Return on Investment and Social Return on Public Investment:
ATP Projects in Tissue Engineering for a Single Application: 5 and 1 Percent Discount Rates
(NPV 1996$ millions)

5 Percent
Expected
Social Return
on Investment

ATP Project

1 Percent

Expected
Social Return
on Public
Investment

Expected
Social Return
on Investment

Expected
Social Return
on Public
Investment

Stem Cell Expansion

$94

$33

$190

$65

Biopolymers for Tissue Repair

$77

$77

$125

$125

$39,930

$10,461

$138,866

$29,634

Living Implantable Microreactors
Proliferated Human Islets
Biomaterials for Clinical Prosthesis
Gene Therapy Applications
Universal Donor Organs
Composite

B.1.2

Social returns are
relatively insensitive
to changes in perpatient treatment
cost and QALYs,
except for one
project.

B-2

($924)

($313)

$8,165

$4,029

$24,339

$11,493

$45,092

$20,041

$449

$990

$2,278

$866

$3,568

$1,001

$1,866

$504

$63,961

$21,992

$193,036

$54,321

Sensitivity to Estimates of Health Benefits
The health benefits models estimate the benefits of ATP-funded
technologies in tissue engineering by calculating the change in the
cost of treating patients and the change in the benefits to patients in
terms of QALYs. Table B-2 demonstrates the sensitivity of the
results with respect to the change in the cost of treatment and the
QALYs gained by using the new technology. The table shows the
percentage change in each project’s social NPV when the perpatient cost or the per-patient change in QALYs is varied by
25 percent. With the exception of “Proliferated Human Islets,”
none of the results are overly sensitive to our data regarding these
benefits and costs. However, the results for this project are very
sensitive to both of these estimates partly because the percentage
changes are calculated on a small base. If the company revises its
estimates of the cost of the diabetes treatment, or if we can develop
more accurate estimates of the QALYs gained by this treatment, the
social returns from this project may be substantially larger or
smaller.
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Table B-2. Sensitivity of
Social NPV to a 25
Percent Change in PerPatient Treatment Cost
and QALYs

Percentage Change in Expected
Social Return on Investment (NPV)
ATP Project

Cost

QALYs

Stem Cell Expansion

25%

N/A

Biopolymers for Tissue Repair

25%

N/A

Living Implantable
Microreactors

11%

36%

Proliferated Human Islets

362%

381%

Biomaterials for Clinical
Prosthesis

N/A

25%

Gene Therapy Applications

1%

26%

Universal Donor Organs

7%

18%

NA = not applicable

B.1.3

Sensitivity to the Probability of Technical Success
Table B-3 shows how the results of our analysis change if we
assume that the probability of technical success is equal to 1. Note
that in our model, the expected benefits and costs following the
R&D phase are multiplied by the probability of technical success.
The table shows how our estimates of the social return on public
investment, NPV, and IRR would be different if there was no
uncertainty about the technical success of these projects. Although
the NPV is significantly higher in some cases, the IRR does not
change a great deal because both costs and benefits in the
commercialization and production phases are multiplied by the
probability of technical success.

B.2

SENSITIVITY OF PRIVATE RETURNS
This section describes the sensitivity of private returns to several
key parameters:
Z discount rate,
Z commercialization cost percentage,
Z production cost percentage,
Z product price, and
Z probability of technical success.
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Table B-3. Sensitivity of Expected Social Return on Investment to Probability of Technical
Success

NPV
(millions)

IRR

Under
Baseline
Assumption

When
Prob of
Success = 1

Under
Baseline
Assumption

When
Prob of
Success = 1

$134

$168

20%

21%

$98

$131

51%

55.36%

$74,518

$78,441

149%

149%

$2,252

$6,787

36%

37%

$32,855

$41,070

118%

121%

Gene Therapy Applications

$2,411

$6,971

106%

129%

Universal Donor Organs

$2,838

$6,310

91%

101%

Project
Stem Cell Expansion
Biopolymers for Tissue Repair
Living Implantable Microreactors
Proliferated Human Islets
Biomaterials for Clinical Prosthesis

For the discount rate, we calculated the value of composite NPV for
5 percent and 1 percent discount rates. For the probability of
technical success, we compared the value of composite NPV under
the baseline assumptions to the NPV when the probability of
success is 1. For the other variables, we varied them from their
baseline values by 25 percent and calculated the percentage
change in composite NPV.
B.2.1

Sensitivity of Results With Respect to the Discount
Rate
As shown in Table B-4, our estimates of private return on
investment are fairly sensitive to the discount rate assumption.
Increasing the discount rate from 3 percent to 5 percent changes
composite private returns by about 38 percent from the baseline
result. Decreasing the discount rate from 3 percent to 1 percent
increases composite NPV by about 54 percent.
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Table B-4. Private NPV for ATP Projects in Tissue Engineering for a Single Preliminary
Application: 5 and 1 Percent Discount Rates (1996$ millions)

5 Percent

1 Percent

Project returns

$977

$2,409

Increment attributable to ATP

$589

$1,369

B.2.2

Sensitivity of Results with Respect to Cost
Parameters
As explained in Section 2, we had very little data on costs that
companies would incur during commercialization and production.
In the absence of information from the companies, we developed
assumptions for these variables based on average values in the
pharmaceutical and biotechnology industries. We assumed that the
Z commercialization cost is 37 percent of expected revenue
and
Z variable cost of production is 42 percent of revenue.

Composite private return
on investment is most
sensitive to changes in
assumptions about the
commercialization cost
and the cost of production.

Table B-5. Sensitivity of
Results with Respect to
Key Parameters

We also made various assumptions about product price, based on
our interviews with company representatives. Table B-5 shows the
percentage change in composite NPV given a 25 percent change in
these parameters. The sensitivity of the NPV estimates varies
widely across projects. For some projects, the NPV is very sensitive
to these assumptions. The composite returns are most sensitive to
changes in our assumptions about production cost and
commercialization cost. Thus, our confidence about our estimates
of private returns depends largely on our certainty about these
assumptions. Given that we used secondary industry information,
we believe these estimates can be improved in the future by
updating them with data from the companies when it is available.

Parameter

Percentage Change in Composite NPV

Commercialization cost

67%

Production cost

72%

Product price

28%

B-5

A Framework for Estimating the National Economic Benefits of ATP Funding of Medical Technologies

B.2.3

Sensitivity to the Probability of Technical Success
Table B-6 shows how the composite private return on investment
changes if we assume that the probability of technical success is
equal to 1. The table shows how our estimates of the composite
NPV and IRR would be different if there was no uncertainty about
the technical success of these projects. The composite NPV is
about 66 percent higher when we assume that all projects are
successful. However, the IRR does not change because the costs of
commercialization and production are higher, as are the benefits,
when we are certain of success.

Table B-6. Sensitivity of
Composite Private
Return on Investment to
Probability of Technical
Success

B-6

NPV of ATP Project
(thousands)

IRR of ATP
Project

Under baseline assumptions

$1,564

12%

When probability of
success = 1

$2,605

12%

